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 ABSTRACT 
 
Diabetes Mellitus is one of the most prevalent and serious metabolic diseases 
in the world which is predicted to increase dramatically. Diabetes is frequently 
associated with longterm complications with macrovascular and microvascular origin. 
Diabetic neuropathy AKKINI SELATHUMAM) is one of the most common 
complications of diabetes mellitus. It is the most common neuropathy; it is estimated 
that about 50 percent of patients with diabetes mellitus will eventually develop some 
form of neuropathy.  The study was aimed at evaluating clinical efficacy of the herbal 
formulation of KADUKKAI CHOORANAM (KC) on AKKINI SELATHUMAM in 
patients with type-II diabetes. This study is an open labelled non randomized Phase-II 
clinical trial spanning 90 days. About 40 subjects of age range between 40-70 years. 
In all 40 diabetic patients who were under treatment were randomly sampled for the 
study. Socio- demographic data were collected using predesigned questionnaires. 
Glycated haemoglobin levels, lipid profile, HBA1-C, fasting blood sugar and other 
haematological investigations were estimated using standard procedures before and 
after treatment. Diabetic Neuropathy was defined as per Use of the leeds assessment 
of neuropathic symptoms and signs pain scale. The Statistical analysis was done by 
SPSS statistical package version 20.0. Paired 2 tailed test revealed that the fasting 
(P<0.0001) and postprandial blood glucose (0.0001) and HbA1c (P<0.0001), in lipid 
profile TC (p<0.0001), LDL (p<0.0001), HDL (<0.0001) and TGL (p<0.0001) 
showed significant reduction after Kadukkai chooranam intervention. The liver, renal 
functions along with the haematological parameters were well within the normal 
range. The trial drug subjected to biochemical and pharmacological studies and gave 
significant results also. The results KC to be beneficial for the treatment of Akkini 
selathumam (Diabetic Neuropathy) in type-II diabetes; further follow-up studies are 
warranted to confirm the safety aspects of kadukkai Chooranam use. 
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                                              CHAPTER-I 
                                      INTRODUCTION 
 
1.1BACKGROUND 
The Siddha system is one of the ancient and Spirituality enriched traditional 
medical system of india. The fundamentals of Siddha system of medicine is to 
strength the   body and mind. The funtamentals of treatment is to neutrolize the three 
vital humours. In the Siddha system of medicine is to formed  creation and genesis of 
matter on earth are controlled and regulated by the Pancha bhoothams, and it based on 
thridoshas and dasa  naadigal  at microcosm and macrocosm plane, an  imbalance in 
the creative forces subsequently causes defective function affecting the existence, 
qualitatively and quantitatively. Siddha system always tries to treat the patient, not the 
disease and hence treatments for the same disease may vary from individual to 
individual.Hyperlipidemia is a  more prevalence  and incidence  in 80% to 88% (Sarit 
et al 2016) with approximately 40% - 48% is more incidence in middle age group. 
According to the classical text Noi nadal and Noi Mudhal Nadal Part II and 
Yugi Vaidhaya Chinthamani 800 are clearly discribed that preclinical symptoms of 
Akkini Selathumam (Diabetic Neuropathy). 
Our ancestors elaborated the knowledge about  Neerizhivu  Noi.   Theraiyar in 
“Therankarisal” has mentioned the classification about the diseases, the urinary 
system into two major categories of “Neerinaiperukkal (Polyurea)” and  Neerinai 
arukkal Noi (Oliguria).According to Noi nadal book it was classified accoding to 
frequency, specific gravity and frothy urination. Diabetes mellitus has to comes under 
Neerinaiperukkal (Polyurea),and Neerinai arukkal Noi (Oliguria) is coming under 
categories of complicalication of diabetic related  disease. According to clinical 
symptoms and envagai thervugal Neerizhivu noi is a main primary criteria for  
classified in  Vali, Azhal and Iyam. 
 As per the Siddha perception classical text Noinadal and NoiMudhalNadal 
Part II and Yugi Vaidhaya Chinthamani 800 are clearly mentioned  that preclinical 
symptoms of Akkini Selathumam.The  main symptoms and signs are  burning 
sensation of the upper and lower limb, Polyurea ,Polyphagia ,Polydepsia and 
Polypepsia, Cough with expectoration, Slight fever and chills. 
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Diabetes Mellitus is one of the most prevalent and serious metabolic diseases 
in the world which is predicted to increase dramatically. It is frequently associated 
with long-term complications with macro vascular and micro vascular origin. Diabetic 
neuropathy is one of the main neurological complications in diabetic disease (Diabetic 
Poly neuropathy. 
 Diabetic neuropathy is  the most prevalent chronic complications of diabetes. 
This heterogeneous group of conditions affects different parts of the nervous system 
and presents with diverse clinical manifestations. The early recognition and 
appropriate management of neuropathy in the patient with diabetes is important for a 
number of reasons (American Diabetes Association.2017) 
1. Diabetic neuropathy is a diagnosis of exclusion. Non diabetic neuropathies  
may be present in patients with diabetes and may be treatable by specific 
measures. 
2. A number of treatment options exist for symptomatic diabetic neuropathy.   
3. Up to 50% of diabetic peripheral neuropathies may be asymptomatic. If not  
     recognized and if preventive foot care is not implemented, patients are at   
     risk for injuries to their insensate feet.  
 4. Recognition and treatment of autonomic neuropathy may improve  
     symptoms, reduce sequelae, and improve quality of life. 
Among the various forms of diabetic neuropathy, distal symmetric 
polyneuropathy (DSPN) and diabetic autonomic neuropathies, particularly 
Cardiovascular Autonomic Neuropathy (CAN). Patients with prediabetes may also 
develop neuropathies that are similar to diabetic neuropathy due to poor control of 
diabetes.  The screening for symptoms and signs of diabetic neuropathy is critical in 
clinical practice, as it may detect the earliest stages of neuropathy, enabling early 
intervention. Although screening for rarer atypical forms of diabetic neuropathy may 
be warranted, DSPN and autonomic neuropathy are the most common forms 
encountered in practice. The strongest available evidence regarding treatment pertains 
to these forms. 
 Prevention of diabetic neuropathies focuses on glucose control and lifestyle 
modifications. Available evidence pertains only to DSPN and CAN, and most of the 
large trials that have evaluated the effect of glucose control on the risk of 
complications have included DSPN and CAN as secondary outcomes or as post hoc 
analyses rather than as primary outcomes 
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 Kadukkai  Chooranam along  is  herbal Siddha formulation taken from the 
classical Siddha literatures “Gunapadam Mooligai Muthal Paakam(Page; 313) and 
Kadukkai  Vallaraiyin Thanimanbu  (Page;09)   drug had been chosen to study its 
efficacy in the management of Akkini Selathumam. The literature collections have 
been proved the individual constituents of the preparation possess hypoglycemic, 
hypolipidemic, analgesic and anti – oxidant activities. 
The above mentioned references and the pharmacological research works 
undergone on the constituents of the trial medicines kadukkai chooranam justified its 
potential effect in the clinical study of the management of Diabetic Neuropathy 
conditions. 
 
RATIONALE  
Kadukkai Chooranam is the single herbal  formulation taken from the classical 
siddha literature.The drug has been chosen to study it was moer efficacy in 
management of Akkini Selathumam. Recently, the plant is of great interest to 
researchers across the global level because of its reported medicinal properties like 
Hypoglycemic, Antioxidant, Anti mutagenic, Acetylcholine inhibition, Anti 
anaphylaxis, Hepatoprotective, Anti bacterial, Hypolipidemic activities. 
The above mentioned references and the pharmacological research works 
undergone on the constituents of the trial medicine Kadukkai Chooranam for the 
management of Diabetic Neuropathy .So, the trial medicine will be safe to 
management of  Diabetic Neuropathy  in Type II patient. 
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1.2 AIM AND OBJECTIVES 
 
 AIM 
         A prospective open labeled  Phase – II Non - Randomized clinical study of 
Kadukkai Chooranam internally for Akkini Selathumam (Diabetic Neuropathy).  
 
OBJECTIVES 
 
A. Primary Objective: 
To evaluate the therapeutic efficacy of  Clinical Trial drugs in Akkini 
Selathumam 
 
B. Secondary Objectives: 
a. To find out the Antidiabetic, hypolipidemic,and Analgesic  
Pharmacological activity of Kadukkai Chooranam. 
b. To determine the addition of effects and siddha parameters changes in 
Akkini Selathumam. 
c. Study about the prevalence of Akkini Selathumam in Relation between 
diet and lifestyle. 
d. To carried out  Siddha and Modern parametric changes in Diabetic 
Neuropathypatient. 
e. To  adjudge the Antimicrobial, Physico,Phytochemical analysis of the 
clinical drug 
f. To assessed contents of chemical compound through FTIR and SEM 
analytic methods. 
g. To disscuss about treatment and prognosis effect after end of study. 
 
1.3 JUSTIFICATION OF RESEARCH 
Apart from classical risk factors like diabetic dyslipidemia, elevated HbA1C 
has now been identified as an independent risk factor for cardiovascular disease in 
subjects with or without diabetes. Estimated risk of cardiovascular disease has shown 
to be increased by 18% for each 1% increase in absolute HbA1C value in diabetic 
population. Although new tests of glycation are now available, they are not without 
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limitations of their own, very expensive and impractical for everyday use in 
developing countries like India.  
 
This study was an attempt to reassess the association of glycemic control and 
lipid profile using HbA1C whiles taking into consideration some of the factors 
affecting its use. This study was also afford health care providers attending to diabetic 
patients, the needed information as to when to use HbA1C in clinical monitoring of 
glycation and diabetic dyslipidemia. 
 
Now a days world turned to herbal medicines for maximum reduce the risk 
factors from chemcials.  Therefore these are simple and efficient herbal formulations 
treated in diabetic dyslipidemia with out adverse / side effects. 
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CHAPTER-II                                                                                                                                                  
                                    REVIEW OF LITERATURE 
  2.1.1IN JOURNAL: 
  The various  journals to collections related to kadukkai (Terminalia chebula) 
 
                 
 Fig. 2;1Kadukkai                                          Fig.2;2 Kadukkai Chooranam 
 
 Taxonomy • 
 • Kingdom:         Plantae-Plants 
 • Subkingdom:    Tracheobionta-Vascular plants  
• Super division:  Spermatophyta-seed plants  
• Division:            Magnoliophyte- flowering plants                                            
• Class:                 Magnoliopsida dicotyledons                                                                
• Subclass:           Rosidae  
• Order:                Myrtales  
• Genus:               Terminalia  
• Species:             Terminalia chebula. 
 
 Macroscopic characters: 
  It is a deciduous tree, younger stems glabrescent and woody. These are 10 – 
20 cm long, sub – opposite, simple; exstipulate; petiolate; laminae broadly elliptic to 
elliptic oblong, rarely ovate, the bases obtuse, the margins entire, the tips acute, 
glabrescent. Resin and a purgative principle of the nature of anthraxquinone and 
sennoside are also present. These are single, rough, ellipsoid, 1.0-2.0 cm by 0.2 -0.7 
cm and without ridges.  
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Microscopic characteristics: 
 Transverse section of the fruit shows epicarp composed of a layer of epidermal 
cells, the outer tangential wall and upper portion of the thick radial walls. Testa, one 
layer of large cubical cells, followed by a zone of reticulates parenchyma and vessel; 
tegument consists of collapsed parenchyma. Cotyledon folded and containing 
aleurone grains, oil globules and some rosette aggregate crystals. The powder of the 
plant is brown in color, shows a few fibers under the microscope, vessels with simple 
pits and groups of sclereids (Aneja Kr,2010).  
  
Chemical constituents:   
 Total phyto-constituents of Terminalia chebula are hydrolysable tannins 
(which may vary from 20-50%) and they are responsible for pharmacological 
activities. The tannin content varies with the geological variation. Flavonol 
glycosides, tri-terpenoids, and coumarin conjugated compounds with gallic acid 
called as chebulin, and also phenolic compounds are isolated. The major  eight 
compounds are present in the kadukkai. Gallic acid, methyl gallate, ethyl gallate, 
chebulagic acid, tetra-O-galloyl-β-D-glucose, and ellagic acid, chebulinic acid and 
penta-O galloyl-β-D-glucose from Terminalia chebula were isolated and checked out 
the reverse phase chromatography. There are seven varieties of Terminalia chebula all 
of which are more or less used in similar fashion but vary in specific usages and 
quality (Baliga MS,2010).  
  
Pharmacological screening:                                  
 The various studies determine Terminalia chebula is one of the most ingenious 
plants having a wide range of pharmacological and medicinal activities. This 
multifaceted medicinal plant is the distinctive source of various types of compounds 
having various chemical structures. Though it has a number of pharmacological 
activities due to the presence of various types of bioactive compounds, little work has 
been done on the probable medicinal applications of this plant against the diseases 
particularly on Hypoglycemic and hypolipedimic activites.  
  The extracts of Terminalia chebula have been widely investigated for its 
various pharmacological effects due to which a number of therapeutic uses have been 
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associated with the plant. Terminalia chebula has been noted to possess potent 
antioxidant (SarmisthaSaha etal,2014) , the properties due to the presence of the 
phenolic compounds present in its extract.  The aqueous extract of the fruits of 
Terminalia chebula showed antioxidant activity as evident by the fact that the extract 
from the plant showed significantly decreased lipid peroxidation ( Thakur CP et al 
and  Shaila et al 1998) effects. Moreover, the antioxidant potential associated with the 
plant helped it in order to possess a hepato-protective effect. Further kadukkai was a 
good anti diabetes properties (NaiamoluKotesswaraRao,2006). 
 Suchalatha et al 2005 has done the work of Cardio productive effect in 
ethanolic extract of T.chebula was investigated in isoproteronol induced myocardial 
tissues in rat. She was reported that T.chebula extract had cardio productive effect due 
to thelysosomal membrane stabilization and preventing myocardial necrosis, 
inhibition of alteration in the heart mitocontrial ultra structure and function in the 
experimental rat was observed.  
Anti-inflammatory and anti-arthritic activity  
 Mehmood.1999 was determined about  aqueous extract of dried fruit of T. 
chebula was high inhibition of inducible nitric oxide synthesis,it is evident to 
anti-inflammatory activity in kadukkai.  
 Vonshak 2003 and Shinde 2011 has found Chebulagic acid is suppressed the 
onset and progression of collagen induced arthritis in mice.    
  Nair V 2010, was done the research of  hydroalcoholic extract of T. chebula 
produced a significant inhibition of joint swelling as compared to control in both 
formaldehyde-induced and CFA-induced arthritis. T. chebula treatment also reduced 
serum TNF-α level and synovial expression of TNF-R1. 
Anti oxidant and anti cancer activity:  
 Ponnusankar S 2011 has worked on  anti-mutagenic and anti-carcinogenic 
activities   of 70% methanolic fruit extract against several malignant cell lines.  The 
Chebulagic acid is a potent dual inhibition  effects against COX and 5-LOX. It is 
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good evident in antiproliferative activity against HCT-15, COLO-205, MDAMB-
231, DU-145 and K562 cell lines and inhibit cytochrome P450. 
  ChenX.2011 has done the work of anti-oxidant activites in six extracts and 
four pure compounds of Terminalia chebula is exhibited in-vitro antioxidant 
properties of anti-lipid peroxidation, anti superoxide radical formation and DPPH  and 
other free-radical scavenger  activities in different concentration.  
Antidiabetic and renoprotective activity: 
             Sabu MC 2002, has done pharmacological study about STZ,Alloxan  induced 
experimental diabetic rats,   he was assesed  by different extract in all group of 
animals, 75% methanolic extract of T. chebula (100 mg/kg body weight has to 
reduced the blood sugar level in normal and alloxan diabetic rats significantly within 
4 h. Continued daily administration of the drug produced a sustained effect.   
             Rao NK 2006 was determine about the chloroform extract of T. chebula seeds 
(100, 200 and 300 mg/kg body weight) produced dose-dependent reduction in blood 
glucose of diabetic rats in both short term and long term study (300 mg/kg body 
weight for 8 weeks). Further he noticed remarkable renoprotective activity of  T. 
chebula treated rats.   
             Kumar GPS 2006 was found oral administration of ethanolic extract of fruits 
of T. chebula (200 mg/kg body weight for 30 days) reduced the levels of blood 
glucose and glycosylated hemoglobin in streptozotocin (STZ)-induced experimental 
diabetic rats. 
              Murali YK 2007 has done a similar study, aqueous extract of T. chebula (200 
mg/kg body weight for two months) reduced the elevated blood glucose and increase 
in glycosylated hemoglobin. The same dose also showed a marked improvement in 
controlling the elevated blood lipids as well as decreased serum insulin levels. The in 
vitro studies with pancreatic islets showed that the insulin release was nearly two 
times more than that in untreated diabetic animals. 
i) Kannan VR 2010 and Senthilkumar2008  was worked in streptozotocin induced 
diabetic rats models.At the end of study revealed the extract of  Terminalia chebula 
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fruit and seeds was   an exhibited dose dependent reduction in blood glucose and 
renoprotective activity . 
 ii) Singh I 2009 did a diabetic work streptozotocin induced  rat models, 200 mg/kg  
of kadukkai choornam was reduced in total body weight and improved the glucose 
tolerance, 44% of reduction in the peak blood glucose at 2nd hour in glucose 
tolerance test. The fruit extract of Terminalia chebula was a significantly reduced  in 
dose-dependent glucose lowering effect. 
Phytochemistry  
                Jagetia GC.2002 has done Terminalia chebula contains high phenolic 
content, especially hydrolyzable tannins, anthraquinone, flavonol,carbohydrates, 
glucose and sorbitol . The triterpenes have been reported which are arjun glucoside 1, 
arjungenin and the chebulosides 1 and 2. Other constituents contains tannins up to 
30%, chebulic acid 3-5%, chebulinic acid 30%, tannic acid 20 40%, ellagic acid, 2,4-
chebulyi– β-D-gluco pyranose, gallic acid, ethyl gallate, punicalagin terflavin A, 
terchebin, some purgative of the nature of nthraquinone, flavonoids like luteolin, 
rutins, and quercetin etc  
. Anti-bacterial and Anti fungal activites  
 Kannan et al.2009 has investigated on two anti-bacterial compounds, Gallic 
acid and ethyl ester against methicillinresistant Staphylococcus, have been isolated 
from ethyl alcohol extract of fruits of Terminalia chebula. Terminalia chebula is well 
effective against Helicobacter pylori, a bacterium responsible for gastritis, ulcer and 
stomach cancers. 
 Khanan et al 2015 was studied about  resistant  to Staphylococcus against 
methicillin , and it was well effective  and sensitive to H.Pylori organism and it was 
effect to Stomach malignancy (Kannan et al 2009). 
 Jeong AHN et al 2002 have did a work of Aqueous extract in T.Chebula  in 
Anti fungal activity, He found the extract was highly  effective  against the  Candida 
albicans ,Epidermophyton floccosum,Microsporumgy pseum and Trichophyton 
rubrum. 
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2.1.1 SIDDHA LITERATURE: 
                    According to the WHO, the herbal medicines have been defined as 
those containing plant parts or plant materials in raw state or processed form 
(Krishnan. KS 1998) containing bioactive principles, are to be considered a important 
form and ensured to follow the Protocol for drug research in traditional system of 
medicine. The Siddha system of medicine encompasses around 600 medicinal plants 
is described in siddha materiamedica (Gunapadam Mooligai vaguppu2016). From the 
abundant source of herbal preparations in different formulations are practiced more 
than ten decades. So, it must be ensured that the quality of the drugs should not be 
compromised, the efficacy of the drugs should be maximized, the adverse effects 
should be minimized when prepared it in a absolute protocol as mentioned by the 
Siddha literatures. In Tibetan literature was mentioned, the therapeutic uses in root 
was used  for bone disease ,Stem for muscular disease ,Bark  used for skin disease, 
and Fruits for internal  organ related diseases (Pandy  GS,Chunekar et al.1999). 
 The Kadukkaichooranam is an Internal medicine comes under the Chooranam types 
of Medicines.  which is used in Siddha and Traditional medicine  for constipation, chronic 
diarrhoea,  gastric ulcer, gastroenteritis, asthma, cough, dyspnoea, dyspepsia, haemorrhoids, 
Candidiasis, parasites, malabsorption syndrome, Hepatomegaly, renal calculi, urinary 
discharge, tumours, skin disease, memory loss, epilepsy, diabetes, cardiovascular disease, 
anorexia and wounds( Nadkarni. K.M. 1976). 
The “Kadukkaichooranam” is mentioned in several Siddha literature 
“Gunapadam Mooligaivaguppu Part -1”is indicated for Mega disorder (Diabetes), 
Burning sensation of upper and lower limbs ( Poly neuropathy), liver diseases and 
anaemia.  
In Siddha system of medicine is classified 4448 types of diseases. According 
to Yugi Vaithiya Chinthaamani-800, Mega noi (or) “neerinai perukkal noikal” is 
classified into 20 types.In Tamil siddha maruthuvam, the synonyms of the 
MadhumegaNoi(kJNkfNeha;)are,Pramegham(gpuNkfk;),Neerilivu(ePupopT),Salaroga
m(ryNuhfk ;),Miguneer(kpFePu;),Vehumooththiram(ntF%j;jpuk;) 
Innippuneer(,dpg;GePu ). The different classifications of Madhumega noi which have 
been documented based on the observations of the complaints of the patients in 
different school of thoughts such as YugiVaithiya Cinthamani-800, Agathiyar 
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kanmakandam, Theraiyar vaagadam and Thirumoolar Vaithiyam-600 and the 
complications due to madhumega noi are explained under Madhumega avathaigal.   
 
2.1.2 GUNAPADAM ASPECT  
Kadukkai 
           Botanical name    :  Terminalia chebula   
Synonyms               : Anthan, Abhayan, Amudham, Devi, Divya, Rohini,    Ammai,     
                                   Abaranam, Aritaki, Varikkai, Jeevandhi Vernacular 
Names   
Tamil                    :  Kadukkai     English        : Myrobalan  
 Hindi                   : Harre, Harad, Harar   Sanskrit : Haritaki, Abhaya,  Siva,         
                                    Pathya     
 Telugu                  : Karaka, Karakkaya   Kannadam : Alalekai  
Other Varieties      : Visayan, Arokini, Prithivi, Amrita,  Sivanthi,     Thiruvirti,    
Abayan Part used  : Dried fruit 
Properties  
Suvai (Taste)      : Thuvarppu, Inippu, Kaarppu, Kaippu, Pulippu        
Thanmai             : (Nature) Veppam   
 Pirivu (Bio- Transformation):  Kaarppu  
 
Actions.         
1. Digestive 
2. Expectorant  
3. Laxative 
4. Appetizer  
5. Nutrient 
6. Hypoglycemic 
7. Hypolipidemic 
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Ingredients and Medicinal uses of  Kadukkai Chooranam 
 
Table 2.1 Ingredients and Medicinal uses of  Kadukkai Chooranam (Gunapadam 
Mooligai Muthal Pagam Page No.201)             
TAMIL 
NAME 
 
Pharmacological
ACTIONS 
THERAPEUTIC USES IN SIDDHA 
 Kadukkai  Anti diabetic, 
Neuropathy 
Anti oxidant, 
Analgesic,                
Hypolipidemic 
activity  
Mega disorders, Burning sensation of 
the upper and Lower limb, Thirst, 
Liver disease, Cardiac disease, 
General Debility polyurea. 
 
 
Table 2;2 Kadukkai vallarien tani manbu page no 09 
 
 
 
 
 
 
 
 
 
 
Table2;3-Pathartha guna Sinthamani, Page no;201 
  
 
 
 
                    
TAMIL 
NAME 
Pharmacological
ACTIONS  
THERAPEUTIC USES IN SIDDHA 
  Kadukkai  Anti dia 
betic,  Anti 
oxidant, 
Analgesic,                
Hypolipidemic 
activity  
Mega disorders, Burning sensation of 
the upper and Lower limb, Thirst, 
Liver disease, Cardiac disease, 
General Debility polyurea. 
TAMIL 
NAME 
ACTIONS THERAPEUTIC USES IN SIDDHA 
  Kadukkai  Anti diabetic, 
Laxative,Periph
eral neuropathy 
Analgesic,                 
Mega disorders, Burning sensation of 
the upper and Lower limb, Thirst, 
Liver disease, Cardiac disease, 
Malachikkal 
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2.2; SIDDHA ASPECT – 
 Akkini selathumam 
 These following  lines denotes the primary  main clinical symptoms of Akkini 
selathumam is cold and worm extremities,Polyphagia Polydepsia,Burning sensation 
of the upper and lower limb and generalised weakness.  
mf;fpdp rpNyl;gk; 
  vd;wNjh upUknyhL Nfhio Az;lh 
   nkopYlk;G mf;fpdpah naupa gwe;J 
  fd;wdNt fhy;ifA kow;rp ahfpf; 
   fz;NzhL %f;FNk nauptha;f; fhZe; 
  jd;nwdNt jhfkJ kpfTz; lhFQ; 
   rapj;jpakha;f; fhy;iffs; Fspu;e;J fhZk; 
  cd;nwdNt Az;l gpd;G grpNa ahF 
   KWjpaf;   fpdp rpNyl;kj; Jz;ik jhNd 
- A+fp itj;jpa rpe;jhkzp-410 
,J ,Ukypy; Nfhio tpOjy; >ru;thq;fj;jpYk; vupr;ry; >iffhy;fspy; rPjsk;>mjpf 
jPgdk; vd;Dk; ,f;Fzq;fis cz;lhf;Fk;. 
 According to chichitcha rathina deepam ,part 2,Vaithitya chinthamani text 
book also mentioned  the same  etiological symptoms of madhumega noi. 
 
gpj;j rpNyj;Jk njhe;j Nuhfq;fs 
 
 In chichitcha rathina deepam book is mentioned combained pitham and 
Silothuman can produced Diarrohea,Respiratory disease ,Jaundice, Hematological  
disease    and Epistaxis. These  are  the complications to produce un treated 
madhumega noi. 
                                gz;ghd gpj;jj;jpy; rpNyj;Jkq; $bg; 
    guprpj;jhy; mjpRu kpisg;Ng aPis 
   fz;fhJ eadkyk; jPUk; kQ;rs; 
    fdtapW nghUky;kQ;rs; Neha;fz; NzhT 
   cz;NghJ kWj;jy;uj;j tpg;GUjp jhD 
    Kiskhe;ij gPdprK uj;j tPf;fk; 
   ez;ghd fhkhiy Nrhif ntg;G 
    eZfpte;j gygpzpAk; ez;Ze; jhNd. 
        -rpfpr;rhuj;e jPgk; 
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2.2.1  ETIO PATHOGENESIS OF THE DISEASE: 
Diagramatic alogorhytham presentation in Akkini selathumam. Fig:2;3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Uyir Thathukkal Affected 
Agakkaranam Purakaranam 
Endogeneous Cause 
Genetic Cause 
Hereditary Cause 
Exogeneous Cause 
     Dietry changes 
           Habits 
Pitham Kabham Vatham 
      
Anal Pitham 
Ranjagam 
Saathagam 
Prasagam 
Avalampagam 
Kilethagam 
Sandhigam 
Tharpagam 
Abanan 
Uthanan 
Vyanan 
Samanan 
Kirukanan 
UDALTHATHUKKAL AFFECTED 
Saaram    Senneer    Oon    Kozhuppu 
Derangements in the Udal thathukal leads to the cause of the 
disease 
AKKINI SILETPAM 
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2.3.  SIDDHA  ASPECT OF   MADHUMEGAM 
 
Human beings are characterised by the reasoning ability and their striving 
towards a greater understanding and control over their bodies in relation to the 
environment. The Thirumoolar in Thirumanthiram,the perception is four conditions 
were prescribed, they are, 
 
 ‘kWg;gJ cly;Neha; kUe;njd yhFk;: 
 kWg;gJ csNeha; kUe;njd yhFk;: 
kWg;gJ Nehia tuhjpUf;f> 
 kWg;gJ rhit kUe;njd yhFk;‛ 
 
 Body ailment should be cured 
 Mental depression should be annihilated 
 Prevention is better than cure 
 Man should live a long, healthy life, almost defying death 
 According to Siddha system, the primordial five elements are Mann 
(earth), Neer (Water), Thee (fire), Vayu (air) and Aakayam (space), each 
substance have contained in different proportions. The five element theory 
of Siddha emphasizes that the forces that are present in Macrocosm 
(Universe) and are identical with the Microcosm (Human body). Thus a 
living human is made of these five elements in different combination and 
the physiological function in the body is mediated by three humours that 
are made of these five elements. The conglomeration of three humours 
(Vatham, Pitham, Kapham), Seven basic tissues (Saaram, Senneer, Oon, 
Kozhuppu, Enpu, Moolai, and Sukkilam/suronitham) and five basic 
elements (Mann, Neer,Thee, Vazhi and vezhi) is responsible for different 
structures and functions of human body.  
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2.3.1.DEFINITION OF MADHUMEGAM 
Madhumegam is a disease characterized by frequent of passing urine (polyuria), 
presence of honey odour in urine on heating. It ultimately deteriorates all the seven 
Udal thathus (seven fundamental tissues of the body).It was mentioned Guru nadi and 
Vaithiya chinthamani 800 in following lines, 
 
‘,dpg;ghd ,dpg;gy;y < te;jhLk; 
xU Jsptha; tpl;lhh;ifg; gpzpaha; Njhd;Wk;‛ 
      - FUehb 
‘mz;ikahabf; fbf;F ePhpwq;F 
 kbf;fbf;F miuehop jdpNy fhZk; 
ntz;ikahd jbajdpw;whd; gpbf;Fk; 
 kpf;fhd rlk; ntSj;J Nkdp fd;Wk;‛ 
- A+fp itj;jpa rpe;jhkzp-800 
2.3.2.ETIOLOGY 
The authentic etiological factors described by various siddhars are as follows, 
i. Excessive sexual desire. 
ii.  Excessive intake of high fat or high tryglyceride foods. 
iii. Chronic alcoholism. 
iv. Obesity 
v. Physical inactivity 
vi. Psychosomatic stress 
vii. Genetic factors are lead to madhumegam. 
 
‘Nfhijah; fytp Nghij 
 nfhOj;j kPd; ,iwr;rp Nghij 
ghJtha; nea;Ak; ghYk; 
 ghpTld; cz;gP uhfpy; 
Nrhj ghz;LUt kpf;f 
 Rf;fpy gpuNkfe;jhd; 
xJ ePhpopT Nru 
 Tz;nld mwpe;J nfhs;Ns‛ 
-mfj;jpah;-1200 
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‚cw;gtpf;Fk; ghy; nea;ahy; ,iwr;rp fs;shy; 
 Thpiraha; kPd;jd;dha; mUtpUe;j 
kw;gtpf;Fk; gjhh;j;jj;;jhy; kJut];jhy; 
 ke;jq;fs; jidGrpj;jy; Ntfhg; gz;lq; 
Fw;gtpf;Fk; FSj;j td;d kq;if Nfh\;b 
 Fwpj;j epj;jpiu jtph;jy; mf;fpdp ke;jk; 
jw;gtpf;Fe; rhPue;jhd; kpfg;gUj;jw; 
 rQ;rye;jhd; kpfg;gaj;jhy; jhpf;Fk; NehNa‛ 
    - A+fp itj;jpa rpe;jhkzp-800 
 Yugimuni in Yugimuni Vaithiya Kaaviyam is comprehensively described the 
causes of akkini selathumam in his poem as,  
 
‘fl;liskpFe;jpl;lhYq; fhyq;fs; jg;gpdhYk; 
 ,l;lkhk; ghYk; nea;Ak; uj;jKk;Gspg;Gk; kpQ;rpy; 
tl;lkhh; Kiyahu; jq;fs; kaf;fj;jpd; fytpahYk; 
 nel;biyNfhiu NghNy ePupopthFe;jhNd‛ 
-A+fpKdp itj;jpa fhtpak; 
 ghYk; nea;Ak; uj;jKk;Gspg;Gk; kpQ;rpy; -Excessive consumption of high fat 
contents including dairy products 
The food contains   high fat diet like ghee, milk and animal flesh are 
precipitate the cause for obesity, it wis difficult to utilized in insulin level in 
peripheral tissues (HYPER INSULINEMIA), for  produced Type II diabetes.  
 
 fytpahYk ; -Excessive sexual activities or pervertated sexual behaviour  
According to siddha system of medicine, human body is made up of seven 
udal thathus. They are saaram (chyle), seneer (blood), oon (bone), kozhupu 
(cholesterol), enbu (bone), moolai(bonemarrow), sukilam/suronitham (semen/ovum), 
where each one is derived from the other in the order and the semen/ova being 
derived from the other six thathus, when wasted injudiciously, results in the 
deterioration of seven body tissues and gives way to weak immune system and 
eventually to Madhumegam. More sexual activity can interference in sexual steroid 
hormone, steroid hormone is resist to produce insulin resistant diabetes. The same was 
mentioned in Nadi nool,Theran maruthuva bharatham and Guru nadi nool. 
                 ‘fd;dp kaf;fj;jhy; fz;bL NkfNk‛ 
 - ehb E}y; 
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 ‘fpue;jp Gz;zPud Nkf fPrfndDe; Jd;khhf;fd; 
 mUe;jjp vd;Dk;  ghQ;rhyp ad;idia fz;Zw;whNd‛ 
-Njud; kUj;Jtghujk; 
 
‘];jphpNghfk; nra;jjpdhy; NtT nfhz;L 
 rpuRkl;Lk; nte;JUfp fdNy kPwpf; 
FwpAlNd Nkfe;jhd; nfhLik nra;J 
 Fiwe;J tUk;  jhJnty;yhk; Fd;wpg; NghFk;‛ 
-FUehb 
 
 rQ;rye;jhd; kpfg;gaj;jhy;  - Psychosomatic Stress 
 
 As per Yugi vaithiya chinthamani-800 was mention in his poem,Stress is 
produced stress related hormone ( 5-HT,Stertonin,ACTH..etc),it was produced  
Oxidative stress and hepatic dysfunction.  
 
‘kjq;nfhz;L nghpNahiu itifahYk; 
 khjh; fw;Gepiyik jd;id mopf;ifahYk; 
gjq;nfhz;l rptNahfp rhgj;jhYk; 
 gj;Jtif rpNyw;gdq;fs; NkfePuhk;"; 
- a+fp itj;jpa rpe;jhkzp-800 
 
 fh;g;gj;jpy; cjpf;Fk; Neha; - Hereditary factors   
 
 In modern text book, one of the classification in gestational diabetes,same to 
described in Thirumoolar in his Thirumanthiram.  
 
‘NgW ,sik ,d;gk; gpzp %g;G rhf;fhL 
 MWk; fUtpy; mike;j gb 
Kiw Nfl;fpy; xd;gJ Kaw;rpahy; te;jJ 
 Jiw Nfl;fpw fUg;gj;jpw; Wtq;fpa  Nkfq;fs; 
eiu g+j;j nfhq;ifahs; ehafd; Nkhfj;jhy; 
 kiwNghw;Wq; fUg;gj;jpy; tsh;e;jJ NkfNk‛ 
       -jpU%yh; 
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 fd;k tpidfs; - Karmia (Genetic disorders) 
Theraiyar vagadam and Agasthiar kanmakandam was stated in madhumegam 
occurs in genetic disorders (Type I DM).Type 1 diabetes  has a codition called type 2 
polyglandular auto immune syndrome ( HLA-DR3,HLA-DR4 and HLA- DR 7-ADA 
2017). 
‘Mkg;gh kdpjh;nra;j fd;kj;jhNy 
 mufuh Nkfnkd;W uhrhthNy 
fhkg;ghy; tPjijjhw; tUq;fd;kj;jhNy 
 iff;flq;fh Neha;fs; tUq;fd;kj;jhNy 
Nghkg;gh Nkfk; te;j fhuze;jhd;‛ 
-mfj;jpah; fd;k fhz;lk; 
 
‘jhNd g+Ut tpjpajdhw; rhUk; gpzpfsy;yhky; 
 khNdhh;  tpopahh; Ntl;ifapdhy; tUe;Jk; gpz;Zk; grpahNy 
jhNd nghWj;J cz;ifapdhy; jhfe; jd;dhy; kpfr;rhh;e;J 
 jhNd fkyk; Gz;zhfpr; nra;Ak; gpukpar; nray;jhNd‛ 
-Njiuah;thflk; 
 
 According to Sarabenthirar Vaithiya Muraikal Neerizhivu Chikitsai text was 
elaborately dicuss about the following etiological  factors for  madhumega noi.  
 
NkfnkDk; ePhpopT tUk; tpjj;ij 
tpsk;Gfpd;Nwd; Kd;nra;j fd;ke;jd;dhw; 
 
whfKld; kJugjhh;j;jq;fs; ed;wha;j; 
jhd; Grpf;ifahY rpj;jj;jpd; kq;if  
  
Nghf kjpifahY Kl;lze;jhd; 
NghjkkpQ;Rif apdhYe;japh;>Nkhh;>nea;>ghy; 
 
Ntfkha;g; Grpf;ifapdhYq; nfhOj;jpiwr;rp 
nad;W Kz;ifahYth; ePUz;ifahNy. 
 
MirAld; rpWtOjyq;fha; jd;id 
ajpfkhAz;lhYq; fhye;jg;gpg; 
Nghrdq;fs; nra;jhY eilaiyr;ry; 
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NghijahapUe;jhYq;fz; tpopf;ifahYe; 
Njrkjpw; gy ePUz;bLifahNy 
rpue;jdpw; #ljpfq;nfhz;LlNd uj;jk; 
Nrh\pj;J Ntfkjpfkha;j; Njhd;wpj; 
njhy;iy nra;Ak; ePhpopTkpUgjhNk 
    - ruNge;jpuh; itj;jpa Kiwfs; ePhpopT rpfpr;ir 
2.3.3 Neha; vz ; (CLASSIFICATION) 
Basically madhumegam is classified according to passing frequency and 
quantity and quality of urine. According to above criteria Madhumega noi was further 
classified in to twenty types, namely Vatham, Pitham and Kapham. In this main 
types,further it was divided to four in vatham, in six pitham and ten in kabha disease. 
 
2.3.4 Kw;FwpFzq;fs; (PRIMARY  SYMPTOMS OF MADHUMEGAM ) 
In Siddha text book  mentioned that increased abana vayu was affected in 
kabalam, decreased blood components and dysfunctioned dhasavayukkal,dysphasia is 
a main cause for madhumegam noi.   
‘rhpahf Nkfj;jhy; mghd thA 
 jhd; Giff;F NkNywpf; fghyr;#lhk; 
nghpjhd Nkfj;jhy; mj;jp nte;J 
 Nghkg;gh jirnte;J uj;jk; tw;wpg; 
ghpthfpj; jrthAthy; ke;jq;nfhz;L 
 ngUe;jPdp kyge;jk; cjhdthA 
thpthfpj; Njfnky;yhk; tplePuhNy 
 nka;aope;j Nkfnkd;w jpUgjhr;Nr‛ 
    - rpj;j kUj;Jtk 
    The dhanvanthri in Dhanvanthiri Vaithyam Part-II manuscript is 
explained same to previous siddha litrature of  premonitory symptoms of 
madhumegam.  
 
‘kz;lye; jd;dpYs;s khjh;f;Fk; GUlh;f;Fq;  
 nfhz;lNjhh; ryf;fopr;ry; nfhs;SKd; fhZNeha;fs; 
fz;bL Kly; fhy; iffs; fhd;woe; njhpe;J fhe;jp 
 Az;lePh; Rtwpf; fhl;b Aile;JePh; fopAnkd;Nw‛ 
      - jd;te;jphp itj;jpak; 
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2.3.5 FwpFzq;fs;(SIGNS AND SYMPTOMS OF MADHUMEGAM) 
 
Yugimuni in his Yugivaidhiya chinthamani-800 has described the following 
common symptoms and signs of 20 types of madhumegam as followed,  
 Frequency of Urination (Polyuria ) 
 Excessive Thirst (Polyphagia) 
 Excessive Appetite (Polydipsia) 
 Tiredness 
 Fatigue 
 Irritability 
 Progessive of weight loss 
 Blurring of vision 
 Recurent UTI and  Epidymo-orchitis. 
 urine may be cold, slimy to touch, brownish yellow in colour and produces 
white sediments 
 Ants and flies are attracted to the site of voided urine 
 Passing urine is heated it gives honey odour in nature 
 
‘$whd NkfkJ ,UgJf;Fk; 
 Fze;jid rptd;nrhy;y NjtpNfl;f 
jhwhd jhfnkhL Nrhf Nkfe; 
 jhpahky; ePhpopjy; ,Uky; %r;R 
MwhdmUrp rj;jp rpj;j gpuik 
 mbf;fbf;Fj; jz;zPh; jhdd;dq; Nfl;ly; 
<whd ,Lg;Gfs; fLg;G fhzy; 
 vYk;G ow;wyow;wNyh  nlhpTz;lhFk;‛; 
 
‘vhpNthL rhPunky;yh kiwgl;lhw; Nghy; 
 vopOlk;G Nehjy; epj;jpiu apy;yhik 
kdJ rQ;ryg;gLjy; fhw;W Ntz;ly; 
 nkhpNthL  Nky;%r;R kpfTz;lhjy; 
tpf;fnyhL kaf;fe;jhd; nkj;jf; fhzy; 
 njhpNthL Njfnkq;Fk; ntSUz;ljhy; 
Njfnkj;j thNyhgg;gLjy; fhNz‛ 
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‘jz;ikaha; rye;jhDk; gRg;G kQ;rs; 
 jhdpwq;Fk; gPrKk; NfhrKq; fLf;Fk; 
mz;ikahabf;fbf;FePhpwq;Fk; 
 mbf;fbf;F miuehop jdpNy jhZk; 
 
‘ntz;ikaha; abajdpw;whd; gpbf;Fk; 
 kpf;fhd rlk;ntSj;J Nkdpfd;Wk;  
gz;ikaha;g; gQ;thz;ljdpw; nfhy;Yk; 
 gfph;fpd;w kJNkfj;jpd; ghq;F jhNd‛ 
 
- a+fp itj;jpa rpe;jhkzp-800 
 
 Agasthiyar in Aayulvagadam also same clinical symptoms and signs has to 
repeated in his poem.  
 Burning sensation on hands, legs, Face-Neuralgia  
 Dryness of mouth 
 Giddiness,vertigo 
 Fatiqueness 
 Tremors 
 Anorexia 
  Profuse Sweating 
  ‘KfNk fhe;jp neQ;Ryh;;e;J KWj;J 
 KlY eLq;fp efNk gupe;J rPh; nefpo;e;J 
    eQ;Rz;lth; Nghy; Njfk; Nrhh;e;J gfYkpuT KUf;fpAly; 
 gfWNkdpAk; jsh;e;J kpfNt jhtzKz;lhFk;‛ 
       - mf];jpaH MAs;thflk; 
2.3.6 Common Sign and Symptoms of Vatha, Pitha and Kapha Megam 
Based on Yugi, described  20 sub types of Madhumega noikal. The different clinico-
pathological conditions are impairement of specific doshas and saptha dhathukkal.The 
fractional changes in  udal dhathus can produced in diabetic complications (Neerlivin 
avasthikal). According to yugi vaidhiya chinthamani-800 the following clinical 
feature are vali,azhal and kabha mega noigal,details are given in Table no1. 
Table 2;4. Clinical features of different sub types of madhumegam. 
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Doshas Types Specific Signs 
Common Symptoms of 
Doshas 
Vatha Megam 
1.  Achiya 
megam (nei 
mana neer) 
 Urine contains colour of ghee, 
stickiness and ghee smell.  
 Polyuria 
 Weight loss 
 Death occurs 7 days after disease 
appeared.  
 
 
 
 
 
 
 Burning sensation of 
hands, feet and face. 
 Dryness of mouth 
 Black discolouration 
of teeth, tongue and 
throat. 
 Difficulty in speech  
 Giddiness  
 Excessive Thirst 
 Excessive Appetite 
 Ache and pain all over 
the body  
2.  Suththa 
megam (pasu 
mana neer) 
 Urine likes cow‟s urine and smell 
 Polyuria 
 Weight loss and fatigue 
 Death occurs 15
th
 day after 
disease appeared.  
3.  Pramiya 
megam  (oon 
mana neer) 
 Polyuria 
 Smell like blood  
 Gives honey odour when burned  
 Killed in 6 months  
4.  Mangisaravi 
megam 
(Elamarik 
kozhuppu 
mana neer) 
 Urine contains particles of flesh 
and membrane  
 Give smell of Billy meat washed 
water (pink). 
 Polyuria  
 Death occurs 3-8 days or 5
th
 
month  
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Pitha Megam   
1.  Appiya 
megam (yanai 
matha neer) 
 Simile of such patients is given 
with adult elephant as regards 
passes of urine. 
 Sediment like sea sand if boiled  
 Killed in 6 months 
 
 
 
 
 Burning sensation 
in all over the 
body  
 Emaciation  
 Excessive 
perspiration  
and bad odour  
 Urine passes like 
pus, honey, aloe 
juice  
 Burning in urethra, 
scrotum, liver and 
stomach  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.  Apiramiya 
megam 
(kattralai mana 
neer) 
 Polyuria  
 Aloe smell  
 Gives putrid odour when boiled 
 Killed in 3 years  
3.  Sampirna 
megam 
(chunna mana 
neer) 
 Urine is like an alkali (ash) 
solution, in smell, colour and 
touch. 
 Killed in 2 years  
4.  Mathumiya 
megam 
(thithippu 
neer) 
 Frequency of micturition 
 Pain in urethra 
  Honey smell when boiled  
 White colour sticky precipitation in 
bottom 
 Pallor of the body 
 Killed in 5 years 
5.  Asaththiya 
(palingu 
mananeer) 
 Dysuria 
 Quality of urine is turbid & slimy. 
It is sticky & threads may be 
demonstrated like gum. 
 Killed in 5 years 
6.  Arkka megam 
(muyatkuruthi 
neer) 
 Frequent and excessive micturition  
 Urine red in colour like hare‟s 
blood and meat smell. 
 Dysuria  
 Killed in 9
th
 month  
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Kapha Megam  
1.  Vasa megam 
(vasa neer) 
 Urine contains fat (vasa) and smell 
 Pain in penis and scrotum  
 Death occurs within 7 years 
  
2.  Uththama 
megam (theli 
neer) 
 Clear urine in larger quantity 
without odour, feels cold sensation 
while passing urine. 
 Killed in 10 years  
3.  Machcha 
megam(moolai 
neer) 
 Urine seems to like contains bone 
marrow (majjai). 
 Polyuria 
 Putrid smell  
 Life span-5 years  
4.  Akiha megam 
(ela neer) 
 Urine like tender coconut water 
and smell.  
 Gives coconut oil smell when 
boiled  
 Polyuria  
 Weight loss  
 Thirst  
 Anxiety  
 Killed in 7 years  
 
 Obesity  
 Pallor of body  
 Skin rashes like 
itching, ulcers and 
allergic rashes  
 Excessive Thirst 
 Excessive Appetite 
 Cough Sputum 
collection in throat   5.  Surari megam 
(kal neer) 
 Urine-white in colour and frothy 
like toddy and smell.  
 Fatigue 
 Killed in 7
th
 year 
6.  Sukkila 
megam 
(thavala neer) 
 Patient passes urine similar to 
quality of semen or semen itself 
may be mixed with urine.  
 Black colour sediment like liver 
after boiled 
 Killed in 3 years   
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7.  Udhaha 
megam (kalu 
neer) 
 Urine incontinence present  
 Precipitation like lime of conch 
 Body odour present 
 Killed in a year 
8.  Pinani megam 
(then neer) 
 Enormous urine output like honey 
and smell 
 Sediment like wax 
 Ants and flies are attracted to the 
site of voided urine 
 Honey odour present in body 
 Killed in 5 months 
9.  Lavana 
megam (uppu 
neer) 
 Urine seems to be salty and white 
and it‟s odour. 
 Polyuria  
 Alkali ash precipitation 
 Sediment salt when boiled  
 Weight loss, worries, loss of 
appetite, and indigestion 
 Killed in 15 years   
10.  Thayiththiya 
megam 
(eraichchi 
neer)  
 Urine red in colour and smell like 
meat washed water. 
 Dysuria 
 Polyuria 
 Killed in 3
rd
 year 
 
tspf;Fw;wj;jhy; tUk;  NkfePh;  Neha;: 
 
‘Mr;nrd;w ehYk;Kq; Fzj;ijf; Nfsh 
 aofhd iffhy;fz; Zly ow;Wk; 
ehr;nrd;w ehtwSk; gy;Y ehf;F  
 eLj;njhz;il fWg;NgW Kjnyl; lhe;jhd;  
Ngr;nrd;w ehtwSk; gy;Y ehf;F  
 eLj;njhz;il fWg;NgW Kjnyl; lhe;jhd; 
Ngr;nrd;w gpyr\akhq; fz;Nky; Nehf;Fk; 
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 ngUftd;de; jz;zPU kpfNt thq;Fe; 
jhr;nrd;w rhPue;jhd; fj;jp ntl;Lj;  
 jhd;Nghyf; fLj;JNk joYz;lhNk‛ 
     - a+fp itj;jpa rpe;jhkzp-800 
 
moy; Fw;wj;jhy; gpwf;Fk; NkfePh; Neha;fs;:  
 
‘mwpaNt gpj;jrykhWNk jhd; 
 mq;fkjpw; nra;fpd;w Fzj;ijf; Nfsha; 
jwpaNt cly;tw;wp vhpTz;lhFk; 
 rlj;jpYe;jhd; ePhpYe;jhd; ftpr;Rz;lhFk; 
njwpaNt rPg;NghYq; fw;whio NghYe; 
 Nry;NghYe; Njd;NghY ehw;wKz;lhk; 
ntwpaNt gPrj;jpw; Nfhrj;jpy; Fj;jy; 
 kpFkPuy; ehgpapYk; Ntf;fhlhNk‛ 
 
‘Ntf;fha; tpuzKz;lha; tha;jhdhYk; 
 tpf;fNyhL mUjpaha;r; RuKz;lhFk; 
jPf;fhlha; Njfe;jhd;  fplf;nfhl;lhJ 
 jpaf;fnkhL %h;r;irAz;lh kaf;fkhr;Nr 
rhf;fhlha; ehtwSq; fz;zPh; jhfQ; 
 rhj;jpnahU  rhPunkyhe;  jsh;r;rp ahFe; 
jhf;fhlha; kyrye;jhd; kpfTz;lhFe; 
 jhf;fhlha; kyrye;jhd; kpfTz;lhFQ; 
rkFze;jhd; gpj;jry khWkhr;Nr‛ 
- a+fp itj;jpa rpe;jhkzp-800 
 
Iaf;Fw;wj;jhy; gpwf;Fk; NkfePh;Neha;fs;: 
‘jrkhd gj;Jf;Fq; Fzj;ij Nfsha; 
 rhPue;jhd; gUj;JNk ntSg;;Gz;lhFk; 
mrkhd jpdTz;lh kbf;fbf;F 
 frkhd tpUkYld; Nfhio Az;lhq; 
fdthpth ahahr KoiyahFq; 
 Frkhd Fzq;fisnay;yhk; rpNyl;Lke; jd;dpy; 
nfhba ryf;Fznkd;W $wpdhNu‛ 
- a+fp itj;jpa rpe;jhkzp-800 
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2.3.7. Kf;Fw;w Kjypa NtWghLfs; (PATHOGENESIS) 
 
The direct inference from these poems is that all Siddhars attribute diabetes 
mainly due to excessive indulgence in sex which results in total loss of body strength 
as a whole including the nervous system. Due to the intrinsic, extrinsic and other 
causes tridoshas are mainly affected. Initially the pitha dosham has vitiated and causes 
burning sensation of the body and altered vayus,further altered  Kapham and Vatham  
and udal kattugal can disturbed  normal  physiological functions. The severity of the 
disease is measured by the functions of three doshas and seven udal thathus. 
Debilitation and other sequence of disease will be occurring due to loss of appetite 
and loss of body strength. 
According to theriyar  in vagada nol and pathinen siddhar nadi nool is same to 
be repeated in below poem.The malnourishment of saptha dhathus is produced 
polyurea,sweety odour in urine and  loss of strength is an important characteristic 
feature of the Mega neer.  
 
‘gfh;gpj;j tpe;ijayhJ Nkfk; tuhJ‛ 
- Njiuau; 
 
‘FwpAlNd Nkfe;jhd; 
 nfhLik nra;J 
Fiwe;JtUe; jhJnty;yhq; 
 Fd;wpg;NghFk;‛ 
- gjpnzd; rpj;jh; ehb E}y; 
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Diagramatic presentation in pathology for Madhumeganoi.Fig.2;4 
PATHOGENESIS OF MADHUMEGAM 
                                 EXTRINSIC AND INTRINSIC FACTORS 
 
 
 
 
 
 
 
    
      
 
     
 
 
 
 
 
  
 
 
 
 
Perspiration, 
Muscular 
cramps 
ALTERED PITHA 
DOSHAM 
Associated With 
Altered Vatham 
 
ALTERED 
Associated With Altered 
Vatham and Pitham 
Associated 
with Altered 
Iyam 
CHANGES IN UYIR DHATHU AND 
UDAL KATTUKAL 
Affected  
Abanan, Udhanan, 
Viyanan,Samanan 
and Ranjagam. 
Saaram, Senneer 
Affected  
Samanan, Kilethagam, 
Analagam, Saaram 
Affected 
Prasagam & Oon 
Polyuria, Nocturia 
Burning Sensation in 
urethrae, Pruritus of 
vulvae, Balanatis 
Pallor, Fatigue, Loss 
of complexion of the 
skin 
Weight loss, Polydipsia. 
Drymouth, Polyphagia, 
Body ache, Dryness of the 
Skin, 
Tiredness. 
Affected Sadhagam & 
Sukkilam/ Suronitham 
Affected Alosagam 
& Kozhuppu 
Affected Pranan, Enbu 
Silethagam &Majjai 
Spermaturia, 
Infertility/ Impotence 
Dysuria, Headache, 
Blurring of Vision, 
Dyspnoea 
Low backache, 
Giddiness 
Irritability, Emaciation  
Exhaustion, Depression   
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2.3.8 kJNkf Nehapy; fhZk; gj;Jtif mtj;ijfs; (COMPLICATIONS OF 
DISEASE)  
 
Saint Yugi well elaborated in the text book of yugi chinthamani, the onset of 
the following sufferings as avathaigal will be followed gradually if the disease is not 
controlled or left untreated.  
 
Avathai-1: Progressive weight gain and dilatation of urinary meatus 
Avathai-2: Excessive urination, disorder of semen (polyuria, Asthenospermia) 
Avathai-3: Dryness of the tongue and gaseous abdominal distension (polydipsia,  
and diabetic gastro enteropathy) 
Avathai-4: Excessive thirst may leads to excessive fluid loss  
(Encephalopathy, polyphagia,   Diabetic metabolic encephalopathy) 
Avathai-5: Frequency of urination, spermatorrhoea (chronic renal failure)  
Avathai-6: Patient awakening in bed, breathlessness (metabolic syndrome)  
Avathai-7: Recurrent nausea with vomiting, breathlessness (metabolic Syndrome)  
Avathai-8: Chronic ulcer, abscess or carbuncles are present in body (Diabetic  
Ulcer) 
Avathai-9: Immoral behaviours, watery diarrhoea (Superadded opportunistic  
infections) 
Avathai-10: Pulmonary and extra pulmonary tuberculosis   
 
‘fhzNt Kjytj;ijr; rhPue; jhDq; 
 fdkhfg; gUj;jpWfp ePh;j;J thuk; 
NtzNt Ntz;lhf;fp afyk; gz;Z 
 kpf;ftuz; lhktj;ij tpsk;gf; Nfsha; 
%zNt %j;jpug;gP ilAkhr; Rf;y 
 KfKOfpj; Nj[Rjhd; kpfNt Fd;Wk; 
ehzNt %d;whF ktj;ijf; Fj;jhd; 
 ehtwSk; thAtJ kPWe; jhNd‛ 
 
‘jhdhd ehytj;ij aq;f jhfQ; 
 rd;dpaJ ghjKz;lh ike; tj;ijj; 
Njdhd ePh; ngUFe; jhJe\;lk;  
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 epiyahw ktj;ijAlw; fpilnfhs;shJ 
%dhd %h;r;irtU Nko tj;ij 
 kpf;ftNuh frQ;Rthre; Njf rhl;bak; 
Vdhd vl;lht jtj;ij jhNd 
 vOfpue;jp gpsit Ae;jhd; kpfTz;lhNk 
 
cz;lhF nkhd;gjh ktj;ijf; Nfsha; 
 cof;fhd tjprhuq; fpUkp Az;lhk; 
gz;lhd gj;jhe;jh itj;ij Nfsha; 
 ghukhk; raq;fz;L guj;Jf; NfFk;‛ 
     - a+fp itj;jpa rpe;jhkzp-800 
 
According to the different school of thoughts, the above 3 avathaigal will be 
cured with medicines and up to nine avathaigal can treat the disease.   
 
2.3.9 jPUk; jPuhjit (PROGNOSIS OF THE DISEASE)  
 
The imbalance in the ratio of Vatham, Pitham and Kapham affects the five vayus 
(abanan, udhanan, viyanan, samanan, pranan), seven udalkattukal,The prognosis is 
depentened to Mukkutram and dhasavayukkal.  
 The second thought of  Yugi is added to three categories are good  prognosis 
namely,  
1. Sadhyam (Manageable) - Kapha megam (10) 
2. Yapyam (Palliative) - Pitha megam (6) 
3. Asadhyam (Complicated) - Vatha megam (4) 
 
‘nra;aNt tr;rpukhe; jz;l khd  
 nrakhd KJFj;jz;ilg; gw;wp epw;Fk; 
nga;aNt ngUeuk;gpy; Nkfe; jhDk;  
 gpwf;Fnkd;Nw jhdwpe;J thje; jd;dhy; 
gpa;aNt gpwde;jryk; ehy rhj;jpak; 
 gpj;jj;jpw; gpwe;jrykhWk; ahg;ak; 
ifaNt Nrl;Lkj;jpw; gpwe;j gj;Jk;  
 gukDiuj; jhh;rhj;jpak; guhg hpf;Nf‛ 
      - a+fp itj;jpa rpe;jhkzp-800 
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 The diarrhea, generalised edema and MDR tuberculosis and other respirotary 
complications, abdominal pain, carbuncle is complications can produce untreatable 
diabetes,it was mentioned in  kannusamiyam book.  
 
‘ePh;NehapdpyjprhuK 
 dpkph;tPf;f kpisg;G 
khh;%r;Rwy; tpf;fybf; 
 fbNatuy; tapw;wpy;  
Nrh;NehNahL gpsittuy; 
 jPuhf;Fwp nad;Nw 
ehh;nfhz;Liw nra;jhhpij  
 ed;whawp thNa‛ 
- fz;Zrhkpak; 
 
 Accoding to Sathaga Nadi is discussed about increased vatham,vatham is 
combained with Chronic abdominal discomport and respirotary disease,Weight loss is 
a poor prognosis of diabetes. 
 
‘Jjpg;ghd Nkfj;jpy; ePupopT khfh 
 Njhd;wpaeP hpopTjd;dpy; thjKkhfh 
kjpg;ghd thjj;jpy; tapw;Wisr;ryhfh  
 tUKisr;ry; jd;dpy;thA nfhOj;J khfh 
nfjpg;ghd tha;tjpNy tpf;f yhfh 
 $z;ltpf;fy;  jdpypisg;G nfhOj;j yhfh 
Fjpg;ghd ,isg;gjpNy Rthrk; te;J 
 fye;jhYk; kuzk; vd;W fUjyhNk‛ 
- rjf ehb 
 
2.3.10 Neha; fzpg;G (DIAGNOSIS OF THE DISEASE) 
 ‘ehbg;ghprk; ehepwk; nkhoptpop  
kyk; %j;jpukpit kUj;JtuhAjk;‛ 
                   - Njiuah 
 
In Siddha System of Medicine Eight different parameters of diagnosis have 
been devised to establish the exact underlying pathology known as envagai 
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thervugal,namely Nadi, Sparisam, Na, Niram, Mozhi, Vizhi, Malamand Moothiram 
and confirmation by  the history,clinical symptoms and lab parameters.  
 
Nadi Nadai paritchai (Reading of Pulse) 
               ‘ghh;j;jpL %d;Wk; gjpe;J nkype;J epw;fpy; 
    Njh;e;jpL Nkfk; te;Njhd;wpNa nghUe;jp nka;apy;‛ 
- jpU%yh; ehb 
 
 The most important parameter of diagnosis is Nadi.  
 The three Vatha, Pitha and Kapha naadis are feeble, the corresponding 
derangement in the doshas leads to Madhumegam. 
 
 
The second opinion of Thirumoolar,Pitha and vatha variation of clinical 
symptoms as followed, excessive hunger, thirst, emaciation and passing of large 
quantities of urine with sweet taste. 
 
‚,Ukpa gpj;jKk; thjKk;  $by; 
 kUTy Nkfk; thUjp NghyhLk; 
cUtk; NtnwhU Kz;lTlw; fha;e;jpLk;  
 cUfNt t+NdhL cwpQ;rp ,dpf;FNk’ 
      - jpU%yh;ehb 
 
Thirumoolar state, Vatham and kapham is combined together,this was 
mentioned in thirumoolar nadi,further appearance of  Kudila Nadi is movement of 
worm and Paripoorana nadi are quoted that,in the developed stage of the disease the 
vatha, pitha and kapha nadi will be feeble. 
 
‘,dpf;fpd;w thjj;jpil Nrhpy; Iae;jhd; 
 gdpf;fpd;w fs;Sg; gjdpNghy; ePNuhLk; 
fdpf;fpd;W Nkdp fiue;;J ntSg;NgWk; 
 fdpf;FkJ Nkfe;; jg;NghijaNk‛  
- jpU%yh;ehb.  
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‘ghh;j;jpL %d;Wk; gjpe;J nkype;J epw;fpy; 
 Njh;e;jpL Nkfk; te;Njhd;wpNa nghUe;jp nka;apy;‛ 
     - jpU%yh; ehb 
‘JuzKld; ePh;g;ghL nfh;g;gg; ghlhzhw; 
 nrhy;YfpNwd; ehbnay;yhe;  fod;W fhZk;‛ 
     - ghpg+uzehb 
 
‘ePh;Nkfkhdth;f;F ehb jhDk; 
 ePh;kakha; ehbnay;yhk; gyNk nfl;Lf; 
fhh;Nkfk; NghNyte; njhpNky; Guz;L  
 tpOk;GOg; NghyNt Guz;L fhl;Lk;‛ 
     - ghpg+uzehb 
 
The increased  Pitha naadi is produced  an excessive burning sensation,this 
willbe poor prognosis of diabetes.  
 
‘gw;gpbf;f Nkfk; vd;why; gpj;jkPWk; 
 ghyfNd fhq;if nfhz;L ePuhk; ghNu‛ 
     - ghpg+uzehb 
 
 SPARISAM (SENSATION OF PATIENT DURING TOUCH) 
 
Warm (or)Dry, pricking pain (or)numbness  all over the body. In mega neer 
due to Vatha, Pitha and Kapha dosham, have cold sensation in extremities. 
 
 NA (EXAMINATION OF TONGUE) 
In tongue examination following things are should be consider as follows,  
 Niram (colour)    - Pale in kapha neer 
                                                   Black in vathaneer  
                                                   Yellow pitha neer 
 Thanmai (character)   -  Dry and fissured  
 Pulan (sense)    - Lethergic and Fatiqueness 
 Umizh neer (salivary secretion) -          Saliva  in sweet taste 
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 NIRAM (EXAMINATION OF COLOUR AND COMPLEXION) 
 
It is differ from their original complexion on the skin. In madhumega disease 
pale or dark complexion is common.   
 
 MOZHI (EXAMINATION OF SPEECH) 
 
Speech due to increase of pitham, the patient is likely to suffer from tiredness 
and giddinees, therefore the bound of speech become low pitched voice.  
 
 VIZHI ( EXAMINATION OF EYE) 
 
In madhumegam visual disturbances is common (blurred of vision, glaucoma 
and pre mature cataract ) may be present and following things also should consider,  
 
 Niram (colour)  -red/pale 
 Thanmai (character) -dry 
 Pulan (sense)   -reduced touch sensation impairment in vision 
 
 MALAM (EXAMINATION OF STOOL) 
 
 Niram (colour)     
 Nurai (frothy)    
 Elagal/ erugal (consistency) are should be consider in examination of 
stools.When Vatham is in high proportion there is constipation, with 
increase of pitham there exists diarrhoea and increase in kapham results 
in white, milky motion.  
 
 MOOTHIRAM (EXAMINATION OF URINE) 
 
Urine examination is done under two categories,  
a) Neerkuri (The common nature of urine) 
b) Neikuri  (oil drop method) 
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a) Neerkuri (The Common Nature of Urine): 
 
The following points have to be taken into account in the urine examination: 
 
 Colour  
 Weight and density  
 Odour   
 Froth  
 Quantity  
 
‘te;j ePh;f;fhp vil kzk; Eiu vQ;rnyd; 
 iwe;jpaYstit aiwFJ KiwNa‛  
  
The common features of neerkuri are,  
 
 Niram (colour) - crystal clear urine 
 Weight and density - thickening of the urine 
 Manam (odour) - honey smell  
 Nurai (froth) - increased 
 Enjal (deposits) - small deposits in urine 
 
 Theriyar in neerkuri and nei kuri script is explained,urine is white (crystal)in 
colour, it indicates of kapha neer  and  poor prognosis.  
 
‘ntz;ikAw;W kpfj; njspTilj;Njy; 
cz;ikahe; Rj;j rPjsj; Jjfkhh; 
,e;ePh;g; grg;glhjpj;tDila ae;juk; 
Ke;ePh; ngUf;fkopthd; ca;jnthf;FNk‛ 
- NjiuaH ePHf;Fwp nea;f;Fwp 
 
b) Neikuri  (Oil Drop) Method: 
A drop of gingely oil is dropped in to a wide vessel containing the urine to be 
tested and kept in sunlight. The variations of three doshas diagnosed by shape and 
spreading of gingely oil on the surface of urine.  
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 ‘FwpaJNfSk; ePupy; Fiwj;jiy NghYe; Njhd;wpy; 
 gpwpe;jpLKliyNghYk; ngUq; fkz;lyk;Nghy;jhDk; 
twpe;jplr;rhjpak;kPjhk; typgpy kDNthHf;nfd;W 
 nrwpe;jpLKdpth;jhKQ; nrg;gpaFwpg;gjhNk.‛ 
                  -a+fpKdp itj;jpa fhtpak;  
 According to yuki muni vaithiya kavium.,the  apperance  of spreading oil in 
the shape of  skull and human body is indicated the good prognosis of  diabetes.The  
irregular round shape is indicated for poor prognosis of diabetes. 
  
‘ifapdpnyz;izthq;fp fope;j ePu;jd;dpw;Fj;j 
 nra;jJtl;lkhFQ; NrUe;Njhuzk;Nghy;jhDk; 
IaKkpy;iyfz;lha; rhj;jpaky;yntd;W 
 Ja;aed;Kdpth;jhDQ; nrhy;ypaFwpg;gjhNk‛ 
-a+fpKdp itj;jpa fhtpak; 
Vatha Neer: 
 
‘%isAk; epzKk;Nghy Kwpe;j Rf;fpyNk Nghy  
 Mshp NtYq;NfhY kzq;fDk; mk;GNghy 
ePspa euk;GNghy ePh;jdp nyz;nza; fhzpy; 
 thspid ntd;w fz;zha;!thjj;jpd; $WjhNd‛ 
       - jd;te;jphp itj;jpak 
According to Thanvanthiri Vaithiyam,  Vatha madhumega noi is an appearance of 
sperm,brain and unusal  urine smell indicated for vatha noi 
 Pitha Neer: 
 
‘igauty;Fy; khNj! ghUs; NshHfpope;j ePhpw; 
 ifapNynaz;nz thq;fpf; fope;jNjhh; JUk;ghw;Fj;j 
ikaWNkdpnahj;j tl;lQ; nra;jpUf;Fkhfpy; 
 ma;AW ePujhF ky;yjhw; gpj;jkhNk‛ 
- jd;te;jphp itj;jpak; 
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The urine is dark  in colour.they indicated pitha type of madhumega noi.  
 
In Siddha Maruthuva Noi Thoguthi- part -I, Mega roga Nithanam is well 
defined  as the prognosis of  madhumega disease, 
 
 The oil drop doesn‟t spread and placed like circle of eye and then adhere to 
the mouth of the dish is indicate the disease curable.  
 When the oil drop sink into the bottom and given sudden spread then oil 
and urine mixed is known as incurable. 
 The oil is spreading quickely,disappeared in early,oil easily to mixed with 
urine  is poor prognosis of diabetes.It was explained in below lines.    
 
 
‘ghuha; ePh; ghz;lj;jpy; ghq;fhajpd;Nky; ey;nyz;nza; 
 rPuha; xU Jsp tpl;lhf;fhy; rpjwp Xb Nghfhky; 
Neuha; epd;W fz; tl;lk; Nghy; neUq;fp rl;btha; vq;Fk; 
 Nru neUq;fp epHf;fpYNk jPUk; ,jw;F kUe;J nra;Na 
 
nra;Ak; tifaJ Nfsha; rpwe;j ePujpNy vz;nzapl;lhy;  
 iga;a fPNo jho;e;jpbDk; gjwp Xb rpjwpbYk;  
nea;Ak; ePUk; xd;whf kpfNt $b fye;jpbDk;  
 ca;Ak; tifaJ jPuhJ cj;jkk; vy;yhk; kj;jpgNk 
 
ifapdhy; vz;nza; thq;fp fope;j ePh; jd;dpy; Cw;wp 
 xa;Awpy; IakhFk; xope;jpby; gpj;jkhFk;  
nka;AWk; vz;nza; jhspy; kpFe;jNjhH thjkhFk; 
 ngha;ay;y ,k; %d;Wf;Fk; Gj;jpaha; mwpe;J ghNu‛ 
     -NkfNuhf epjhdk;-rpj;jkUj;Jt njhFjp 
 
2.3.11 Neha;f;fzpg;G tpthjk ; (DIFFERENTIAL DIAGNOSIS) 
 
 Theli Neer (Diabetes insipidus) 
 Neer Kiricharam (Urinary Tract Infection) 
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2.3.12 kUj;Jtk; (LINE OF TREATMENT) 
In Siddha system of medicine is not only for treat the disease, but also prevent 
the disease and improve the immunity. It is mentioned in  text book Thirumoolar-800       
Kaapu  - Prevention  
Neekkam - Treatment 
Niraivu - Restoration 
 
‘itj;jpa nray; itj;jpakhNk 
 gythW khWjyile;J nfLf;fpd;w cliy epiyf;Fk;gb 
khWjy; mZfhkYk; xNu jd;ikahf 
 nra;Jk; mjdhyhQ; nrapyf; Fiwtpd;wp 
elf;fr; nra;tJ njJNth mJNt itj;jpak;‛ 
       -jpU%yh;-800 
Over intake or consuming unbalanced  incompatible diet is considered as the 
prime causative factor to disturb the tridosha equilibrium leading to multitude of 
ailments. Special attention has been rendered to the diet regimen in madhumegam 
which is evident in Agasthiyar Kanma Kandam, Yugi Vaithiya Cinthamani-800 and 
Agasthiyar Ayurvedam-1200. 
 
Since the pathogenesis of madhumegam is mainly depends on the altered 
doshas,  
• Restoring the chemical constitution of a dosha  
• Sub-due their levels if they are excited  
• Stimulate their levels if they are subdued.  
 
Observing the precautions and following the directions given by a 
physician on the three Ds (Drug, Diet and Deeds) of health, a person can achieve 
the state of equilibrium.The aim of treatment is normalise the altered tridoshas and 
affected vayus and seven udalkattugal. Moreover, as the Akkini selathumam 
disease is caused by many other causes, it should be treated for primary causes.  
‘NtHghU jioghU kpQ;rpdf;fhy; nky;ynky;y  
 gw;g nre;J}uk; ghNu‛  
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 The basic treatment of  Siddha, neutrilize the three doshas and  first line of 
treatment is plant orgin and second line of treatment is tobe use in metals and 
minerals preparation.  
The following basic principles are added to prescribed medicine.The selection of drug 
is classified in three varieties, namely 
 xg;Giu   
 vjpUiu   
 fyg;Giu 
 The Siddha literature reveals that, the following types of diet  regimens with  
or without internal treatments.  
 
PATHIYA - APATHIYAM (DIET-DOS & DON’TS) 
 
The diet should be strengthen the udalkattugal and control the urine output. All the 
below points are mentioned, to be avoid more carbohydrate foods, low glycemic 
contents fruits, more green leaves and vegatables are adviced in diabetic patients.  
 
A) ADD:  
 Rice Or Kanji -Clear Soups, Hand Pounded Boiled Rice, Mani  
Samba Rice, Kezhvaragu, Kambu, Thinai  
 Unripe Vegetables -Pahal, Surai, Vendai, Kathari, Avarai, Murungai, Vellai  
Mullangi, China Venkayam, Atti, Kovai   
 Greens   -Neerarai Keerai, Kothamalli, Puthina, Karivepilai, Kavaipoo,  
Puliyaarai, Murungai, Vasalai, Ponmusuttai, Vallarai,  
Manathakkali, Surai, Kadivasalai, Keerai Thandu 
 Fruits  -Koiya, Mathulai, Naval, Nelli  
 Pulses   -Ulunthu, Pasipayaru 
 Dairy Products -Cow‟s Butter Milk 
 Non-Vegetarian Diet-Ayirai Meen (Loach)  
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B) AVOID: 
 
The following foods and milk products are avoid during the line treatment,   
 Sweets, backery, products such as cakes, pastries, cream biscuits, concentrated 
milk preparations  
 Ice-creams, soft drinks, fruit juices  
 Tubers like potato, sweet potato, yam, carrot, beet root and colacasia. 
 Saturated fats ghee and butter 
 Nuts, dry fruits like pista, badam, cashew 
 Fatty meats, organ meat such as liver, kidney, brain, heart, egg yolk may be 
avoided. 
  YOGAM: 
The following yogasanam are adviced in diabetes patients, 
 Pranayamam 
 Sarvaangasanam 
 Halasanam 
 Patchimothasanam 
 Thanurasanam   
 Shavasanam 
 Salapasanam  
 Mayurasanam  
 pujangasanam 
 Padmasanam 
PREVENTION 
 Sprouted granules, ginger added with food 
 Regular walking (6km/hr) 
 Avoid tabacco/ alcohol 
 Excessive sexual activity 
 Take sprouted fenugreek,onian, garlic, turmeric, terminalia chebula, Indian 
goosbery    
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 2.3. MODERN ASPECT - DIABETES MELLUTUS  
2.3.1 Definition and description of diabetes mellitus 
Diabetes is a group of metabolic diseases characterized by hyperglycemia 
resulting from defects in insulin secretion, insulin action or both. The chronic 
hyperglycemia of diabetes is associated with long-term damage, dysfunction, and 
failure of different organs, especially the eyes, kidneys, nerves, heart, and blood 
vessels. Several pathogenic processes are involved in the development of diabetes.  
 
These range from autoimmune destruction of the pancreatic β-cells with 
consequent insulin deﬁciency to abnormalities that result in resistance to insulin 
action. The basis of the abnormalities in carbohydrate, fat, and protein metabolism in 
diabetes is deﬁcient action of insulin on target tissues. Deﬁcient insulin action results 
from inadequate insulin secretion and/or diminished tissue responses to insulinatone 
or more points in the complex path ways of hormone action.Impairmen to  insulin 
secretion and defects in insulin action frequently coexistin the same patient, and it 
isoftenunclear which abnormality, if either alone, is the primary cause of the 
hyperglycemia. The Symptoms of marked hyperglycemia include polyuria, 
polydipsia, weight loss, sometimes with polyphagia, and blurred vision, Impairment 
of growth and susceptibility to certain infections may also accompany chronic 
hyperglycemia. Acute, life-threatening consequences of uncontrolled diabetes are 
hyperglycemia with ketoacidosis or the nonketotic hyperosmolar syndrome.  
 
Long-term complications of diabetes include retinopathy with potential loss of 
vision; nephropathy leading to renal failure, peripheral neuropathy with risk of foot 
ulcers, amputations, and Charcot joints; and autonomic neuropathy causing gastro 
intestinal, genitor urinary, and cardiovascular symptoms and sexual dysfunction. 
Patients with diabetes have an increased incidence of atherosclerotic cardiovascular, 
peripheral arterial and cerebrovascular disease. Hypertension and abnormalities of 
lipoprotein metabolism are often found in people with diabetes(Rodica Pop-Busui.et 
al.2007) 
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2.3.2Epidemiology 
The mortality rate of diabetes mellitus is high, and is  5
th 
rank in
 
 the ten major 
causes of death in southern part of India. The rising prevelance of diabetes is 
associated with industrialization and socioeconomic development. Although the 
prevelance of type-I and II diabetes mellitus is increasing world wide. The prevelance 
of type-II diabetes mellitus is expected increase more rapidly in future because of 
increasing obesity and reduced physical activity. The WHO estimates that 75 percent 
of the 300 million adults with diabetes in 2025 will live in devolopig countries. 
 
2.3.3 Classification of diabetes mellitus 
 
Etiologic classification of diabetes mellitus: 
 
I. Type-1 diabetes (β-cell destruction, usually leading to absolute insulin 
deficiency) 
A. Immune mediated 
B. Idiopathic 
II. Type-2 diabetes (may range from predominantly insulin resistance with 
relative insulin deficiency to a predominantly secretory defect with insulin 
resistance) 
III. Other specific types 
A. Genetic defects of β-cell function 
1. Chromosome 12, HNF-1α (MODY3) 
2. Chromosome 7, glucokinase (MODY2) 
3. Chromosome 20, HNF-4α (MODY1) 
4. Chromosome 13, insulin promoter factor-1 (IPF-1; MODY4) 
5. Chromosome 17, HNF-1β (MODY5) 
6. Chromosome 2, NeuroD1 (MODY6) 
7. Mitochondrial DNA 
8. Others 
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B. Genetic defects in insulin action 
1. Type A insulin resistance 
2. Leprechaunism 
3. Rabson-Mendenhall syndrome 
4. Lipoatrophic diabetes 
5. Others 
C. Diseases of the exocrine pancreas 
1. Pancreatitis 
2. Trauma/pancreatectomy 
3. Neoplasia 
4. Cystic fibrosis 
5. Hemochromatosis 
6. Fibrocalculous pancreatopathy 
7. Others 
D. Endocrinopathies 
1. Acromegaly 
2. Cushing's syndrome 
3. Glucagonoma 
4. Pheochromocytoma 
5. Hyperthyroidism 
6. Somatostatinoma 
7. Aldosteronoma 
8. Others 
E. Drug or chemical induced 
1. Vacor 
2. Pentamidine 
3. Nicotinic acid 
4. Glucocorticoids 
5. Thyroid hormone 
6. Diazoxide 
7. β-adrenergic agonists 
8. Thiazides 
9. Dilantin 
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10. γ-Interferon 
11. Others 
F. Infections 
1. Congenital rubella 
2. Cytomegalovirus 
3. Others 
G. Uncommon forms of immune-mediated diabetes 
1. “Stiff-man” syndrome 
2. Anti-insulin receptor antibodies 
3. Others 
H. Other genetic syndromes sometimes associated with diabetes 
1. Down syndrome 
2. Klinefelter syndrome 
3. Turner syndrome 
4. Wolfram syndrome 
5. Friedreich ataxia 
6. Huntington chorea 
7. Laurence-Moon-Biedl syndrome 
8. Myotonic dystrophy 
9. Porphyria 
10. Prader-Willi syndrome 
11. Others 
IV. Gestational diabetes mellitus 
Type-I diabetes characterized by deficiency of insulin due to destructive 
lesions of pancreatic β-cells; usually progresses to the stage of absolute insulin 
deficiency. Typically, it occurs in young people with acute-onset with typical 
symptoms of diabetes together with weight loss and tendency to ketosis, but type 
1diabetes may occur at any age, sometimes with slow progression.   
 Type-II diabetes is caused by a combination of decreased insulin secretion and 
decreased insulin sensitivity. Typically, the early stage of type-II diabetes is 
characterized by insulin resistance and decreased ability for insulin secretion causing 
excessive post-prandial hyperglycaemia. This is followed by a gradually deteriorating 
first-phase insulin response to increased blood glucose concentrations.Type-II 
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diabetes, comprising over 90% of adults with diabetes, typically develops after middle 
age. The patients are often obese or have been obese in the past and have typically 
been physically inactive. Ketoacidosis is uncommon, but may occur in the presence of 
severe infection or severe stress. Diabetes related to specific single genetic mutations 
that may lead to rare forms of diabetes, as for instance Maturity Onset Diabetes of the 
Young (MODY).Diabetes secondary to other pathological conditions or diseases (as a 
result of pancreatitis, trauma, or surgery of pancreas).Drug or chemically induced 
diabetes.  
 
TABLE 
CRITERIA FOR DIABETIC DIAGNOSIS. FIG. 2:5 
 
 
The clinical classification also comprises different stages of hyperglycaemia, 
reflecting the natural history of absolute or relative insulin deficiency progressing 
from normoglycaemia to diabetes.  The following criteria for diagnosis of diabetes 
(American Diabetic Association.2010).  
 
2.3.4 Complications of diabetic mellitus 
2.3.4.1 Acute Complications   
 
The usual clinical symptoms of DM include polyuria, polydipsia, weight loss, 
fatigue, weakness, blurred vision, frequent superficial infections, and poor wound 
48 
 
healing. However, patients can occasionally present with acute complications, such as 
hypoglycaemia, diabetic ketoacidosis, hyperosmolar non-ketotic coma.  
 
2.3.4.2 Chronic Complications   
 
The major chronic complications of DM are usually microvascular, 
neuropathic and macrovascular in nature. The microvascular and neuropathic 
complications present as retinopathy, nephropathy, peripheral neuropathy, autonomic 
neuropathy and foot disease. The macrovascular complications present as myocardial 
infarction/ ischaemia, transient ischaemic attack, stroke and claudicationhave also 
indicated that other chronic complications of diabetes may be non vascular, e.g. 
gastroparesis, infections and skin changes.  
 
2.3.4.3 Macrovascular Complications   
 
Almdal et al 2004 was  mentioned, indicated that type-II diabetes typically 
occurs in the setting of the metabolic syndrome, which also includes abdominal 
obesity, hypertension, hyperlipidaemia, and increased coagulability. These other 
factors can also act to promote cardiovascular disease. In this setting of multiple risk 
factors, type-II diabetes itself acts as an independent risk factor for the development 
of ischemic disease, stroke, and death.  Diabetic retinopathy which occurs in all forms 
of diabetes is the commonest cause of blindness in adults in most developed countries. 
The development of retinopathy, as with all diabetic complications, depends on the 
duration of the disease. The clinical features of diabetic retinopathy are; 
„microaneurysms, retinal haemorrhages, exudates, cotton wool spots, 
neovascularisation, fibrosis, pre-retinal and vitreous haemorrhages‟. These features 
occur in various combinations in different patients and are used to classify the 
severity of the disease. 
  2.3.4.5 Neuropathy   
 Diabetic neuropathy (DN) is a common disorder and is defined as signs and 
symptoms of peripheral nerve dysfunction in a patient with diabetes mellitus (DM) in 
whom other causes of peripheral nerve dysfunction have been excluded.  
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Clinical classifications of diabetic neuropathies.are, 
Symmetric 
 Diabetic polyneuropathy 
 Painful autonomic neuropathy 
 Painful distal neuropathy with weight loss “diabetic cachexia” 
 Insulin neuritis 
 Polyneuropathy after ketoacidosis 
 Polyneuropathy with glucose impairment 
 Chronic inflammatory demyelinating polyneuropathy with diabetes mellitus 
Asymmetric 
 Radiculoplexoneuropathies-  
-Lumbosacral 
                   -Thoracic 
                    -Cervical 
 Mononeuropathies 
 Median neuropathy at wrist 
 Ulnar neuropathy at the elbow 
 Peroneal neuropathy at the fibular head 
 Cranial neuropathy 
Distal symmetrical polyneuropathy(DSPN) 
 
DSPN is the commonest type of DN and probably accounts for 75% of DNs . 
Many physicians incorrectly presume that DSPN is synonymous with DN. It may be 
sensory or motor and may involve small or large fibres, or both. Sensory impairment 
occurs in glove and stocking distribution and motor signs are not prominent. Its is 
further classified into large fibre and small fibre neuropathy. Large fibre neuropathy is 
characterised by painless paresthesia with impairment of vibration, joint position, 
touch and pressure sensations, and loss of ankle reflex. In advanced stage, sensory 
ataxia may occur. Large fibre neuropathy results in slowing of nerve conduction, 
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impairment of quality of life, and activities of daily living. Small fibre neuropathy on 
the other hand is associated with pain, burning, and impairment of pain and 
temperature sensations, which are often associated with autonomic neuropathy.  
Painfull Diabetic neuropathy 
About 10% of diabetic patients experience persistent pain. Pain in DN can be 
spontaneous or stimulus induced, severe or intractable. DN pain is typically worse at 
night and can be described as burning, pins and needles, shooting, aching, jabbing, 
sharp, cramping, tingling, cold, or allodynia. Some patients develop predominantly 
small fibre neuropathy manifesting with pain and paresthesia early in the course of 
diabetes that may be associated with insulin therapy (insulin neuritis).  
Diabetic autonomic neuropathy 
Diabetic autonomic neuropathy affects various organs of the body resulting in 
cardiovascular, gastrointestinal, urinary, sweating, pupils, and metabolic disturbances. 
Because of diversity of symptoms, autonomic DN often goes unnoticed by both the 
patient and the physician. Autonomic nerve involvement can occur as early as one 
year after the diagnosis of DM. Diabetic autonomic neuropathy usually correlates 
with severity of somatic neuropathy.  
Asymmetrical proximal diabetic neuropathy 
It is also referred to as diabetic amyotrophy but should better be called as 
diabetic proximal neuropathy. The other examples of proximal DN include thoracic 
radiculopathy and proximal diffuse lower extremity weakness that should be grouped 
under a single term diabetic polyradiculopathy, as these are diverse manifestations of 
same phenomena; root or proximal nerve involvement. The weakness of pelvic 
femoral muscles occurs abruptly in a stepwise manner in the people above 50 years of 
age.  
Most of these patients have NIDDM but it is unrelated to the severity or 
duration of diabetes. The patients complain of pain in low back, hip, anterior thigh, 
typically unilateral but may be bilateral. Within days or weeks, the weakness and 
wasting of thigh and leg muscles follows . Knee reflex is reduced or absent. 
Numbness or paresthesia is minor phenomena. Weight loss occurs in more than half 
the patients 
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Limb neuropathies 
There are two major mechanisms of limb neuropathies in diabetics: nerve 
infarction and entrapment. Nerve infarctions are associated with abrupt onset pain 
followed by variable weakness and atrophy. As the primary pathology is axonal 
degeneration, the recovery is slow over a period of months. Median, ulnar, and 
peroneal nerves are most commonly affected. 
Mononeuropathy 
In diabetic patients, nerve entrapment is commoner than nerve infarction. The 
entrapment neuropathies have insidious onset, have characteristic electro diagnostic 
features such as conduction block or segmental nerve conduction slowing in the 
entrapped segment of the nerve. Carpal tunnel syndrome is three times more common 
in diabetic patients than the normal population. The other entrapment neuropathies in 
diabetic patients are ulnar, radial, lateral femoral cutaneous nerve of thigh, peroneal 
and medial and lateral planter nerves. 
Cranial neuropathy 
Cranial neuropathy in diabetic patients, most commonly involve the 
oculomotor nerve followed by trochlear and facial nerve in order of frequency. Third 
nerve palsy with pupillary sparing is the hallmark of diabetic oculomotor palsy and is 
attributed to nerve infarction. The pupillary fibres are peripherally located; therefore 
escape in diabetic oculomotor palsy. 
Multiple neuropathies 
Multiple neuropathies refer to the involvement of two or more nerves. As in 
mononeuropathy the onset is abrupt in one nerve and occurs earlier than the other 
nerves, which are involved sequentially or irregularly. Nerve infarctions occur 
because of occlusion of vasa nervosum and should be differentiated from systemic 
vasculitis. 
Diagnosis of diabetic neuropaty 
The American Academy of Neurology recommends that DN is diagnosed At least one 
of each of the five criteria is needed:  
1. Symptoms 
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2. Signs 
3. Electrodiagnostic tests 
4.Quantitative sensory  
5.Autonomic testing.  
                      This may be necessary in research protocols. However. in clinical 
practice two of five criteria have been recommended.  
 Nerve conduction studies 
                         Motor nerve conduction, F response, and sensory nerve conduction 
studies are important methods of documentation and follow up of nerve functions in 
DN. Motor nerve conduction studies are affected in a small subset of DN (large fibre 
neuropathies). Even in large diameter fibre neuropathy nerve conduction velocity 
(NCV) is insensitive for many pathological changes known to be associated with 
DN.The nerve conduction changes are non‐ specific and key to the diagnosis lies in 
excluding other causes or those superimposed on DN. Entrapment neuropathies are 
common in diabetic patients and result in unilateral NCV changes, especially across 
the entrapped segment of the nerve. The commonest abnormality in diabetes is 
reduction in the amplitude of motor or sensory action potentials because of 
axonopathy. Pronounced slowing of NCV suggests demyelinating neuropathy, which 
is rarely associated with diabetes; therefore pronounced slowing of NCV in a diabetic 
patients should prompt investigations for an alternative diagnosis. However, the 
likelyhood of CIDP occurring in diabetic patients is 11 times higher than the normal 
population. The NCV is gradually diminished in DN, with estimates of a loss of about 
0.5 m/s/y. 
                                        
        Pathogenesis 
                            The cause of DN though remains unknown but ischaemic and 
metabolic components are implicated. Hyperglycaemia induces rheological changes, 
which increases endothelial vascular resistance and reduces nerve blood flow. 
Hyperglycaemia also causes depletion of nerve myoinositol through a competitive 
uptake mechanism. Moreover, activation of polyol pathway in the nerve through 
enzyme aldose reductase leads to accumulation of sorbitol and fructose in the nerve 
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and induces non‐ enzymatic glycosylation of structural nerve proteins. 
Hyperglycaemia also induces oxidative stress. Activation of protein kinase C has been 
linked to vascular damage in DN. These changes result in abnormal neuronal, axonal, 
and Schwann cell metabolism, which result in impaired axonal transport. Direct 
measurement of glucose, sorbitol, and fructose in nerves of diabetic patients showed 
correlation with the severity of neuropathy.Endoneural hypoxia is produced by 
increased vascular resistance and reduced blood flow in the nerve. Hypoxia leads to 
further capillary damage, which in turn aggravates disturbance in axonal transport and 
reduced Na‐ K ATPase activity leading to axonal atrophy and impairment of nerve 
conduction. 
 
2.3.5 Diabetic dyslipidemia  
The defects in insulin action and hyperglycemia could lead to dyslipidemia in 
patients with diabetes. In the case of T2DM, the obesity/insulin resistant state that is 
at the basis of the development of this disease can in itself lead to lipid abnormalities 
independently of hyperglycemia. In poorly controlled T1DM hypertriglyceridemia 
and reduced HDL-commonly occurred.  
 
2.3.6 Glycated Haemoglobin (HbA1C)   
HbA1c was introduced into clinical use in the 1980s and subsequently has 
become a cornerstone of clinical practice. HbA1C reflects average plasma glucose 
over the previous eight to 12 weeks.It can be performed at any time of the day and 
does not require any special preparation such as fasting. These properties have made it 
the preferred test for assessing glycaemic control in people with diabetes. More 
recently, there has been substantial interest in using it as a diagnostic test for diabetes 
and as a screening test for persons at high risk of diabetes.The International Expert 
Committee recommended the use of HbA1C to diagnose diabetes mellitus with a 
threshold > 6.5%.However, the diagnosis should be confirmed by a repeat test unless 
symptoms of hyperglycaemia and blood glucose level of >11.1 mmol/l (>200mg/dl) 
are available.In addition, those with an HbA1C level between 6 and 6.5% have been 
identified as being at very high risk of developing diabetes, and the risk increases 
substantially as the values increase.  
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CHAPTER-3 
MATERIALS AND METHODS 
 
3.1 STUDY AREA AND SETTING   
 
The study period is covered from June 2017 to July 2019 at the Govt. Siddha 
Medical College and Hospital, Palayamkottai- 627 002, Tirunelveli, Tamil Nadu. All 
procedures were carriedout before getting the permission from Instutional Ethical 
Commitee.  
3.2 STUDY DESIGN 
 
 The study design is a prospective open labelled non randomized Phase-II 
clinical trial of 40 type-II diabetic study. The included selection were newly 
diagnosed and already diagnosed as type-II diabetic patients with or without taking 
treatment.  A written informed consent form was recruited in the study. The purpose 
of the study was explained to the patients before administration of trial drug.  The 
patients information, life style, anthropometric measurements and Siddha parameters 
were recorded to starting the treatment.   
 The total number 40 patients, equally in both sex and  age between 40 to 70 
were taken for  this study. The selected patients were treated  the trial drug at end of 
the study period (90 days).  
3.3 SELECTION OF PATIENTS 
 
After inclusion of cases is screening before starting the treatment. The criteria 
for selection of patients is already diagnosed in type 2 Diabetes ( fasting, post 
prandial,Random blood sugar, high range of HbA1C ). 
 
Detailed personal history, family history, occupation, habits, clinical 
symptoms, medical history, and the duration of illness were recorded in all patients 
(Proforma annexed). 
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3.3.1 Inclusion Criteria 
1. Age between 40 and 70 years   
2. Type-II diabetes mellitus  
If yes in any of three, FBS - > 126 mg/dl or PPBS - > 200mg/dl or HbA1C > 6.5 
and<10 (ADA 2017). 
3.  Total cholesterol - >199 mg/dl or LDL - >159 mg/ dl or Triglycerides - >150 
mg/dl or HDL level - < 60 mg /dl 
4. Willing to give blood sample for the Lab investigations 
5. Diabetic Neuropathy Pain Score greater than 4/10 
3.3.2 Exclusion Criteria 
 
1. Age below 40 and above 70  
2. If yes in any one of three 
FBS - < 125 mg/dl or PPBS - <199mg/dl or HbA1C < 6.5  
3. High lipid profile, dyslipidaemia has values of, Total cholesterol <199 mg/dl or 
LDL<159 mg/ dl or Triglycerides <150 mg/dl  
4. Type-I diabetes mellitus 
5. Secondary hypertension 
6. Pregnant woman  
7. Lactating mother  
8. Chronic kidney disease / Renal failure 
9. Corticosteroid therapy 
10. Chronic active viral hepatitis/cirrhosis/ascites 
11. Endocranial disorder  
12. Femoral/Sciatic  Nerve dysfunction 
13. Demyelinating polyneuropathy 
14. Mechanical and Traumatic nerve injury/Compressive mylo radiculopathy 
 
3.3.3 Diagnosis 
The Siddha diagnostic procedure were included this study, which are,                  
 Poriyal Arithal 
 Pulanal Arithal 
 Vinathal 
 Mukkutra nilaigal 
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 Envagai thervugal 
 Nilam 
 Kaalam & Udal kattugal 
3.3.4 Investigations 
Blood: 
 TC, DC, ESR, Hb% 
 Blood Sugar (Fasting and Post Prandial), Serum Urea, Serum Creatinine 
 HbA1C 
 Fasting lipid profile 
Urine: 
 Albumin, Sugar, Deposits 
The Biochemical Analysis were carried out before and after administration of 
trail drug.The blood sugar and other lab investication have monitored once in twenty 
days.  
 
3.4 TREATMENT 
3.4.1 Preparation of Trial Medicine (Annexure-I ) 
The  herbal preparation of kadukkai chooranam   have been selected from the Classical Siddha 
literature. Reference: Gunapadam Mooligai Muthal Pagam Page No.201  
      Kadukkai, Vallaraiyin Thanimanbu  Pg.No. 9 
3.4.2Collection and authentication of TrialMedicine (Annexure-II) 
      The  Terminalia chebulla fully matured fruits was collected from the Nagar kovil Siddha 
medical shop, Tamilnadu. The fruits will be identified and authenticated by the Medicinal 
Botanist and Gunapadam experts at Government Siddha   College and Hospital, Palayamkottai 
- 627002..   
3.4.3 Preclinical Analysis of Trial Medicine 
                All the preclinical studies of the study drug which havebeen included in  
Bio chemical and pharmacological studies and cross checked before starting the 
treatment.The Biochemical analysis were done in Dept. of Biochemistry, GSMCH, 
Palyamkottai. 
   The pharmacological activities- Anti- hyperglycaemic, Anti- 
Hyperlipedemic, Acute and sub-acute toxicity,Analgesic and Anti microbial activities 
were  carried out in this study.  studies were done in  K.M. College of Pharmacy, 
Madurai -625107.  
57 
 
3.4.4 Ethical Review 
 
 The study was conducted in accordance with the ethical principles that are 
consistent with Good Clinical Practice guidelines and obtained prior approvals before 
start of the trial from the Institutional Ethics Committee of GSMCH, Palayamkottai 
(GSMC-IV-IEC/2017/Br.-I/08/29.05.2017) and Institutional animal ethical 
committee (IEAC) of K.M. College of Pharmacy, Madurai 
(TNMGRMU/KMCP/IEAC/19/2018).  The trial was applied and approved by the  
Clinical Trial Registry of India. 
 
3.4.5 Study Enrolment   
Participants were informed in Tamil language, regarding the trial, the expected 
benefits and their right to opt-out of trial at any time without pre judice.  Informed 
written consent was obtained from each participant, prior to his/her inclusion into the 
trial.  
 
Before commencing the trial all the subjects were advised diet based on their 
body mass index, but no recommendations on diet were given during trial period. All 
subjects of age range between 40-70 years with Fasting Plasma Glucose (FPG) 
>126mg/dl and two-hour Postprandial Plasma Glucose (PPPG) between >200mg/dl 
and with lipid profile Total cholesterol->199 mg/dl, LDL->159 mg/ dl, Triglycerides - 
>150 mg/dl and HDL level - < 60 mg /dlwere included in the study.  
 
The subjects with history of serious adverse effects or hypersensitivity 
reactions to the medication such as rashes, diarrhoea, vomiting etc., and history of 
treatment with other anti-hyperglycaemic drugs, active liver disease or hepatic 
dysfunctions, higher serum creatinine (> 2.5 mg/dl) and serious or unstable medical or 
psychological condition are excluded from the study.   
 
During the visit, body weight, blood pressure, cardiovascular,neurological  
and respiratory system were  clinically recorded . During the treatment any adrverse 
reaction or side effects of patients, immediately to inform patient and 
pharmacovigilance committee. At the end of the study period, all the patients were 
instructed to follow diet control, regular exercise, yoga, meditation and to monitor 
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their blood sugar levels, HbA1C, and lipid levels periodically. They were also advised 
to pursue the further treatment in the PG, Pothu Maruthuvam OP for the follow up 
study. 
3.4.6 Statistical Analysis  
All data were analysed using the SPSS 20.0 (IBM). Data were expressed as 
means and standard deviation. The significance of the difference between the means 
of the baseline and the final examinations was tested using the paired “t” test. A 
probability value of <0.05 was considered to be statistically significant. 
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.  CHAPTER  IV 
                                 RESULT AND OBSERVATION 
4.1 PRE CLINICAL STUDY 
4.1.1 ANTI HYPERGLYCEMIC: 
 Table no: 4.1.2a is showed, the levels of initial and final blood glucose, and 
change in body weight, in normal rat, and treatment control animals in each group. 
The mean body weight of diabetic rats (G2) was significantly decreased as compared 
to normal control rats. The body weight of diabetic control rats treated with siddha 
formulation KADUKKAI CHOORANAMat a dose of 100 and 200mg/kg  was  
increased the body weight non-significantly as compared to normal control animals.   
 Table No: 4.1.2.a - Effect of siddha formulation KADUKKAI CHOORANAM on 
initial and final body weight and blood glucose in normal and treated animals 
                                             
 
 
 
 
 
 
 
 
 
 
As per table 4.1.2;b the blood sugar level was showed after useing  the  test 
control dose  100, 200 mg of KC administrated in  Wister albino Rats. The control 
group was compaired in standard (Group III) and treatment control (Group IV &V). 
The above table shows 100 and 200 mg of KC was compaired group II &III.           
GROUP Body weight (g)  Blood 
glucose 
(mg / 
100ml) 
Initial 
Blood 
glucose 
(mg / 
100ml) 
Initial Final Final 
G1 230 ± 
7.15 
241± 
7.35 
89.55 ± 
3.37 
91.78 ± 
3.85 
G2 231 ± 
6.68 
176 ± 
4.50**(a) 
89.78 ± 
3.45 
219.48 ± 
6.96**(a) 
G3 237 ± 
7.30 
240 ± 
7.30 
89.70 ± 
4.20 
125.38 ± 
4.35**(b) 
G4 231± 
7.32 
240 ± 
7.38 
83.77± 
3.65 
141.43± 
5.32**(b) 
G5 231 ± 
7.35 
244 ± 
7.45 
96.42 ± 
3.78 
131.49 ± 
4.45**(b) 
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The blood sugar and lipid was   rdecreased. The conclusion of the above results 
refined significantly decreased blood sugar level.  Standarded and  control  result 
showed, initial blood glucose level was 89.70 ± 4.20  and final glucose level was  
125.38 ± 4.35**(b) ; treatment control (& IV &V) showed initial blood glucose level  
96.42 ± 3.78  final glucose level  131.49 ± 4.45**(b). 
Table no: 4.1.2.b; Effect of siddha formulation KADUKKAI CHOORANAM on 
plasma insulin, Hemoglobin & Glycosylated hemoglobin in normal and treated 
animals. 
GROUPS                     Haemoglobin 
(gm/100ml) 
Glycosylated 
haemoglobin HbA1 (%) 
Plasma Insulin (µU/ml) 
G1 12.85 ± 1.65         0.45 ±0.06 38.57 ± 2.84 
G2 6.27 ± 0.79**(a)         0.99 ±0.18**(a) 13.85 ± 1.85**(a) 
G3 14.2 ± 1.46**(b)          0.43 ±0.08**(b) 29.48 ± 2.48**(b) 
G4 12.75 ± 0.87**(b)          0.49 ±0.16**(b) 26.76 ±2.45**(b) 
G5 11.98 ± 1.22**(b)         0.45±0.06**(b) 28.95± 2.76**(b) 
 
 Values are expressed as mean ± SEM. 
 Values were compared by using analysis of variance (ANOVA) followed 
by Newman-Keul's multiple range tests.   
 ** (a) Values are significantly different from normal control G1 at 
P<0.001. 
 
        ** (b) Values are significantly different from Diabetic control G2 at  P<0. 
As per table 4.1.2;b the HBA1-C was showed standard and 100, 200 mg of 
KC administrated in  Wister albino Rats. The control group was compaired in 
standard and treatment control (Group IV &V). The above table was  showed  100 
and 200 mg of KC, it was  reduced the HBA1-C level in standard control (gRoup III). 
The conclusion of the above results revealed that,  the significantly reduced HBA1-C. 
The standard control results showed haemoglobin  level 14.2 ± 1.46**(b) , HbA1-C 
level 0.43 ±0.08**(b) ; plasma insulin level -  29.48 ± 2.48**(b), was decreased  in 
compared in  treatment and  control groups ( Haemoglobin - 11.98 ± 1.22**(b); HbA1-
C - 0.45±0.06**(b);  plasma insulin level -  28.95± 2.76**(b)) . 
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4.1.2 ANTI  HYPERLIPIDEMIC ACTIVITY 
Table 4.1.2;a: Effect on siddha formulation KADUKKAI CHOORANAM in Lipid 
Profile 
 
GROUPS 
Total 
cholest
erol 
(mg/dl) 
Tri 
glyceri
des 
(mg/dl) 
HDL 
(mg/dl) 
LDL 
(mg/dl) 
VLDL 
(mg/d) 
AI 
LDL/ 
HDL 
Normal 
Control 
49.70 ± 
1.70 
57.10 ± 
0.90 
26.45 ± 
1.18 
14.30 ± 
0.76 
30.86 ± 
1.05 
0.87 ± 
0.50 
0.54 ± 
Cholesterol 
Control 
115.40 
± 
1.56
**(a)
 
161.50 
± 
1.68
**(a)
 
11.90 
± 
0.65
**(a)
 
30.96 
± 
1.32
**(a)
 
13.05 
± 
0.70
**(a)
 
8.51 
± 
1.33
**(a)
 
2.60 
**(a)
 
Standard 
Control 
72.60 ± 
1.42
**(b)
 
82.10 ± 
1.80
**(b)
 
21.5 ± 
0.40
**(b)
 
20.05 ± 
0.76
**(b)
 
24.85 ± 
0.76
**(b)
 
2.34 ± 
2.33
**(b)
 
0.92 
**(b)
 
Treatment 
control 
(100mg) 
92.86 
± 
1.24
**(b)
 
114.40 
± 
1.96
**(b)
 
17.0 
± 
0.50
**(b)
 
25.25 
± 
0.60
**(b)
 
17.84 
± 
0.42
**(b)
 
4.39 
± 
1.48
**(b)
 
1.46
**(b)
 
Treatment 
control 
(200mg) 
83.85 ± 
0.94
**(b)
 
96.5 ± 
1.10
**(b)
 
20.30 ± 
1.28
**(b)
 
22.12 ± 
0.72
**(b)
 
21.25 ± 
0.52
**(b)
 
3.13 ± 
0.24
**(b)
 
1.08 
**(b)
 
  
RESULTS 
The reduction of plasma total cholesterol was associated with a decrease in its 
LDL fraction which is a major, potentially modiﬁable risk factor of cardio vascular 
disease and the target of drug. Many suggest that the cholesterol lowering activity of 
this product appears to be due to the enhancement of LDL – C catabolism through 
hepatic receptors (C.Vijaya et al.2009). In addition siddha formulation KADUKKAI 
CHOORANAMshowed protective action which is reported to have a preventive 
function against atherogenesis since an independent inverse relationship between 
blood HDL – C levels and cardio vascular risk incidence is reported.( T.Chidambaram 
et al.2007) .The mechanism of reduced hyperlipidemia  is the enhancement of 
Lecithin Cholesterol Acyl Transferase (LCAT) and inhibition of Hepatic Triglyceride 
Lipase (HTL) on HDL which may lead to a rapid catabolism of blood lipids through 
entero hepatic tissues. (A.E. Ahire et al. 2005),( L.Anila et al.2002).  It reported that 
triglycerides (M.A.Austin et al.1984) layed a key role in the regulation of lipoprotein 
interaction to maintain normal lipid metabolism. Indeed, the elevated plasma TG 
levels were associated with an increased .incidence of coronary artery disease . More 
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over these higher plasma TG levels have been attributed mainly to increase population 
of small, dense LDL deposits which are very atherogenic  and enhanced cholesteryl 
ester mass transfer from apolipoprotein containing lipoproteins (VLDL , LDL and 
TG) has also been proposed to be major determined of cholesteryl esteriﬁcation, its 
transfer and HDL remodeling in human plasma. Administration of siddha formulation 
KADUKKAI CHOORANAM( KC) is provides a beneﬁcial action on rat lipid 
metabolism with regard to the reduction of AI. Infarct, the AI was decreased in all 
treated groups. Similar results were reported by others when studying the 
hypolipidemic effects of natural products. This ameliorative action was due to the 
plasma lipid lowering activity of different constituents of the formulation. 
As for table 4.1.1;a the lipid profile was showed stamdard and 100, 200 mg of 
KC administrated in  Wister albino Rats. The cholesterol control was compaired in 
standard and treatment control. The above table shows 100 and 200 mg of KC, it was 
compaired to reduced the lipid level in standard control. The conclusion of the above 
results refined significantly reduced lipid profile.  
Standard control showed : Total cholesterol - 72.60± 1.42
**(b) 
; Tri glycerides -  
82.10 ± 1.80
**(b) 
; HDL - 21.5 ± 0.40
**(b) 
; LDL - 20.05 ± 0.76
**(b)  
; VLDL - 24.85 ± 
0.76
**(b) 
; VI -2.34 ± 2.33
**(b) 
; LDL/HDl -0.92 
**(b) 
, and Treatment control showed ; 
Total cholesterol - 83.85 ± 0.94
**(b) 
; Tri glycerides -  96.5 ± 1.10
**(b)
; HDL - 20.30 ± 
1.28
**(b)) 
; LDL - 22.12 ± 0.72
**(b)
;  VLDL - 21.25 ± 0.52
**(b)
; VI -3.13 ± 0.24
**(b) 
; 
LDL/HDl - 1.08 
**(b)
. The Values are found\ by using ONE WAY ANOVA followed 
by Newman Keul‟s multiple range tests.** (a) values were significantly different from 
normal control at P< 0.01.** (b) Values were significantly different from 
hyperlidemic control at P< 0.01.  In Table no 4.1.1;a. the end of result found, after the 
treatment of Kadukkai choornam, TC, Triglycerides & LDL was decreased in 
treatment control (Group IV,V), it was compared  Group I,II and III standard control . 
 
 
 
 
63 
 
4.1.3 PHYTOCHEMICAL STUDY:  
The KADUKKAI CHOORANAMwas subjected to qualitative chemical 
investigation details of the various tests performed for the presence of phyto constituents 
is shown in Table 4. 1.3.a. The structural characterization of the herbal drugs is need of 
the hour and the objective is to establish the elemental and structural characteristics of 
KADUKKAI CHOORANAM. Although, many research works has been  done  the 
herbal drugs.So, performed standardization, structural standardization, Physio and 
phytochemical parameters is very nesceessiate  to stantardization of KADUKKAI 
CHOORANAM. 
Table 4.1.3;a: Phyto chemical tests for KADUKKAI CHOORANAM 
TEST INFERENCE 
 
Mayer‟s test  
Dragendroff‟s test  
Hager‟s test  
 
 
 
Alkaloids 
Present 
 
Present 
 
Present 
 
Molisch test  +ve  
Legal‟s test  +ve  
Borntrager‟s test for anthraquinones  +ve  
 
       Carbohydrates  
         and  
        Glycosides 
 
Present 
 
Present 
 
Present 
Liebermann-Burchard test  
Salkowski test  
 
 
 
Phytosterols 
 
Present 
 
Present 
 
Shinoda test  
Magnesium turnings and hydrochloric acid  
Fluorescence test  
 
 
Flavanoids 
 
 
 
Present 
 
Present 
 
Present 
Ferric chloride test  
Potassium dichromate test  
Lead acetate test  
 
 
TANNINS 
 
 
 
Present 
 
Present 
 
Present 
 
Millon‟s test  
Biuret test  
PROTEINS 
Present 
 
Present 
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Above the 4.1.3.a results are, the presence of phytochemical Alkaloids, 
Carbohydrates and Glycosides, Phytosterols. Flavanoids, Tannins, Proteins and Fixed 
oils and Fats, Lignin, Saponins are absence from this study. 
4.1.4 ANALGESIC ACTIVITY 
Acetic acid-induced writhing response 
The different doses of siddha formulation KADUKKAI CHOORANAMhad 
significant analgesic effects in  animals models.The results of  100 and 200 mg/Kg  of 
kadukkai choornam waa significantly reduced,it was compared the modern medicine 
Diclofenac sodium.(Table 4.1.4;a). 
 
Table No;4.1.4;a- Effects of siddha formulation KADUKKAI CHOORANAM on 
acetic acid–induced writhing response (N=6 in each group). 
 
Groups Treatment 
(number of writhing 
movements) 
(Mean ± S.E) 
Percentage % 
Group I Distilled water 38.5±2.8 - 
Group II Diclofenac sodium 10mg/kg 6.5±0.6 83.11%** 
Group III 
100mg/kg KADUKKAI 
CHOORANAM 
12.0±1.3 68.83%** 
Group IV 
200mg/kg KADUKKAI 
CHOORANAM 
11.8±1.0 69.35%** 
 
 Values are expressed as mean ± SEM. 
        * (b) Values are significantly different from Toxic  control G2 at  P<0.01. 
 
Ninhydrin test  
 
 
Present 
 
Spot test  
Saponification test  
 
Fixed oils and fats 
Abscent 
Abscent 
 
Phloroglucinol test 
Lignin Present 
Frothing test 
Saponins Abscent 
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As for table 4.1.4;a The above table showed, 100 and 200 mg of KC, it was 
reduced the Pain level  compared in standard groups. The Number of writhing 
movements 6.5±0.6) and treatment groups writhing movements  was 11.8±1.0HbA1-
C - 0.45±0.06**(b);    
Discussion 
  
The analgesic activity was assessed by writhing test which has been reported 
to be useful for investigation of peripheral antinociceptive activity and performed as a 
chemical pain model (IV, V). The siddha formulation KADUKKAI CHOORANAM 
demonstrated a dose-dependent, significant antinociceptive activity in animal models 
of pain. Acetic acid believed to increase the PGE2 and PGF2α in peritoneal fluid (6). 
The analgesic activity shown in models of pain is indicative that siddha formulation 
KADUKKAI CHOORANAMmight possess centrally and peripherally mediated 
antinociceptive properties.  
Chemical components of siddha formulation KADUKKAI 
CHOORANAMsuch as flavonoids, saponins or phenolic compounds may be 
responsible for the antinociceptive activities of this formulation. Since the findings of 
this study revealed a significant analgesic effect of the siddha formulation 
KADUKKAI CHOORANAM, it can be concluded that terpenoids and specially 
saponins of siddha formulation KADUKKAI CHOORANAMmay be responsible for 
the observed analgesic effect which should be proved by further investigations. 
  
4.1.5 TOXICITY STUDY 
4.1.5.1 Acute Toxicity study for Kadukkai Chooranam:  
 
In the acute toxicity study was carried out the female and male and albino 
mice. All the study animals are feded by oral dose 50, 100,200 and 400 mg of 
KADUKKAI CHOORANAM for 60 days. At the end of the study, the animals were 
sacrificed and assessed by the effect of KADUKKAI CHOORANAM. The body 
weight and relative organs, hematological, biochemical and histopathological 
parameters are noted. The Acute toxicity and mortality ratio was given in Table 
4.1.5a.  
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Table No: 4.1.5;a;- Sign of Acute toxicity  and mortality ratio :      
 Dose (mg.kg
-1
) Sign of Toxicity (ST.NB
-1
) Mortality (D.S
-1
) 
Group I              0                      0/3            0/3 
Group II            300                      0/3            0/3 
Group III           2000                      0/3            0/3 
 
ST- sign of toxicity; NB- normal behavior; D- died; S- survive.  Values are 
expressed as number of animals (n=3). 
                   There was no mortality or morbidity were observed in three group of 
animals, during 14-days period in single daily dose administered 50, 300, 2000 
mg/kg/bw (Table-4.1.5.a). The animals did not shows no changes in the general 
physical appearance during the observation period. Morphological characteristics 
such as skin, eyes and nose  were appeared in normal and  no tremors, convulsion, 
salivation, diarrhea, lethargy or unusual behaviors were observed.   Gait and posture, 
reactivity to handling or sensory stimuli, grip strength was also normal in state. 
 
4.1.5.2; SUB ACUTE TOXICITY STUDY 
   
 The effect of KC was observed, the effect on the body weight changes, 
significant increase (p<0.05) in body weight in all the treated animals were observed. 
The values are expressed as mean ± S.E.M. n=6. The results of group I were 
compared with other groups such as II, III, IV, and V.   The statistical analysis was 
carried out using one way ANOVA method, where **P<0.01 *P<0.05(Table 4.1.5. b). 
Table4.1.5.b The Effect on Sub acute study in body weight 
 
 
Treatment        Day 1 Day 07 Day 14 Day 28 
Control    185.15±6.8 185.45  ±6.20 194.15 ±6.35 194.7±6.58 
KC  50 mg.kg
-1
    192.30 ±6.4 191.30  ±6.30 196.25 ±6.70 196.30±6.72
*
 
KC 100 mg.kg
-1
    184.35 ±5.7 187.30  ±6.40 194.55  ±7.10 195.36±6.30
*
 
KC 200 mg.kg
-1
   193.30  ±7.2 193.15±6.50 193.90  ±7.20
**
 204.45±7.26
**
 
KC 400 mg.kg
-1
  185.65  ±6.05 190.15 ±5.60 193.60  ±6.35
**
 205.66±7.38
**
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The Sub acute Effect of KADUKKAI CHOORANAM on  internal organs in rats  
 The effects of KC on kidney, heart, liver and brain of the rats were recorded. 
From the significant (p<0.01) changes in the weights of various organs of the animals 
occurred with higher doses of the extract (400 mg.kg
-1
 bwt), but macroscopic 
examinations visualized   no changes in color of the organs of the treated animals 
compared with the control group. The statistical analysis was carried out using one 
way ANOVA method, where **P<0.01.The results are expressed  in Table.4.1.5.c. 
      Table No.4.1.5.c. Changes in internal organs 
                    Treatment Heart (gms) Kidney 
(gms) 
Liver (gms) Brain (gms)   
Control 0.34 ± 0.05 0.64± 0.03 3.30± 0.05 0.65± 0.05 
KC  50 mg.kg
-1
 0.35± 0.02 0.80± 0.03 3.42± 0.03 0.68± 0.3 
KC 100 mg.kg
-1
 0.36± 0.06 0.78± 0.04 3.34±0.02 0.66± 0.2 
KC 200 mg.kg
-1
 0.35± 0.04 0.73± 0.02 3.32± 0.02 0.73± 0.05 
KC 400 mg.kg
-1
 0.34± 0.03 0.74± 0.03 3.35± 0.03 0.75± 0.05 
 
Sub acute effect of KADUKKAI CHOORANAM on lipid profile in rats   
Table.4.1.5.dThe effect of KC on biochemical parameters .  
Treatment 
Glucose 
(mg.dl
-1
) 
Cholesterol 
(mg.dl
-1
) 
Triglyceride 
(mg.dl
-1
) 
HDL 
(mg.dl
-1
) 
LDL 
(mg.dl
-1
) 
Control 92.65± 0.62 37.62± 0.56 26.25± 0.45 133.25± 0.55 82.15±1.72 
KC 50 mg.kg-1 90.50± 0.56 23.85± 0.25
*
 11.22± 0.23
*
 173.28±0.65
*
 69.59±1.28 
KC  100 mg.kg-1 87.45± 0.47 24.74± 0.26* 13.42± 0.28* 163.18±0.78* 67.84±1.10 
KC  200 mg.kg-1 88.25±0.55
**
 31.18± 0.30 15.84± 0.38
*
 182.30±0.84
*
 46.60±1.30 
KC  400 mg.kg-1 84.25±0.45
**
 30.78± 0.28 17.28± 0.34
*
 180.2± 0.85
*
 44.50±0.84 
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The effect of KC on various biochemical parameters of the experimental 
animal „rats‟ were tested.  From the study it was evident that, there was significant 
decrease (p<0.05) in the plasma glucose level in treated rats especially at higher dose 
(400 mg.kg
-1
) compared with control rats.   The control rats were administered only 
with 5 ml of normal saline.   Significant decrease (p<0.05) in the plasma total 
cholesterol (TC), triglyceride (TG) and LDL-cholesterol levels were observed.   But a 
significant increase (p<0.05) in HDL-cholesterol levels were observed in all the 
treated animals compared with the control studies, AST, ALT and ALP levels were 
also normal in the KC used animals. From the results of biochemical study there was 
no evidence of Sub acute toxicity associated with the administration of higher 
concentration of KC.  
 
 Changes in hepatic enzymes 
Table 4.1.5e .The AST, ALT, ALP, TP and Albumin values was  compared in Group 
I  and other groups II, III, IV, and V.  The statistical analysis was carried out using 
one way ANOVA method, where determined **P<0.01 *P<0.05. 
Table.4.1,5.e; The results and  effects of KC on biochemical parameters such as 
AST, ALT, ALP, TP and Albumin in rats are, 
 
 
 
Effect of KADUKKAI CHOORANAM on Hematological parameters 
in rats; 
The effects of KC were observed for its effect on hematological parameters in 
experimental rat. Final study, a significant increased (p<0.01) in the 
haemoglobin,RBC  values are increased after  treated groups.There was no significant 
Treatment 
AST 
(IU.l
-1
) 
ALT 
(IU.l
-1
) 
ALP 
(IU.l
-1
) 
TP 
(g.l
-1
) 
ALBUMIN 
(g.l
-1
) 
Control 326.5±12.40 69.5± 3.18 251.58± 8.80 67.85± 3.32 37.15±2.35 
KC 50 mg.kg
-1
 315.0±9.50
**
 67.5± 2.20
**
 264.10± 2.75
**
 68.30± 2.32 34.30±2.65 
KC  100 mg.kg
-1
 316.3±7.20
**
 65.1± 3.15
**
 258.18± 6.70
**
 78.15± 2.82 36.30±3.05 
KC 200 mg.kg
-1
 311.4±7.95 60.4± 2.90 263.00± 5.20 67.25± 3.32 38.20±2.75 
KC 400 mg.kg
-1
 321.2± 8.20 62.3± 3.52 267.40± 4.40 72.05± 2.58  37.48±2.70 
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changes  in the calcium level in all the treated animals compared to the control.  The 
values are expressed as mean ± S.E.M. n=6. The results of group I were compared 
with other groups such as II, III, IV and V.  The statistical analysis was carried out 
using one way ANOVA method, where *P<0.05 (Table.4.1.5.f). 
 Table.4.1.5.f The effect of KADUKKAI CHOORANAM on hematological 
parameters 
Treatment 
Haemoglobin 
(g.dl
-1
) 
RBC 
(10
6
 /mm
3
) 
WBC 
(10
6 
/mm
3
) 
Calcium 
(mg.dl
-1
) 
Control 13.3± 0.25 9.10± 0.02 11.4± 0.05 9.40 ±0.02 
KC  50 mg.kg-1 14.5± 0.26
*
 9.45± 0.04
*
 9.5± 0.01
*
 9.16 ±0.02 
KC 100 mg.kg-1 14.3± 0.15
*
 9.50± 0.02
*
 8.3± 0.32
*
 9.22 ±0.20 
KC 200 mg.kg-1 12.7± 0.20
*
 8.28± 0.12
*
 11.4± 0.03
*
 9.56 ±0.13 
KC 400 mg.kg-1 13.5± 0.35
*
 8.46± 0.45
*
 10.5± 0.13
*
 9.70 ±0.02 
 
DISCUSSION 
The acute toxicity study of KADUKKAI CHOORANAM(KC)was carried out 
as per OECD-423 guidelines, no mortality was observed in  control group as well as 
treated groups animals,maximum dose of 2000 mg.kg
-1 
 was not produced toxicity.  
Hence, 1/10
th
 of 2000 mgkg
-1
 i.e. 200 mg.kg
-1
 of dose was selected as a minimum 
dose for acute  toxicity study.  The results of sub acute toxicity study showed that 
treated animals were normal  in growth pattern and body weight compared with 
control rats treated with normal saline. So, the changes in body weight can be used as 
an indicator of adverse effects of drugs and chemicals. Serum cholesterol and proteins 
mainly regulated via synthesis in the liver and increase or decrease in serum 
concentrations of constituents suggest liver toxicity.  All test animals were subjected 
to gross necropsy .There was a slight decrease in plasma glucose level, when higher 
doses of KC (400 mg.kg
-1
) were administered in the treated rats..The significant 
increase in the levels of hemoglobin (Hb) was found in treatment with KADUKKAI 
CHOORANAM(KC) with a higher dose of 200mgkg
-1
. The possible reason could be 
that one of the constituents KC may increase absorption of iron.  
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4.1.6: FTIR and EDAX ANALYSIS 
4.1.6.1; Scanning electron microscopic study (SEM) 
  The Scanning electron microscopy is a complementary technique and shows 
the nature of kadukkaichooranam and its particle size(Bruneton,J., 
1995). Pharmacognosy, Phytochemistry, Medicinal Plants)
[7]
.Sample for SEM 
analysis were mounted on the specimen  using carbon adhesive sheet. Small sample 
were mounted with 1sq. cm glass slide And kept in carbon adhesive sheet. Samples 
were coated with gold to a thickness of 100 AO using Hitachi vacuum evaporator. 
Coated sample were analysed in a Hitachi Scanning electron Microscope 3000 H 
model.  
Elemental analysis by EDAX  
EDAX  was  used for multiple sampling in various parts of the plant and can 
also provide information from an area of fewer manometers. This is very useful to 
characterize the crystals and other inclusions like trace elements present in the given 
sample KADUKKAI CHOORANAM( World Health Organization, Geneva, 2007).  
4.1.6.2 Fourier Transform – Infra Red Spectroscopy Study (FTIR)  
The  FT-IR Spectrometer was carried out in KBr Pellet  methods 
(Sathyanarayana B,2011) About 1/8th of the solid powder of Kadukkaichooranam 
was taken on a microspatula and about 0.25-0.50 teaspoons of KBr was added and 
thoroughly ground in an agate mortar with the pestle until Kadukkaichooranam 
became very fine. It was placed in a pellet die. The sample was pressed at 5000-
10,000 psi and the sample was removed carefully from the die and placed in the FTIR 
sample holder (Chattopadhyay, R.R. and S.K. Bhattacharyya, 2007)
 
. The computer 
was turned on and the software was launched and certain fine details of the working 
method were done. The sample was placed on Zn,Se crystal with a spatula until the 
pressure marker showed. The  values are recorded.  
Results and Discussion 
The results of Scanning electron microscope in two different view and EDAX Trace 
elements profile & FT-IR data has compiled as follows, 
71 
 
Scanning Electron Microscope Analysis  
The SEM picture (Fig. 4.1.6.a) is under 1.00 KX resolution and the examining 
area of 800x800μm2 surface were taken for the samples (SarafASamant A 2013) . 
The surface of the sample is marked with cluster arrangement and in agglomerates 
form (Bruneton, J., 1995). The above SEM images showed average Particle Size 
ranges from 101 μm to 1115μm. In 100mu view, the surface of the sample grains is 
uniformly arranged in agglomerates. Particle Size ranges from 107 μm to 1244μm 
(Fig;4.1.6.b) and overall particles shape and angles are representd in Ferrets graph. 
 
Figure 4.1.6.a. SEM image of Kadukkaisuranam of 10 µm view 
Figure.4.1.6.b; SEM image of Kadukkaichooranam of 100 µm view 
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Elemental Quantification of Kandukkaichooranam by EDAX 
 The elemental quantification of Kaddukaichooranam was done by  EDAX 
method (Kesarla Mohan kumar et al,).The overall trace elements like Calcium, 
potassium has almost 4.3%, 2.5% of Oxygen and Potassium, 2.5% Magnesium & 
Hydrogen as the major compounds  were found the results. Figure 4.1.6.c. 
Identification of trance elements through EDAX 
 
Figure.4.1.6.c Graaphical representation of EDAX profile of KADUKKAI 
CHOORANAM(in percentage) 
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Figure ;4.1.6.d; FTIR Spectra of KadukkaiChooranam 
 
Table .4.1.6.A. FTIR observed Peak value of Kadukkaichooranam 
Wave 
number  
(cm-1) 
Vibration modes of 
sample in IR region 
Intensity of the 
bond 
Functional groups 
1708.93 C=O Stretching strong conjugated aldehyde 
1616.35 C=C stretching Strong α,β-unsaturated ketone 
1535.34 N-O stretching Strong nitro compound 
1450.47 C-H bending Medium Alkane 
1336.67 S=O stretching Strong Sulphonamide 
1205.51 C-O stretching strong alkyl aryl ether 
1033.85 S=O stretching Strong Sulfoxide 
873.75 C-Cl stretching Strong Halogen compounds 
759.95 C=C bending Strong Alkene 
518.85 C-Br bending week Alkyl 
In FT-IR Spectra analysis, the specified drug Kadukkaichooranam has exhibits 
the FTIR Spectra values and peak value at 1708.93 has C=O Stretching , 1616.35 has 
C=C stretching, 1535.34 has N-O stretching, 1450.47 has C-H bending, 1336.67, 
1205.51 has C-H bending, 1033.85 has S=O stretching, 873.75 has C-Cl stretching, 
759.95 has C=C bending, 518.85 has C-Br bending.So,KC is contains conjugated 
aldehyde, α,β-unsaturated ketone, nitro compound, alkane, sulphonamide, alkyl aryl 
ether, sulfoxide, Halogen compounds, Alkene and Alkyl compounds were observed  
respectively( Ahn, M.J., C.Y. Kim, J.S. Lee, T.G. Kim and S.H. Kim et al., 2002). 
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4.2 .IN CLINICAL STUDY: 
The results were observed with respect to the following criteria by clinical 
study on 20 out patients and 20 In patients of both sexes. The criteria were. 
1. Distribution of Gender  
2. Distribution of Age  
3. Distribution of Educational  
4. Distribution of Occupation  
5. Distribution of Religion  
6. Distribution of Marital Status 
7. Distribution of Clinical Manifestation  
8. Distribution of Duration of Illness  
9. Distribution of Family History 
10. Distribution of History of Previous Treatment of Madhumegam  
11. Distribution of Personal History 
12. Distribution of Socio-Economical Status 
13. Distribution of Other System Involvement 
14. Distribution of Body Mass Index 
15. Distribution of Constitution of Body 
16. Distribution of Gunam 
17. Distribution of Kaalam 
18. Distribution of Paruva Kaalam 
19. Distribution of Thinai 
20. Distribution of Mukkutram 
a). Derangement of Vatham  
b). Derangement of Pitham  
c). Derangement of Kapham 
21. Distribution of Involvement of Udal Thathukkal  
22. Distribution of Kanmenthiriyam  
23. Distribution of Imporigal (Gnanendrium) 
24. Distribution of Kosam 
25. Distribution of Conditions of Envagai Thervugal  
26. Distribution of Neer Kuri  
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27. Distribution of Nei Kuri  
28. Distribution of Laboratory Analysis  
                  a). HbA1C 
b). Blood Glucose  
c). Lipid Profile 
29. Changes in diagnostic findings before and after treatment 
a) Changes in Nerve conduction study and Neuropathic pain score  
b) Changes in HbA1C, Blood Sugar and Lipid Levels before and after       
treatment 
       c). Changes in Body Mass Index  
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1. DISTRIBUTION OF GENDER 
 
       TABLE-1 DISTRIBUTION OF GENDER 
   Sex 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Male 11 55% 14 70% 
2. Female 09 
 
45% 
06 30% 
Total 20 100% 20 100% 
 
 
       FIGURE-1 DISTRIBUTION OF GENDER 
 
 
 
 
 
 
 
 
 
 
 
 
In 40 patients included in the study Akkini Selathumam is not equally 
distributed in both sexes. Table shows among 20 OP patients 45% were female and 
55% were male, among 20 IP patients 70% were male 30% were female.  
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2. DISTRIBUTION OF AGE  
 
 TABLE-2DISTRIBUTION OF AGE 
Sl. 
No. 
Age group 
(In years) 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. 40-50 05 25% 04 20% 
2. 51-60 12 60% 09 45% 
3. 61-70 03 15% 07 35% 
Total 20 100% 20 100% 
 
FIGURE-2DISTRIBUTION OF AGE 
 
 
The highest incidence was in Akkini Selathumam. Among the 20 OP and 20 
IP patients observed 60% and 45% were affected in age group of 51-60 years, age 
group of 61-70 closely followed and given among 20 patients in OP 15% were 
affected and among 20 patients in IP 35% were affected.  
 
 
 
 
 
0
2
4
6
8
10
12
14
40-50 51-60 61-70
Out Patients (OP)
In Patients (IP)
78 
 
0%
5%
10%
15%
20%
25%
30%
35%
40%
Illiterate Read & 
Write
Primary Middle 
School
High 
School
College Others
5% 5%
10%
30%
40%
10%
0%
10% 10%
35%
40%
10%
5%
0%
P
e
rc
e
n
ta
ge
Educational Status
3. .DISTRIBUTION OF EDUCATIONAL  STATUS   
 
TABLE-3 DISTRIBUTION OF EDUCATIONAL STATUS 
 
Sl. 
No. 
Educational 
Status 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Illiterate  1 5% 2 10% 
2. Read & Write 1 5% 2 10% 
3. Primary 2 10% 5 35% 
4. Middle School 6 30% 8 40% 
5. High School 8 40% 2 10% 
6. College 2 10% 1 5% 
7. Others - - - - 
Total 20 100% 20 100% 
 
FIGURE-3 DISTRIBUTION OF EDUCATIONAL STATUS 
 
 From the above table 3 and Fig 3. it is observed that highest incidence of 
Akkini Selathumam  among 20 out patients was attended high school with 40% and 
among 20 in patients was attended middle school with 40%. 
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4. DISTRIBUTION OF OCCUPATION 
 TABLE-4 DISTRIBUTION OF OCCUPATION 
Sl. 
No. 
Occupation 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Business 2 10% 1 5% 
2. Agricultural Labours - - 1 5% 
3. House wife 12 60% 9 45% 
4. Cook - - 2 10% 
5. Painter - - 2 10% 
6. Policeman/Army 2 10% - - 
7. Office worker 2 10% 1 5% 
8. Coolie Worker - - 4 20% 
9. Driver 1 5% - - 
10. Welding worker 1 5% - - 
Total 20 100% 20 100% 
 
FIGURE-4DISTRIBUTIONOFOCCUPATION 
 
The above Table no 4 & Fig 4. Showed the total Population employed in 
various occupations have observed the highest incidence of Akkini Selathumam.The 
result found   60% OP 45% IP patients were house wives.  
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5. DISTRIBUTION OF RELIGION 
 
 TABLE-5 DISTRIBUTION OF RELIGION 
Sl. 
No. 
Religion 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Hindu 16 80% 16 80% 
2. Christian 1 5% - - 
3. Muslim 3 15% 4 20% 
Total 20 100% 20 100% 
 
       
FIGURE-5 DISTRIBUTION OF RELIGION 
 
 
 
 
 
 
 
 
 
 
From the  table 5 and Fig no 5 reveals that  80% were Hindus, 15% were 
Muslims and 5% were Christians. 
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6. DISTRIBUTION OF MARITAL STATUS 
 
TABLE-6 DISTRIBUTION OF MARITAL STATUS 
Sl. 
No. 
Marital Status 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentag
e (%) 
No. of 
cases 
Percentag
e (%) 
1. Married 18 90% 15 75% 
2. Widowed 2 10% 5 25% 
3. Divorced - - - - 
4. Separated - - - - 
5. Single - - - - 
Total 20 100% 20 100% 
 
 
          
 FIGURE-6 DISTRIBUTION OF MARITAL STATUS 
 
 
 
 
 
 
 
 
 
 
The Table and Fig  no 6 showed.the  highest incidence is   90% in married  
and 10% in  Widowed at OPD .The  IPD was 75% and 25% respectively.  
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7. DISTRIBUTION OF CLINICAL MANIFESTATION 
TABLE-7DISTRIBUTION OF CLINICAL MANIFESTATION 
Sl. 
No. 
Clinical 
Manifestation 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Polyuria 17 85% 16 80% 
2. Polyphagia  15 75% 16 80% 
3. Polydipsia 15 75% 16 80% 
4. Nocturia 15 75% 14 70% 
5. Pain  19 95% 18 90% 
6. Burning sensation 20 100% 20 100% 
7. Numbness 20 100% 20 100% 
8. Tingling Sensation 18 90% 17 75% 
9. Loss of body weight 8 40% 7 35% 
10. Visual impairment 2 10% 7 35% 
11. Calf muscle pain 3 15% 2 10% 
12. Giddness 9 45% 11 55% 
 
FIGURE-7 DISTRIBUTION OF CLINICAL MANIFESTATION 
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From the above table 7 showed that 20 Out patients, 85% of cases had 
polyuria and 75%,polydipsia and 75% had Nocturia.  95% had pain, 100% Burning 
sensation, 100% had Numbness, 90% had Tingling Sensation, Loss of body weight 
40% . 10% had visual impairment, 15% had calf muscle pain. 100%  clinical 
symptoms were presentd in burning pain and  numbness.  
  The 80% of in patients cases had polyuria polydipsia and polyphagia, and 
100% had Burning sensation. 90% had pain, 70% nocturia, 100% had Numbness, 
75% had Tingling Sensation, 40% had loss of body weight, 35% had visual 
impairment, 10% had calf muscle pain and 55% had Giddiness. 
8. DISTRIBUTION OF DURATION OF ILLNESS 
 
 TABLE-8 DISTRIBUTION OF DURATION OF ILLNESS 
Sl. 
No. 
Duration of illness 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
3. 6 months -2 Years 6 30% 3 15% 
4. 2 Years - 4 Years 08 40% 07 35% 
5. 4 Years - 6 Years 6 30% 10 50% 
Total 20 100% 20 100% 
FIGURE-8 DISTRIBUTION OF DURATION OF ILLNESS 
 
According to Table  &Fig 8 showed that Akkini Selathumam was greatly noticed 
in the 40 patients were suffering with in madhumegam was incidence about  more 
than 2 years to 4 years. In IPD the percentage of  madhumegam  was 40% in OPD and 
35% in IPD. 
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9. DISTRIBUTION OF FAMILY HISTORY 
 
 TABLE-9 DISTRIBUTION OF FAMILY HISTORY 
 
Sl. 
No. 
Family History 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Paternal 6 30% 4 20% 
2. Maternal 4 20% 3 15% 
3.  Both 3 15% 1 5% 
4.  No family history 7 35% 12 60% 
Total 20 100% 20 100% 
 
 
FIGURE-9 DISTRIBUTION OF FAMILY HISTORY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The table & Fig no 9 showed the incidence   of Akkini selathumam in  family 
history were presence in OP 30% had paternal history, 20% had maternal history, 
15% had both and 35% had no family history.  Among IP 20%  of IP patient had 
paternal history, 15% had maternal history and 5% had both history. 
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10. DISTRIBUTION OF HISTORY OF PREVIOUS TREATMENT OF 
MADHUMEGAM 
 
TABLE-10 DISTRIBUTION OF PREVIOUS TREATMENT 
 
Sl. 
No. 
Previous 
Treatment 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Yes 18 90% 19 95% 
2. No 2 10% 1 5% 
Total 20 100% 20 100% 
 
 
FIGURE-10 DISTRIBUTION OF PREVIOUS TREATMENT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Table and Fig shows that 90% of OP and 95% of IP patients had a history 
of previous treatment for Madhumegam.  
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11. DISTRIBUTION OF PERSONAL HISTORY  
 
TABLE-11 DISTRIBUTION OF PERSONAL HISTORY 
 
Sl. 
No. 
Personal History 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. 
DIET 
Vegetarian 6 30% 7 35% 
Non Veg - - - - 
Mixed Diet 14 70% 13 65% 
 
 
 FIGURE-11 DISTRIBUTION OF PERSONAL HISTORY 
 
 
 
Table and Fig no 11.The Akkini selathumam was reported the  95% of OP and 
90% of IP patients have mixed diet. 
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12. DISTRIBUTION OF SOCIO-ECONOMICAL STATUS 
 
TABLE-12 DISTRIBUTION OF SOCIO-ECONOMICAL STATUS 
 
Sl. 
No. 
Socio-Economical 
Status 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. 
of 
cases 
Percentage 
(%) 
1. Upper High - - - - 
2. High 3 10% 1 5% 
3. Upper Middle 5 20% 2 10% 
4. Lower Middle 9 45% 7 35% 
5. Poor 2 10% 7 35% 
6. 
Very Poor or Below 
Poverty Line                                
1 5% 3 15% 
Total 20 100% 20 100% 
 
 
FIGURE-12 DISTRIBUTION OF SOCIO-ECONOMICAL STATUS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Among the 40 patients of the study group there is a marked percentage of the 
disease of the population of lower middle socio economic status in relative 
percentages of 45% were in OP and 35% were in IP.The heighest incidence was lower 
middle class peoples (Table no 12).  
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13. DISTRIBUTION OF OTHER SYSTEM INVOLVEMENT 
TABLE-13 DISTRIBUTION OF OTHER SYSTEM INVOLVEMENT  
Sl. 
No. 
System Involvement 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentag
e (%) 
No. 
of 
cas
es 
Percentage 
(%) 
1. Cardiovascular System - - - - 
2. 
Gastro Intestinal 
System 
2 10% 1 5% 
3. 
Musculo Skeletal 
System 
15 75% 18 90% 
4. 
Central Nervous 
System 
- - - - 
5. Respiratory System 3 10% 1 5% 
6. Endocrine system - - - - 
Total 20 100% 20 100% 
 
FIGURE-13 DISTRIBUTION OF OTHER SYSTEM INVOLVEMENT 
 
The table & Fig no 13 showed the System involvement  of Akkini selathumam 
were presence in OP 10% had GIT System, 75% had Musculo Skeletal System, 15% 
had both and 35% had no family history.   IP 90% of IP patient had Musculo Skeletal 
System, 15% had Respiratory System and 5% had both system involved. 
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14. DISTRIBUTION OF BODY MASS INDEX 
 
TABLE-14 BODY MASS INDEX 
 
Sl. 
No. 
 
Body Mass Index 
(Kg/m
2
) 
Out Patients 
(OP) 
In Patients (IP) 
No. of 
cases 
Percenta
ge (%) 
No. of 
cases 
Percentage 
(%) 
1. Under weight (<18.5) - - - - 
2. Normal  (18.5-24.9) 6 30% 3 15% 
3. Over weight (25.0-29.9) 5 25% 6 30% 
4. Obesity (30.0-39.9) 9 45% 11 55% 
5. Extreme obesity (>40.0) - - - - 
Total 20 100% 20 100% 
 
FIGURE-14 BODY MASS INDEX 
The table and Fig No 14 shows that the body mass index the 40 patients of the 
study group patients had normal BMI 30% in OP and 15% in IPD. 45% in OP and 
55% in IP patients had obesity (Class-I &II). 25% in OP 30%  in IP patients having 
(over weight) in Akkini Selathumam.  
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15. DISTRIBUTION OF CONSTITUTION OF BODY 
 
 TABLE-15 DISTRIBUTION OF CONSTITUTION OF BODY 
 
Sl. 
No. 
Constitution of body 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Pitha Vatham 11 55% 13 65% 
2. Pitha Kapham 09 45% 07 35% 
Total 20 100% 20 100% 
 
 
FIGURE-15  DISTRIBUTION OF CONSTITUTION OF BODY 
 
 
From the above table 14 and Fig no 14 was reveals that Akkini Selathumam 
have 20 Out patients were Pitha Vatha Thegi with 55%, Pitha kapa45%,  In IP 
patients Pitha Vatha Thegi with 65%,  Pitha Kapa Thegi with 35% were observed 
from this study. 
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16. DISTRIBUTION OF GUNAM 
 
 TABLE-16 DISTRIBUTION OF GUNAM 
 
Sl. 
No. 
Gunam 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Sathuvam - - - - 
2. Rajasam 20 100% 20 100% 
3. Thamasam - - - - 
Total 20 100% 20 100% 
 
FIGURE-16 DISTRIBUTION OF GUNAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From the above Table and Fig 16 is showed that highest incidence of Akkini 
selathumam among Out patients and In patients with cent percent belongs to Rajo 
Gunam. 
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17. DISTRIBUTION OF KAALAM 
 
 TABLE-17 DISTRIBUTION OF KAALAM 
 
Sl. 
No
. 
Kaalam 
Out Patients (OP) In Patients (IP) 
No. 
of 
cases 
Percentag
e (%) 
No. 
of 
cases 
Percentage 
(%) 
1. Vatham (1-33 Years) - - - - 
2. Pitham (34-66 Years) 15 75% 17 85% 
3. 
Kapham (67- 100 
Years) 
5 25% 3 15% 
Total 20 100% 20 100% 
 
FIGURE-17 DISTRIBUTION OF KAALAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table and Fig no 17  is  observed  from this study, the highest incidence of 
Akkini selathumam among 20 Out patients is in Pitha Kaalam with 75%, Kapha 
Kaalam with 25%. Among 20% In patients, is also Pitha Kaalam with 85%, Kapha 
Kaalam with 15%.  
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18. DISTRIBUTION OF PARUVA KAALAM 
TABLE-18 DISTRIBUTION OF PARUVA KAALAM 
 
Sl. 
No. 
Paruva Kaalam 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Elavenil Kaalam - - - - 
2. Muthuvenil Kaalam - - - - 
3. Kaar Kaalam - - 1 5% 
4. Koothir Kaalam 5 25% - - 
5. Munpani Kaalam 15 75% 2 10% 
6. Pinpani Kaalam - - 17 85% 
 Total 20 100% 20 100% 
 
FIGURE-18 DISTRIBUTION OF PARUVA KAALAM 
 
 
Table and Fig No 18  is the  highest incidence of Akkini Selathumam among 20 
Out patients highest  incidence of the disease is in Munpani Kaalam 75% and among 
20 In patient were in Pinpani Kaalam 85%. 
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19. DISTRIBUTION OF THINAI 
 
 TABLE-19 DISTRIBUTION OF THINAI 
 
Sl. 
No. 
Thinai 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Kurinji 1 5% 1 5% 
2. Mullai - - - - 
3. Marutham 18 90% 19 95% 
4. Neithal 1 5% - - 
5. Paalai - - - - 
 Total 20 100% 20 100% 
 
 
         
 FIGURE-19 DISTRIBUTION OF THINAI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table and Fig 19 showed that the  highest incidence of Madhumega Avathaigal-I 
among 20 Out patients were in the Marutham land  is  90% and among In Patients 
also affected in Marutham land with 95%. 
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20. DISTRIBUTION OF MUKKUTRAM 
(a). DERANGEMENT OF VATHAM 
 
TABLE-20 (a) DERANGEMENT OF VATHAM 
 
Sl. 
No. 
Derangement of 
Vatham 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Piraanan 05 25% 7 35% 
2. Abaanan 20 100% 20 100% 
3. Viyaanan 20 100% 20 100% 
4. Uthaanan 20 100% 20 100% 
5. Samaanan 20 100% 20 100% 
6. Naagan - - - - 
7. Koorman - - - - 
8. Kirukaran 15 75% 18 90% 
9. Devathathan - - - - 
10. Dhananjayan - - - - 
 
FIGURE-20 (a) CONDITION OF VATHAM 
 
The table and Figure no 20 (a) showed that among 20 out patients 100% were 
affected in  Viyaanan, Samaanan, Uthaanan and Abaanan; 75% were affected in 
kirukaran.  Among 20 In patients 100% were affected in Viyaanan, Samaanan, 
Uthaanan and Abaanan. 90% were affected in kirukaran. 
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20 (b) DERANGEMENT OF PITHAM  
 
 TABLE-20 (b) DERANGEMENT OF PITHAM 
 
Sl. 
No. 
Derangement of 
Pitham 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Analagam 20 100% 20 100% 
2. Ranjagam 20 100% 20 100% 
3. Sathagam 20 100% 20 100% 
4. Prasagam 6 30% 7 35% 
5. Aalosagam 1 5% 5 25% 
 
 
 FIGURE-20 (b) CONDITION OF PITHAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The  table and Fig no 20(b) is reveal  that among 20 Out patients 100% were 
affected in Analagam, Ranjagam and Sathagam pitham; 30% were affected in 
Prasagam; 5% were affected in Aalosagam; Among 20 In patients 100% were 
affected in Analagam, Ranjagam and Sathagam; 35% were affected in Prasagam; 25% 
were affected in Aalosagam pitham. 
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20(c) DERANGEMENT OF KAPHAM   
 
 TABLE-20 (c) DERANGEMENT OF KAPHAM 
 
Sl. 
No. 
Derangement of 
Kapham 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Avalambagam 20 100% 20 100% 
2. Kilethagam 20 100% 20 100% 
3. Pothagam - - - - 
4. Tharpagam - - - - 
5. Santhigam 13 65% 15 75% 
 
 
FIGURE-20 (c) DERANGEMENT OF KAPHAM  
According  Table and Fig no 20 (c).the Akkini selathumam was reported the  
20 Out patients 100% were affected in Avalambagam and Kilethagam; 65% were 
affected in Santhigam pitham. Among 20 In patients100% were affected in 
Avalambagam and Kilethagam 75% were affected in Santhigam. 
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21. DISTRIBUTION OF INVOLVEMENT OF UDAL THATHUKKAL 
 
TABLE-21 INVOLVEMENT OF UDAL THATHUKKAL 
 
Sl. 
No. 
Involvement of Udal 
Thathukkal 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Saaram 20 100% 20 100% 
2. Senneer 20 100% 20 100% 
3. Oon  13 65% 15 75% 
4. Kozhuppu 16 80% 17 85% 
5. Enbu 4 20% 5 25% 
6. Moolai - - - - 
7. Sukkilam / Suronitham 1 5% - - 
 
       
FIGURE-21 INVOLVEMENT OF UDAL THATHUKKAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table and Figure No 21 is showed  that among 20 Out patients and 20 In 
patients 100% were affected in Saaram and Senneer, 65% were affected in Kozhuppu 
and 20% were affected in Enbu.  Among 20 Out patients 100% were affected in 
Saaram and Senneer, 75% were affected in Kozhuppu and 20% were affected in Enbu 
thathu.  
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22. DISTRIBUTION OF KANMENTHIRIYAM 
 
TABLE-22 DISTRIBUTION OF KANMENTHIRIYAM 
 
Sl. 
No. 
Kanmenthiriyam 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Kai 05 25% 8 40% 
2. Kaal 20 100% 20 100% 
3. Vai - - - - 
4. Eruvai 12 60% 14 70% 
5. Karuvai - - - - 
 
 
FIGURE-22 DISTRIBUTION OF KANMENTHIRIYAM 
 
 
 Figure and Table.22 it is observed that among 20 Out patients, 100% were 
affected in Kaal, 65% in Kai and 60% in Eruvai.  Among 20 In patients 100% were 
affected in Kaal and 70% in Eruvai was affected. 
 
 
 
0
2
4
6
8
10
12
14
16
18
20
No. of cases in OP
No. of cases in IP
100 
 
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
Mei Vaai Kan Mooku Sevi
50%
5%
10%
0% 0%
25%
5%
20%
0%
5%
P
e
rc
e
n
ta
ge
Gnanenthirium
23. DISTRIBUTION OF IMPORIGAL(GNANENDRIUM)  
.   
TABLE-23 DISTRIBUTION OF IMPORIGAL (GNANENTHIRIUM) 
 
Sl. 
No. 
Gnanenthirium 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Mei 10 50% 5 25% 
2. Vaai 1 5% 1 5% 
3. Kan 2 10% 4 20% 
4. Mooku - - - - 
5. Sevi - - 1 5% 
 
 
  
FIGURE-23 DISTRIBUTION OF IMPORIGAL (GNANENTHIRIUM) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From the above table and Fig no.23 is showed that among 20 Out patients and 
20 In patients 50% and 25% were affected in Mei.  Among 20 Out patients 10% and 
20 In patients 20% were affected in Kan. 
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24. DISTRIBUTION OF KOSAM 
 
TABLE-24 DISTRIBUTION OF KOSAM 
 
Sl. 
No. 
Kosam 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Annamya Kosam 20 100% 20 100% 
2. Pranamaya Kosam 1 5% - - 
3. Manomaya Kosam 8 40% 7 35% 
4. Vinganamaya Kosam 6 30% 6 30% 
5. Anandamaya Kosam 1 5% - - 
 
 
FIGURE-24 DISTRIBUTION OF KOSAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
According to Table and Fig 24, is observed that among 20 Out patients 100% 
were affected in Annamaya Kosam, 40% were affected in Manomaya Kosam and 
30% affected in Vinganamaya kosam.  Among 20 In patients, 100% were affected in 
Annamaya Kosam, 35% were affected in Manomaya Kosam and 30% were affected 
in Vinganamaya Kosam affected. 
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25. DISTRIBUTION OF CONDITIONS OF ENVAGAI THERVUGAL 
 
TABLE-25 DISTRIBUTION OF CONDITIONS OF ENVAGAI THERVUGAL 
 
Sl. 
No. 
Conditions of 
Envagai Thervugal 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. 
Naadi (Thontha Naadi) 
3). Pitha Vatham 11 55% 13 65% 
4). Pitha Kapham 9 45% 7 35% 
2. Sparisam 10 50% 5 25% 
3. Naa 12 60% 15 75% 
4. Niram 6 30% 7 35% 
5. Mozhi - - 2 10% 
6. Vizhi 2 10% 4 20% 
7. Malam 6 30% 6 30% 
8. Moothiram 15 75% 14 70% 
 
From the table no.25 is observed that among 20 Out patients 55% had Pitha 
Vatha Naadi, 45% had  Pitha Kapha Naadi, 100% were affected in Naa and 
Moothiram; 50% were affected in Sparisam; 30% were affected in Niram and Malam; 
10% were affected in Vizhi. Among 20 In patients 65% had Pitha Vatha Naadi, 35% 
had Pitha Kapha Naadi; 100% were affected in Naa and Moothiram; 25% were 
affected in Sparisam;35% were affected in Niram; 30% were affected in Malam; 20% 
were affected in Vizhi 
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26. DISTRIBUTION OF NEER KURI 
 
TABLE-26 DISTRIBUTION OF NEER KURI 
 
Sl. 
No. 
Neer Kuri 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Niram (crystal clear)  11 55% 9 45% 
2. Manam (honey odour) 6 30% 4 20% 
3. Edai  - - - - 
4. Nurai (present) 7 35% 5 25% 
5. Enjal - - - - 
 
FIGURE-26 DISTRIBUTION OF NEER KURI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
According to table and Fig no 26 showed that, among 20 Out patients 55% 
were affected in Niram; 30% were affected in manam; 35% were affected in 
Nurai.Among 20 In patients 45%  were affected in Niram; 20%  were affected in 
Manam and Nurai. 
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27. DISTRIBUTION OF NEI KURI 
 
 TABLE-27 DISTRIBUTION OF NEI KURI 
 
Sl. 
No. 
Nei Kuri 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
2.  Pitha vaatha Neer  11 55% 13 65% 
3. Pitha Kapha Neer 9 45% 7 35% 
                   Total 20 100% 20 100% 
 
FIGURE-27 DISTRIBUTION OF NEI KURI 
# 
 
 According to Table and Figure no 27,the 20 OP patients showed 55% of Pitha 
vatha Neer; 45% of Pitha Kapha Neer. Among 20 IP patients showed 65 of Pitha 
vatha Neer ; 35% of Pitha Kapha Neer was affected  in Akkini selathumm.  
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28. DISTRIBUTION OF LABORATORY ANALYSIS  
 
28 (a) HbA1C 
   
 TABLE-28(a) PERCENTAGE OF HbA1C 
 
Sl. 
No. 
HbA1C 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Good Control (4-6%) - - - - 
2. Moderate Control (7-8%) 4 20% 8 40% 
3. Poor Control (>8) 16 80% 12 60% 
Total 20 100% 20 100% 
 
FIGURE-28(a)  PERCENTAGE OF HbA1C 
 
 
 
 
 
 
 
 
The table 28(a) is showed  among 20 out patients 80% had poor control and 
20% had fair control, among 20 In patients 60% had poor control and 40% had 
moderate control of HbA1C in recruitment of study. 
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28 (b) LIPID PROFILE   
 
TABLE-28(b) LIPID PROFILE 
 
Sl. 
No. 
Lipid Profile 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percenta
ge (%) 
No. of 
cases 
Percentage 
(%) 
1. 
Total Cholesterol 
Normal (>200) - - 6 30% 
Borderline high (200-239) 10 50% 9 45% 
High (>240) 10 50% 5 25% 
2. 
LDL Cholesterol (mg/dl) 
Normal (<100) 1 5% 1 5% 
Above optimal (100-129) - - 9 45% 
Borderline High (130-159) 12 60% 8 40% 
High (160-189) 7 35% 1 5% 
Very High (>190) - - 1 5% 
3. 
HDL Cholesterol (mg/dl) 
Low (<40) 10 50% 8 40% 
Normal (40-60) 10 50% 10 50% 
High (>60) - - 2 10% 
4. 
Triglyceride (mg/dl) 
Optimal (<150) 2 10% 6 30% 
Borderline (150-199) 10 50% 7 35% 
High (200-499) 8 40% 7 35% 
Very High (>500) - - - - 
5. 
VLDLCholesterol (mg/dl)  
Normal (<40) 11 55% 15 75% 
High (>40) 9 45% 5 25% 
 
A major ratio of the 40 patients included in the study had total cholesterol 
within the range of borderline and  LDL level was above optimal,triglycerides  is 
borderline  and HDL and VLDL  are normal.  
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29. CHANGES IN DIAGNOSTIC FINDINGS BEFORE AND AFTER 
TREATMENT 
29(a) Changes in Electro diagnostic findings and Neuro pathic -   pain score 
levels  
Table 29(a): Electro diagnostic findings of patients with  Diabetic neuropathy 
before and after treatment (N = 8) 
 
Electro diagnostic study  
Mean ± SD 
(Before)  
Mean ± SD 
(After)  
     P value  
NCV- Peroneal Nerve (m/sec)  44.87 ± 4.38 46.37 ± 4.35  0.041 
NCV- Tibial Nerve (m/sec)  41.75±3.37 45.35±5.63 0.018 
Distal Latency- Sural Nerve (millisecond)  3.25 ±0.39 3.00 ±0.43 0.017 
Sensory Amplitude- Sural Nerve (microvolt)  12.12± 6.53 13.00± 5.99 0.109 
Motor Amplitude- Proneal Nerve (microvolt)  1.55± 1.08 1.91 ±1.16 0.018 
Motor Amplitude- Tibial Nerve (microvolt)  2.17 ±1.03  2.78 ±0.08 0.016 
 
 Table 29 (a) was showed Significant improvements were documented in nerve 
conduction velocity and motor amplitude of common peroneal and tibial nerves. In 
addition, the distal latency of sural nerve was significantly improved after three 
months.  
 
 
 
 
 
 
 
 
 
 
 
108 
 
29(b)- NEUROPATHIC PAIN SCORE  
29.b DISTRIBUTION OF NEUROPATHIC-PAIN SCORE 
TABLE 29 (c) NEUROPATHIC-PAIN   
TABLE 29(d) NEUROPATHIC-PAIN 
SCORE CHART FOR IN-PATIENT      SCORE CHART FOR OUT-PATIENT 
O/P NO 
   
AGE 
NEUROPATHIC-PAIN 
SCORE  
 
I/P 
NO 
   
AG
E 
NEUROPATHIC-PAIN SCORE  
DUR
ING 
1ST 
VISI
T 
FOLL
OWI
NG 1 
mont
h 
END OF 
THE 
TREAT
MENT 
 
DURI
NG 
1ST 
VISIT 
FOLLO
WING 1 
month 
END OF 
THE 
TREATME
NT 
38680 55 8  2 3 
 
1281 55 7 1  2 
38599 59 7  1 2 
 
1324 59 7 2 3 
38871 60 8  4 3 
 
1379 60 8 2  4 
39099 59 7  3 2 
 
1391 59 7 1  2 
41759 58 8  3 5 
 
1652 58 8 2 2 
42633 61 6  3 4 
 
1804 61 8  1 2 
44668 52 7  1 2 
 
1926 52 7 1  3 
44644 40 5  1 2 
 
1942 40 6 2  1 
45076 54 8  2 3 
 
2036 54 6 2  3 
49053 49 8  2 3 
 
2162 49 5 2  2 
50529 65 9  4 7 
 
2300 65 5 1 1 
51787 58 7  1 2 
 
2397 58 7  1 2 
52435 50 9  2 3 
 
2711 50 8 2  3 
68789 40 6  1 2 
 
2783 40 6  1 2 
63112 42 7  1 2 
 
2810 42 5  0 1 
63732 54 7  1 2 
 
1379 54 7 1  2 
68002 65 7  2 3 
 
3014 65 5 1  2 
103590 56 6  1 2 
 
351 56 5 1  2 
11871 59 7  2 2 
 
458 59 7 2  3 
14898 52 5  1 2 
 
459 52 8 2  3 
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FIGURE 29(c) NEUROPATHIC-PAIN SCORE OUT-PATIENT 
 
 
FIGURE 29(d) NEUROPATHIC-PAIN SCORE IN-PATIENT  
 
 
Table  and FIG 29(c,d) was showed, Detailed information on patients' basic 
characteristics is summarized  Neuropathic pain scores reduced significantly one 
month and three months after the intervention.  
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OUT-PATIENT CASE SHEET: 20 PATIENTS TREATED IN OP FOR AKKINI SELATHUMAM 
Sl.
No
. 
OP No. Name 
Age/
Sex 
Occupation 
Duration of 
Illness 
Date of Onset of 
Treatment 
Date of 
Tremination 
of Treatment 
Total 
Days 
Results 
1. 38680 V.VEALLAMBAL 55/F House wife 5 Years 30.04.2018 29.07.2018 90 Good 
2. 38599 S.PERUMAL 59/M Business 6 Years 30.4.2018 2.08.2018 92 Good 
3. 38871 S.MUMTAJ 60/F House wife 1 Year 01.5.2018 05.08.2018 93 Good 
4. 39099 P.SUBRAMANI 59/M Business 3 Years 2.5.2018 01.08.2018 90 Moderate 
5. 41759 K.RAJASUNDARY 58/F Police 3 Years 11.5.2018 08.08.2018 91 Good 
6. 42633 V.SORNAM 61/F House wife 1 Year 14.5.2018 21.08.2018 97 Good 
7. 44668 K.SELLAMMAL 52/F Post master 5 Years 22.5.2018 26.08.2018 96 Good 
8. 44644 T.NALLASAMY 40/M Police 6 Years 22.5.2018 20.08.2018 91 Good 
9. 45076 S.JAYA 54/F House wife 2.5 Years 23.5.2018 22.08.2018 91 Good 
10. 49053 G.KASIVISVANATHAN 49/M Clark 3 Years 08.06.2018 08.09.2018 90 Moderate 
11. 50529 T.THANKAMANI 65/F Beedi maker 5 Year 14.06.2018 13.09.2018 90 Good 
12. 51787 V.SAROJA 58/F House wife 3 Years 19.07.2018 16.10.2018 88 Good 
13. 52435 K.POOLAMBAL 50/F Beedi maker 3 Years 21.6.2018 26.09.2018 97 Moderate 
14. 68789 U.SATHEESKUMAR 40/M Driver 1 Year 28.07.2018 02.11.2018 95 Good 
15. 63112 T.BEARNAD 42/M Welding worker 1 Year 30.07.2018 4.11.2018 95 Good 
16. 63732 T.SHANKAR 54/M Clark 2 Years 1.08.2018 06.11.2018 97 Good 
17. 68002 S.KOMATHY 65/F House wife 1 Year 16.08.2018 19.11.2018 94 Good 
18. 103590 K.SIVASAMY 56/M Business 2 Years 14.12.2018 15.03.2018 92 Good 
19. 11871 P.RAMACHANDRAN 59/M Teacher 4 Year 1.02.2019 02.05.2018 92 Good 
20. 14898 T.RAMALUXMY 52/F Housewife 3 Years 9.02.2019 11.05.2018 92 Good 
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IN-PATIENT CASE SHEET: 20 PATIENTS TREATED IN IP FOR Akkini selathumam 
Sl. 
No. 
IP No. Name 
Age/Se
x 
Occupatio
n 
Duration 
of Illness 
Date of 
Admission 
Date of 
Discharge 
No.of Days Total 
Days 
Results 
IP OP 
1. 1281 T.MARUTHAVALLI 68/F Labour 6 years 12.5.2018 21.6.2018 39 51 90 Moderate 
2. 1324 V.SANKARAPANDY 66/M Business 2 years 18.5.2018 03.6.2018 15 75 90 Good 
3. 1379 K.THEVATHASH 68/M Painter 5 years 24.5.2018 28.6.2018 35 60 85 Good 
4. 1391 T.JANAKI 54/F Housewife 3 years 26.5.2018 25.6.2018 30 57 87 Moderate 
5. 1652 V.AARUMUGAM 68/M Clerk 3 years 26.6.2018 25.7.2018 31 52 83 Good 
6. 1804 P.RANJITHM 60/F Housewife 6 years 16.7.2018 15.8.2018 30 62 92 Good 
7. 1926 T,JESUMANI 60/F farmer 2years 28.7.2018 14.9.2018 16 66 82 Moderate 
8. 1942 K.SELLATHURI 49/M cooley 3 years 30.7.2018 10.9.2018 41 49 90 Moderate 
9. 2036 K.NALLAMBAL 48/F Housewife 2 years 07.8.2018 11.9.2018 34 51 85 Good 
10. 2162 R.ESAKKIAMBL 63/F Housewife 6 years 23.8.2018 8.10,2018 46 44 90 Poor 
11. 2300 T.SELVI 40/F 
Agri.Labou
r 
2 years 07.9.2018 09.10.2018 32 53 85 Good 
12. 2397 K.POOMANI 65/F Housewife 5 years 22.9.2018 15.10.2018 22 58 80 Moderate 
13. 2711 S.MANONMANI 60/F Cook 4 years 8.11.2018 27.11.2018 20 65 85 Moderate 
14. 2783 T.PAARVATY 60/F Housewife 3 years 15.11.2018 7.12,2018 22 68 83 Good 
15. 2810 T,AVUDITHI 58/F Cooley 5 years 17.11.2018 16.12,2018 29 59 88 Good 
16. 1379 S.THEVATHS 68/M farmer 6 years 23.11.2018 12.12.2018 20 60 80 Good 
17. 3014 A.RAJIYA 50/F Cooley 4 years 10.12.2018 01.1.2019 22 60 82 Moderate 
18. 351 V,RAJAMMAL 59/F Housewife 5 years 13.2.2019 13.03.2019 31 57 88 Moderate 
19. 458 T.SUBRAMANIJAM 60/M Ret.Police 5years 23.2.2019 23.3.2019 30 62 92 Good 
20. 459 S,NANKAYAR 55/F Housewife 3 years 23.2.2019 23.3.2019 30 60 90 Moderate 
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INVESTIGATION CHART FOR OUT-PATIENT: BLOOD INVESTIGATIONS 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hb-Hameoglobin,TC- Total White Cell Count, DC- Differential Count White Cell Count, P-Polymorph, L-Lymphocyte, E-Eusinophil 
 
 
Sl.
No. 
OP No. 
BEFORE TREATMENT AFTER TREATMENT 
Hb TC 
DC 
Hb TC 
DC 
P L E P L E 
01. 38680 12.3 8100 60 38 02 12.3 8400 62 28 10 
02. 38599 11.6 7000 65 32 03 10.4 6400 60 36 04 
03. 38871 10.3 7500 52 45 03 12.3 7000 68 28 04 
04. 39099 10.6 9000 70 26 04 11.2 8800 70 28 02 
05. 41759 10 7600 62 36 02 12.1 7500 60 36 04 
06. 42633 14.4 9000 62 32 02 10.8 8000 62 33 05 
07. 44668 11.7 5500 62 35 03 11.9 6200 63 34 03 
08. 44644 9.4 8400 64 32 04 11.6 4.2 64 33 03 
09. 45076 12.5 7000 62 34 04 13 7000 62 34 04 
10. 49053 10.5 6400 60 36 04 13 7300 61 26 03 
11. 50529 10.2 7500 64 29 04 10 7400 62 36 02 
12. 51787 12.8 8000 65 29 06 12 8000 64 30 06 
13. 52435 12.9 6400 64 32 04 13 7200 65 32 03 
14. 68789 10.9 8800 56 40 04 11 8300 58 40 02 
15. 63112 12.6 7800 65 31 04 11.6 7500 66 30 04 
16. 63732 9.8 9000 59 37 04 10.2 8700 60 38 02 
17. 68002 13 8400 68 30 02 12.5 8200 68 30 02 
18. 103590 10.3 7500 52 45 03 12.3 7000 68 28 04 
19. 11871 11.4 8100 60 36 04 11.8 7300 64 30 06 
20. 14898 13.5 8500 64 31 02 13 8500 64 31 03 
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INVESTIGATION CHART FOR IN-PATIENT: BLOOD INVESTIGATIONS 
 
Sl.
No. 
IP No. 
BEFORE TREATMENT AFTER TREATMENT 
Hb TC 
DC 
Hb  TC 
DC 
P L E P L E 
1. 1281 11.6 7000 65 32 03 10.4 6400 60 36 04 
2. 1324 12.5 8000 64 30 03 13 8500 64 31 03 
3. 1379 11 9100 54 44 02 12.0 9500 60 33 07 
4. 1391 12 8100 64 32 04 12 8000 66 28 06 
5. 1652 12.3 8100 60 38 02 12.3 8400 62 28 10 
6. 1804 11.5 8100 60 35 05 12.2 8100 60 38 02 
7. 1926 12.8 6500 61 35 04 13.8 6500 60 36 04 
8. 1942 10.6 7500 62 36 02 11.5 7500 64 32 04 
9. 2036 13.9 9600 55.3 31.6 03 11.7 7000 62 38 00 
10. 2162 10.8 8000 66 28 06 11.1 6500 60 34 06 
11. 2300 12.6 7800 65 31 04 11.6 7500 66 30 04 
12. 2397 12.1 9800 70 26 04 12.0 8900 68 28 04 
13. 2711 15 9000 58 38 04 13.2 7200 65 33 02 
14. 2783 12 8000 62 36 02 12.5 8000 62 36 02 
15. 2810 12 7100 58 37 05 12 7000 60 34 06 
16. 1379 10.9 8200 60 35 05 10 8000 62 36 02 
17. 3014 12.3 7100 62 32 06 13 8000 58 38 04 
18. 351 12 8600 60 24 16 12.4 8100 60 36 04 
19. 458 10.5 8800 64 34 06 9.9 7800 64 32 04 
20. 459 10.3 6800 58 38 04 10.6 7000 60 38 02 
                 
Hb-Hameoglobin,TC- Total White Cell Count, DC- Differential Count White Cell Count, P-  Polymorph, L-Lymphocyte, E-Eusinophil 
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INVESTIGATION CHART FOR OUT-PATIENT: PATIENTS BLOOD SUGAR & URINE SUGAR 
Sl. 
No. 
OPNo. 
BLOOD TEST URINE TEST 
BEFORE 
TREATMENT 
AFTER TREATMENT BEFORE TREATMENT 
AFTER 
TREATMENT 
FBS PPBS S.U FBS PPBS S.U ALB SUGAR DEPOSITS ALB SUGAR DEPOSITS 
1. 38680 170 307 33 140 210 30 Nil +++ Few Pus cells ++ Nil + Nil 
2. 38599 213 284 35 106 144 34 Nil ++ Nil Nil Nil Nil 
3. 38871 136 191 33.2 125 152 19 Nil ++ Pus cells 10-12 Nil Nil Few pus cells + 
4. 39099 210 280 20 136 170 20 Nil + Nil Nil Nil Nil 
5. 41759 276 378 25 202 253 23 Nil ++ Nil Nil + Nil 
6. 42633 194 227 33 180 196 13 Nil ++ Few pus cells ++ Nil Nil Nil 
7. 44668 172 272 28 155 204 30 Nil + Nil Nil Nil Nil 
8. 44644 138 202 30 125 175 25 Nil ++ Pus cells 10-12 Nil Nil Nil 
9. 45076 178 245 30 150 198 30 Nil + Nil Nil Nil Nil 
10. 49053 203 267 20 144 200 18 Nil + Few pus cells ++ Nil Nil Nil 
11 50529 208 298 23 175 204 21 Nil ++ Nil Nil Nil Nil 
12. 51787 191 270 30 180 204 26 Nil ++ Nil Nil Nil Nil 
13. 52435 291 315 18 233 218 29 Nil +++ Nil Nil ++ Nil 
14. 68789 199 242 29 152 198 27 Nil ++ Nil Nil Nil Nil 
15. 63112 150 288 30 132 204 28 Nil Nil Nil Nil Nil Nil 
16. 63732 170 330 24 162 220 30 Nil ++ Nil Nil + Nil 
17. 68002 169 304 22 151 209 26 Nil + Nil Nil Nil Nil 
18. 103590 201 304 30 135 213 26 Nil + Nil Nil Nil Nil 
19. 11871 178 244 26 132 194 27 Nil Nil Nil Nil Nil Nil 
20. 14898 139 191 23 129 144 26 Nil Nil Nil Nil Nil Nil 
FBS-Fasting Blood Sugar, PPBS-Post Parandial Blood Sugar, S.U-Serum Urea, ALB-Albumi 
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INVESTIGATION CHART FOR IN-PATIENT: PATIENTS BLOOD SUGAR & URINE SUGAR 
 
Sl. 
No. 
IP No. 
BLOOD TEST URINE TEST 
BEFORE TREATMENT AFTER TREATMENT BEFORE TREATMENT AFTER TREATMENT 
FBS PPBS S.U FBS PPBS S.U ALB SUGAR DEPOSITS ALB SUGAR DEPOSITS 
1. 1281 205 205 26 95 105 26 Nil ++ Nil Nil Nil Nil 
2. 1324 204 204 24 122 268 28 Nil ++ Pus cells ++ Nil Nil Nil 
3. 1379 192 192 22 135 204 25 Nil Nil Nil Nil Nil Nil 
4. 1391 213 213 32 145 237 34 Nil +++ Nil Nil +++ Nil 
5. 1652 160 160 26 132 202 28 Nil + Nil Nil + Nil 
6. 1804 261 261 19 264 288 26 Nil + Nil Nil Nil Nil 
7. 1926 186 186 26 113 260 28 Nil + Pus cells ++ Nil + Pus cells ++ 
8. 1942 179 379 12 160 260 25 Nil + Nil Nil Nil Nil 
9. 2036 182 182 22 160 217 21 Nil ++ Pus cells ++ Nil + Pus cells ++ 
10. 2162 185 185 34 138 204 27 Nil +++ Pus cells ++ Nil ++ Nil 
11. 2300 174 274 26 155 270 24 Nil + Nil Nil + Nil 
12. 2397 135 135 30 130 223 26 Nil +++ Pus cells ++ Nil ++ Nil 
13. 2711 237 237 35 220 300 38 Nil +++ Nil Nil Nil Nil 
14. 2783 192 192 26 188 240 28 Nil Nil Nil Nil Nil Nil 
15. 2810 119 119 28 110 190 26 + +++ 5-7 pus cells Nil + Nil 
16. 1379 198 198 26 175 235 30 Nil + Pus cells ++ Nil Nil Nil 
17. 3014 174 174 28 143 204 26 Nil Nil Nil Nil Nil Nil 
18. 351 135 135 30 95 127 28 Nil + Nil Nil Nil Nil 
19. 458 240 240 24 202 280 46 Nil + Nil Nil Nil Nil 
20. 459 220 220 28 190 310 30 Nil + Pus cells ++ Nil Nil Nil 
 
FBS-Fasting Blood Sugar, PPBS-Post Parandial Blood Sugar, S.U-Serum Urea, ALB-Albumin 
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INVESTIGATION CHART FOR OUT-PATIENT: PATIENTS HbA1C & LIPID PROFILE 
 
Sl.N
o 
OPNo 
BEFORE TREATMENT AFTER TREATMENT 
HbA1
C 
LIPID PROFILE 
HbA1C 
LIPID PROFILE  
TC HDL LDL VLDL TGL TC HDL LDL VLDL TGL 
1. 38680 9.2 242 40.1 149.1 52.8 264.1 8.7 180 48 99 33 165 
2. 38599 8.7 226 39 136 52 260 8.5 210 68 120 22 110 
3. 38871 8.7 270 54 183 83 416 8.3 219 54 140 25 127 
4. 39099 10 263 42 131 48 242 9.7 202 33 125 56 280 
5. 41759 10 238 26 159 53 263 9.7 176 52 110 32 158 
6. 42633 8.7 253.2 39.2 174.4 39.6 198.1 8.5 197 67 109 21 105 
7. 44668 9.4 267 36 184 47 233 9.2 130 42 82 45 133 
8. 44644 8.9 208 40 154 14 170 8.5 211 65 121 25 127 
9. 45076 9.4 223 42 131 12 149 9.2 190 45 126 12 110 
10. 49053 9.7 247 42 160 16 182 9.5 203 66 120 17 84 
11. 50529 10 219 48 141 30 169 9 185 40 180 15 75 
12. 51787 9.4 240 30 169 20 195 9.3 213 42 128 12 153 
13. 52435 9.9 213 30 68 95 475 9.8 223 57 91 80 398 
14. 68789 8.1 247 60 158 29 193 8 167 43 82 32 121 
15. 63112 8.9 284 57.2 193 34 168 8.2 190 58 102 33 175 
16. 63732 9.2 254 35 195 24 171 9 154 35 95 24 121 
17. 68002 9.3 223 44.6 132 47 235 9.1 145 38 86 21.8 109 
18.      103590 7.6 224 44 158 22 110 7.3 210 61 89 28 98 
19. 11871 8.3 220.5 34.2 158.4 27.9 139.9 8.1 158 61 79 18 88 
20. 14898 9.8 211 44 130.3 36.1 144 9.23 166 39 95 46 76 
 
TC-Total Cholesterol, HDL-High Density Lipoprotein, LDL-Low Density Lipoprotein, TGL-Triglyceride 
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INVESTIGATION CHART FOR IN-PATIENT: LIPID PROFILE AND HbA1C 
 
Sl. 
No. 
IP No. 
BEFORE TREATMENT AFTER TREATMENT 
HbA1C 
LIPID PROFILE 
HbA1C 
LIPID PROFILE 
TC HDL LDL VLDL TGL TC HDL LDL VLDL TGL 
1. 1281 7.7 196 39 127 23 118 6.8 192 50 122 20 102 
2. 1324 9.8 278 38 119 21 105 9.6 192 46 102 28 120 
3. 1379 9.1 190 39 117 23.6 392 8.7 192 50 122 20 102 
4. 1391 8.1 226 30 117 78.4 392 7.9 154 40 84 30 115 
5. 1652 8.8 227 39 136 52 260 8.1 215 46 146 23 75 
6. 1804 8.5 175 48 103 24 170 8.3 181 52 96 26 120 
7. 1926 8.5 275.3 35 122.8 17.4 87.1 8.3 163 72 66 25 127 
9. 1942 8.0 190 45 118 58 110 7.09 181 50 150 31 186 
10. 2036 9.1 227 61 142.4 23.6 118 7.9 200 44 128 27 157 
11. 2162 7.3 181 50 150 31 186 7.1 154 40 84 30 150 
12. 2300 9.23 206 31 190 49 190 8.2 166 39 111 55 76.3 
13. 2397 7.1 230 54 152 24 178 6.8 230 54 132 34 118 
14. 2711 7.7 240 58 236 46 232 7.5 223 36 140 47 236 
15. 2783 7.3 191 37.4 129.94 23.66 118.3 7.3 180 30 137 13 67 
16. 2810 8.7 205 57 119 29 145 8.3 201 54 97 17 98 
17. 1379 9.3 230 54 152 24 178 9.2 168 46 88 34 171 
18. 3014 8.3 270 50 150 20 180 8.2 208 48 106 17 186 
8. 351 7.8 182 48 98 30 176 7.7 175 58 93 25 113 
19. 458 9.8 255 72 150 33 151 9.7 240 80 130 30 148 
20. 459 9.1 201 53 126 22 112 8.9 210 58 102 25 138 
 
TC-Total Cholesterol, HDL-High Density Lipoprotein, LDL-Low Density Li 
poprotein, TGL-Triglyceride 
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BMI  CHART FOR OUT-PATIENTS (OP) 
 
WT-Weight, HT-Height, BMI-Body Mass Index, WC-Waist circumference, HC-Hip circumference, WHR-Waist Hip Ratio 
Sl. 
No. 
OP No. Name Age/ Sex 
BMI 
Before Treatment After Treatment 
WT HT BMI WT HT BMI 
1. 38680 V.VEALLAMBAL 55 63 160 24.61 62 160 24.2 
2. 38599 S.PERUMAL 59 110 167 39.44 105 167 37.6 
3. 38871 S.MUMTAJ 60 65 149 29.28 65 149 29.3 
4. 39099 P.SUBRAMANI 59 80 165 29.38 76 165 27.9 
5. 41759 K.RAJASUNDARY 58 45 142 22.32 46 142 22.8 
6. 42633 V.SORNAM 61 93 170 32.18 91 170 31.5 
7. 44668 K.SELLAMMAL 52 63 152 27.27 62 152 26.8 
8. 44644 T.NALLASAMY 40 75 173 25.06 74 173 24.7 
9. 45076 S.JAYA 54 55 145 26.16 55 145 25.9 
10. 49053 G.KASIVISVANATHAN 49 65 161 25.08 63 161 24.3 
11. 50529 T.THANKAMANI 65 60 160 23.44 59 160 23 
12. 51787 V.SAROJA 58 66 143 32.28 65 143 31.8 
13. 52435 K.POOLAMBAL 50 56 154 23.61 55 154 23.2 
14. 68789 U.SATHEESKUMAR 40 76 179 23.72 73 179 22.8 
15. 63112 T.BEARNAD 42 72 174 23.78 70 174 23.1 
16. 63732 T.SHANKAR 54 65 168 23.03 65 168 23 
17. 68002 S.KOMATHY 65 65 149 29.28 63 149 28.4 
18. 103590 K.SIVASAMY 56 91 173 30.41 90 173 30.1 
19. 11871 P.RAMACHANDRAN 59 60 164 22.31 59 164 21.9 
20. 14898 T.RAMALUXMY 52 64 154 26.99 63 154 26.6 
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  BMI CHART FOR IN-PATIENTS (IP) 
Sl.No. OPNo. Name Age/ Sex 
BMI 
Before Treatment After Treatment 
WT HT BMI WT HT 21.9 
01. 1281 T.MARUTHAVALLI 68 54 154 22.77 52 154 28.4 
02. 1324 V.SANKARAPANDY 66 88 172 29.75 84 172 27 
03. 1379 K.THEVATHASH 68 82 172 27.72 80 172 26.6 
04. 1391 T.JANAKI 54 78 170 26.99 77 170 22.4 
05. 1652 V.AARUMUGAM 68 58 161 22.38 58 161 26.2 
06. 1804 P.RANJITHAM 60 60 150 26.67 59 150 21.2 
07. 1926 T,JESUMANI 60 45 149 20.27 47 149 17.2 
08. 1942 K.SELLATHURI 49 50 169 17.51 49 169 27.5 
09. 2036 K.NALLAMBAL 48 75 163 28.23 73 163 32.4 
10. 2162 R.ESAKKIAMBAL 63 60 136 32.44 60 136 23.7 
11. 2300 T.SELVI 40 70 168 24.8 67 168 22.3 
12. 2397 K.POOMANI 65 56 160 21.88 57 160 27.3 
13. 2711 S.MANONMANI 60 60 147 27.77 59 147 25.8 
14. 2783 T.PAARVATHY 60 55 146 25.8 55 146 28 
15. 2810 T,AVUDITHAI 58 65 150 28.89 63 150 30.8 
16. 1379 S.THEVATHAS 68 75 155 31.22 74 155 30.8 
17. 3014 A.RAJIYA 50 57 150 25.33 56 150 24.9 
18. 351 V,RAJAMMAL 59 43 157 17.44 45 157 18.3 
19. 458 T.SUBRAMANIJAM 60 63 168 22.32 62 168 22 
20. 459 S.NANKAYAR 55 53 163 19.95 52 163 19.6 
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CHAPTER-V 
 
DISCUSSION 
 
The Akkini selathumam is correlated in modern science is Diabetic 
Neuropathy, which affects up to 50% of type 2 diabetic patients. Whereas some 
patients may have extremely painful symptoms, others with a more marked 
neuropathic deficit may be asymptomatic. Diagnosis requires careful examination of 
the lower limbs. Uncontrolled long standing diabetes is the main cause for developing 
the diabetic complications. This clinical study is designed to target the risks of macro-
vascular complications ensuing diabetes and to improve the quality of living of the 
diabetic individuals, with an efficacious herbal formulation mentioned in Siddha 
literature. 
In this study, 40 type-II diabetic patients who are attending the OP and IP at 
the Dept. of Pothu Maruthuvam, Govt. Siddha Medical College and Hospital, 
Palayamkottai were randomly selected for carried out this study. 20 screened and 
selected patients were admitted as Inpatients in Post Graduate Department of Pothu 
Maruthuvam and were treated with the trial medicine. After discharge all the twenty 
patients were followed as the Outpatients. 20 Out patients in the Outpatients 
Department of Pothu Maruthuvam were also treated with the trial drug.  From my 
entire study the following findings are observed.Details are given below, 
 
1. Distribution of Gender 
 
The subjects included females 65% in OP, 50% in IP and males 35% in OP and 
50% in IP were affected proving gender disparity in the onset of the disease.  The 
female population was more than the male counterpart. This compares well with a 
study on WHO global data which stated that the prevalence ratio of diabetes between 
men and women varies markedly, with no consistent trend. The ADA stated the 
relative difference in frequency between the sexes is probably related to the presence 
of underlying factors, such as post-delivery leads to obesity, rather than to a sex-
specific genetic tendency.   
 
2. Distribution of Age 
 
The highest incidence of Akkini selathumam is among the age group of 51-60 
years, closely followed by 61-70 years. From this study, it was observed that the 
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diabetic subjects were averagely older. This shows type-II diabetes begins typically in 
middle life or later, the prevalence rises with age. 
 
3. Distribution of Educational Status 
 
The assessment of patient‟s knowledge showed the majority of patients were 
middle(35%) and high school(45%) educated.The educational level had no impact on 
glycemic control, but the patients of high educational level had better awareness of 
the complications and a high rate of adherence to diet.   
 
4. Distribution of Occupation 
 
The highest (55%) incidence of Akkini selathuma is among OP and IP patients 
were housewives, it belongs to female counterpart. 
 
5. Distribution of Religion  
 
The majority of patients were Hindus among OP and IP as 80%. The highest 
incidence is among the Hindu population, which is the major population in India. Diet 
and lifestyle of rituals may influence the control of blood sugar and dyslipidaemia.   
 
6. Distribution of Marital Status  
 
The highest incidence among the OP and IP patients were married. Pregnancy 
and obesity can influence the married status in Akkini selathumam.  
 
7. Distribution of Clinical Manifestation  
 
Diabetes is a chronic illness that requires continuing medical care and patient 
self-management education to prevent acute complications and to reduce the risk of 
long-term complications.The data from the observation showed 100% of incidence of 
polyuria, polydipsia, Polyphagia and nocturia in both In Patients and out-patients. 
 
Diabetic neuropathy itself usually causes Numbness,Burning sensation of the 
limb, Tingling Sensation and pain .  These features also(100%) present among OP & 
IP patients in  who were recruited for this study.  
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8. Distribution of Mode of Onset  
 
The onset of Akkin Selathumam ensures a chronic mode of onset with relative 
percentage of 75% in OP and 95% in IP. The percentage of recently found supports 
the fact that in many diabetics the disease is first detected when the patient presents 
with a complications.  
 
9. Distribution of Duration of Illness  
Akkini Selathumam is greatly noticed in 40 patients were suffering more than 
3 to 6 years are more suffering with Madhumegam. 
 
It was observed that duration of type-II diabetes had a positive correlation with 
glycated haemoglobin. This is because the body becomes more resistant to insulin 
with increasing duration of diabetes.  
 
10. Distribution of Family History 
 
Among the Outpatients, 65% of the patients had positive family history and 
35% of the patients had negative family history in In patients 60% had negative 
family history.  Family history is high prevalence to got diabetic complications.  
 
11. Distribution of Previous Treatment 
 
Among OP and IP patients of 90% and 95% were taken previous therapy. 
Majority of patients despite of previous therapy for madhumegam had developed 
Akkini Selathumam, reflecting the resistance developed to the undertaken therapy. 
 
12. Distribution of Personal History  
 
The observations illustrate that the disease was majority of patients were taken 
mixed diet.  According Yugi Vaidhya Chinthamani, the dietary factors that cause the 
disease are taking excessive consumption of non-vegetarian diet. Here the 
observations coincide with Yugi‟s concept. 
Although regulation of blood glucose and lipid profile to achieve near normal 
levels is a primary goal in the management of diabetic dyslipidaemia, and thus, 
dietary techniques that limit hyperglycaemia following a meal are important in 
limiting the complications of diabetes.Indian diets rich in carbohydrate and low in 
Omega -3PUFA exacerbate hypertriglyceridemia (Srinivas et al.2014).  
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Distribution of Socio economic Status  
 
Among the Out-patients 45% belonged to the lower middle Socio-Economic 
status and 35% belonged tolower middle and poor group.  
 
This Observation indicates no class variation in the manifestation of the 
disease. But the low income should influence the awareness of diet, health care and 
routine medical check-up of patients.  
 
13. Distribution of Other System Involvement 
 
Both In patients, Out Patients had Respiratory system, cardiovascular system 
and musculo skeletal system(90%) affected. Among this majority of cases affected 
with musculo skeletal system in OP and IP patients. The course may be due to 
degenerative changes.  
   
14. Body Mass Index  
 
According to WHO 60% of the quality of an individual's health depends on 
his/her diet and regimens.  Early adoptions of healthy habits can problems of future 
years. Present study reflected that there was a higher prevalence of overweight and 
obesity among OP and IP patients (65% & 85%). Increased  BMI is  a risk factor of 
diabetic related complications.  
 
15. Distribution of Constitution of Body  
 
Among, 40 Outpatients and Inpatients 100% were  affected in thontha thegi. 
The study reflected that higher prevalence was Pittham  with other doshas.  
 
16. Distribution of Gunam 
 
100% of all  40 patients had Rajogunam 
 
 
17. Distribution of Kaalam 
 
The maximum numbers of cases were treated in their pitha kaalaM(80%) 
among OP and IP patients.  Siddha text also denoted the pittha kaalam is more 
prevalence to Akkini selathumam.  
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Paruva Kaalam  
There was high incidence of this study reflected munpanikaalam (75%) among 
OP patients and pinpanikaalam (85%) among IP patients. The text book of Siddha 
maruthuvam stated elavenil and mudhuvenil kaalam are  more prevalence for 
Madhumegam occurs.  
 
Akkini selathumam is the complications or sequence of Madhumega disease. 
Therefore it could not counterpart of the disease origin.   
 
18. Thinai  
 
Among, Outpatients 90% belonged to Marutham (i.e. Plain & its 
surroundings) and 85% in Inpatients.  
 
19. Mukkutram  
 
a. Derangement of Vatham 
 
 Abanan, Viyanan, Samanan and Uthanan were  mostly affected in all the 
100% of the Outpatients and Inpatients. Kirukaran was affected in 75% of the Out and 
In- patients . Piranan was affected in 5% of the Outpatients and 7% of the Inpatients; 
Pranan maintains the life force in a normal healthy body, this vayu when affected 
causes fatigue as presentd along with Akkini selathumam. 
 Abanan is the  responsible for excretion of urine and motion. This vayu is 
affected in this disease causing constipation and polyuria. 
 Viyaanan functions to induce normal physiological movements in the body. 
This vayu is affected leading to decreased activity due to tiredness, 
claudication pain and weakness. 
 Uthanan is responsible for speech, strength of the mind and the body. Since 
there is a decrease in the strength of the body and mind.  
 Altered Samanan  is leads  to polyphagia and indigestion. 
  Kirukaran is responsible for appetite which is affected in this disease. 
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b.Derangement of Pitham 
 
Analagam, Ranjagam and Sathagam were affected in 100% of both Inpatients 
and Outpatients. Prasagam was affected in 30% of the Outpatients and 35% of the 
Inpatients. Alosagam was affected in 25% of the Outpatients and 5% of the Inpatients. 
 
 Analagam is responsible for appetite. Since there is excess appetite or loss of 
appetite among the patients. 
 Ranjagam contributes to the normal function of the blood components. This 
pitham is affected since there is a decreased haemoglobin level and increased 
burning sensation in Akkini selathumam. 
 Sathagam enables the performance of the intended actions if altered causing 
tiredness.  
 Prasagam gives lustre to the skin, which is affected also. 
 Altered alosagam causing blurring of vision. 
 
c. Derangement of Kapham 
 
In types of Kapha dosham, Avalambagam and Kilethagam were affected in all 
the 100% of both Inpatients and Outpatients. Santhigam was affected in 65% of 
Outpatients and 75% of Inpatients.  
 
 Avalambagam resides in the lungs and helps the other four types of kapham to 
function in equilibrium. Since the equilibrium is altered due to involvement of 
other forms of kapham also affected. 
 Deranged Kiethagam excessive appetite or loss of appetite is present. 
 Santhigam resides in the joints and helps in its movement. Since there was 
joint pain, 
 
20. Involvement of Ezhu Udalthathukkal 
 
In ezhu udal Kattugal, Saaram and Senneer was affected in all 100% of the 
Outpatients and Inpatients. Oon was affected in 65% of the Out patients and 15% of 
the Inpatients. The kozhuppu was affected in 80% of the Outpatients and 85% of the 
Inpatients. Enbu was affected in 20% of the out-patients and of the 25% Inpatients 
and sukkilam was affected in 5% of Outpatients only.  
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 Saaram strengthens the body and mind, since, there is loss of appetite and strength 
less causing body tiredness the first thathu is affected.  
 Senneer is affected which produces decreased haemoglobin and accelerated 
atherosclerosis. Oon is responsible for the structural muscular component of the 
body, this is affected in the weakness caused by stroke. Excessive kozhuppu 
thathu also causes accelerated atherosclerosis in Akkini selathumam.  
 Enbu and Kozhuppu are responsible for the movements of the body and gives 
lubrication to the joint cavities. There was reflected in masculo skeletal disorders 
like Oteo arthritis, back pain, shoulder pain etc.,due to obesity, and senility.  
 
21. Kanmenthiriyam  
 
The present study showed kaal and eruvai were affected in majority of cases in 
OP and IP patients (100% & 40%). It was reflected regarding the altered functions of 
Kanmenthiriyam due to the sequence of Akkini selathumam.  
 
22. Gnanenthiriyam  
 
Among Outpatients and In patients Mei was affected in 50% and 25% of the 
cases leads to altered sensation and pain in madhumegam due to altered Viyanan and 
Devathathan. The pathology also can be overlap with sign and symptoms of diabetic 
neuropathy causes peripheral vascular diseases, stroke etc.  
 
23. Kosam  
 
Among 40 patients annamaya kosam (100%) was affected due to altered 
abanan, samana vayu, anaila Pitham and kilethagam, in udalkattukal saaram and 
senneer.  
 
24. Envagai Thervugal 
 
 Sparisam was affected in 50% of Outpatients and 25% of Inpatients due to altered 
sensations of pain in claudication and numbness in neuropathy. 
 Niram was affected in 30% of Outpatients 35% of Inpatients due to loss of lustre. 
 Vizhi was affected in 10% of Outpatients and 20% of Inpatients, blurring of vision 
due to cataract and aging.  
 Malam was affected in 30% of Outpatients and Inpatients due to constipation. 
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 Naa and Moothiram were affected in Inpatients and Outpatients. There was 
presence of dryness of tongue due to dehydration and polyuria with excretion of 
albumin, glucose, and abnormal neerkuri.  
 Mozhi was affected 10% among Inpatients only with Akkini selathumam in the 
study. 
 In Naadi examination majority of cases had pitha vatha naadi in OP and IP 
patients (55% & 65%) pitham kapham were 45% in OP and 35% in IP. 
 
25. Neerkuri 
 
In Neerkuri, Niram was affected in 55% of Out-patients and 45% of Inpatients 
which the colour was replicated crystal clear urine and indicates asathiyam.  Manam 
was affected like honey odour in 20% of Outpatients and 30% of Inpatients. Nurai 
was affected in 35% of Outpatients and 25% of Inpatients. 
 
26. Neikuri 
 
In Neikuri, 100% of  patients had Thontha neer. Which was reflected some 
Asathiya Neerkuri such features like conch shape, decoration type, bat shape, bow 
shape etc. 
 
27. Laboratory Analysis 
 
A. HbA1C 
 
Among the 40 patients recruited for the study most patients in OP & IP (80% 
& 85%) had poor control (>8%) of HbA1C.  
 
This study reveals high prevalence of hypercholesterolemia, 
hypertriglyceridemia, high LDL-C and low HDL-C levels among subjects with high 
HbA1C levels which are well known risk factors for cardiovascular diseases. Insulin 
affects the liver Apo-lipoprotein production. It regulates the enzymatic activity of 
Lipoprotein Lipase (LPL) and Cholesterol ester transport protein.  
 
All these factors are likely cause of dyslipidaemia in Diabetes mellitus. 
Moreover, insulin deficiency reduces the activity of hepatic lipase and several steps 
in the production of biologically active LPL may be altered in DM. 
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B.  Lipid Profile 
 
Above  this study, the pattern of lipid profile parameters in diabetic subjects 
and it‟s among the 40 patients included in the study, major ratio of the patients had 
TC within the range of borderline high (OP-50% & IP-45%) and high (OP-45% & IP-
25%), LDL within the range ofborderline high (OP-60% & IP-40%) and high (OP-
35% & IP-5%) above optimal were 45% in Inpatients only.  
 
50% of OP and 40% of IP patients had low HDL levels. Both IP & OP 
patients had 50% normal HDL levels. 
 
High prevalence of TGL in range of borderline (OP-50% & IP-35%) and high 
(OP-40% & IP-35%) were among 40 patients.  
 
Majority of OP and IP patients had normal levels of VLDL cholesterol. 
 
28. Gradation of results 
 
Good response was found in 70% of Outpatients and 75% of Inpatients. 
Moderate improvement was found in 20% of Outpatients and in 20% of Inpatients. 
Poor result was found in 10% of Out patients and 5% of the Inpatients. 
 
Bio statistical analysis showed significant difference in the action of the trial 
drug in lowering elevated blood sugar levels, HbA1C, total cholesterol, LDL, TGL, 
and HDL with a „p‟ value of p<0.001 for blood sugar, p< 0.001 for HbA1C, p<0.001 
for total cholesterol, p<0.001 for LDL p<0.001, for HDL p<0.001 and for TGL 
p=0.001 before and after treatment with the trial drug. The p value for VLDL 
cholesterol level was not statistically significant, although difference exists in their 
mean value with SD.  
 
It shows that though statistically significant clinically the trial drug had an 
effect in reducing the elevated Blood sugar, HbA1C, Total cholesterol, LDL, HDL 
and triglyceride levels. At the same times good Response was found in Diabetic 
neuropathic patient.  
 
Anthropometric measurements also showed significant difference in the action 
of trial drug in lowering body weight and BMI with p value of <0.001. 
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CHAPTER-VI 
 
SUMMARY 
 
Diabetic neuropathies are neuropathic disorders that are associated with 
diabetes mellitus. These conditions are thought to result from diabetic microvascular 
injury involving small blood vessels that supply nerves (vasa nervorum) in addition to 
macrovascular conditions that can culminate in Akkini selathum ( Diabetic 
neuropathy). 
 
 The clinical trial was conducted in selected 40 patients after the including and 
excluding criteria,who are affected in Akkini selathum, The  sex , age  and other 
parameters were screened and used for this study The patients were subjected to 
investigations based on  lab investications in modern aspect  as well as Siddha. The 
trial drug KADUKKAI CHOORANAMwas administered to all selected patients, at a 
dose of 25mg/kgBW, for a study period of 90 days. 
 
Blood sugar (FBS, PPBS), HbA1c, lipid profile and Neuropathic- pain score 
was recorded before and after treatment. Siddha diagnostic parameters of Naadi 
examination and neerkuri, nei kuri were also observed. The blood sugar was observed 
once in 28 days. 
 
All the cases administered with the trial drug, they were not reported any 
adverse reactions. Few patients adapted to the medicine and recovered spontaneously, 
for such patients the textual dosage of the trial drug was followed. In those who had a 
persistent complaint, the dosage of the trial drug was titrated according to their Body 
Mass Index. 
 
Significant improvement was observed in almost all the cases included in the 
study. Symptoms of tiredness, peripheral neuropathy (pain, Burning sensation and 
numbness),pain due to vascular claudication, gastric disturbances were remarkably 
reduced. Significant decreases in the mean values of blood sugar levels, HbA1C, 
Lipid levels BMI and Neuropathic- pain score were noted before and after treatment. 
For blood sugar and HbA1C the “p” value was p<0.001 and “p” value was p<0.001 
and for total cholesterol “p” value was p<0.001, for LDL “p” value was p<0.001, for 
HDL “p” value was p<0.001,for TGL “p” value was p<0.001for BMI  „p‟ value was 
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<0.001,Neuropathic-pain score “p” value was p<0.001, which implies that statistically 
the trial drug has KADUKKAI CHOORANAMis potent anti-hyperglycemic  anti-
hyperlipidemic and Neuropatic actions. 
 Biochemical analysis of the trial drug showed the presence of Calcium, 
starch, ferrous iron, tannic acid, unsaturated compound, reducing sugar and amino 
acids. The pharmacological analysis showed that the trial drug produced significant 
changes in, plasma glucose, haemoglobin, glycosylated haemoglobin HbA1C, plasma 
insulin,Inflamation and lipid profile.  
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CHAPTER-VII 
CONCLUSION  
  
In conclusion, the significant effect of KADUKKAI CHOORANAM in diabetic 
neuropathy.. Trail medicine was showed markedly decreased body weight. In this 
clinical study 75% of the patients showed good improvement, 17.5% showed 
moderate improvement and 7.5% showed poor improvement.The moderate and poor 
response means the patients are not attending in opd and Ipd (or) irregulary taken the 
medicine. 
 
Clinically analysing the before and after treatment of KADUKKAI 
CHOORANAM, there was a significant decrease in the mean values of different 
clinical parameters. Neuropathic- pain score was considerably reduced from 6.9 to 
2.7. FBS was reduced from 171 to 151 whereas PPBS was reduced from 213 to 172 
.Three month average value of HbA1C levels had revealed slight decrease from 8.7 to 
8.18 on average.Noticeable changes were also present in average lipid profile values. 
Average values of  HDL were raised from 43 to 50 whereas average LDL levels had 
shown decrease from 146 to 109 along with down values of TGL from 207 to 142 
.BMI ratio had decreased  from 25.00 to24.67 which proves the effective management 
of body weight. 
 
 Akkini selathumam is managed by the trial drug KADUKKAI CHOORANAM, 
it is reduced blood sugar, lipid levels and HbA1C along with elevated lipid levels, a 
biochemical state desirable for the prevention of diabetes and its macrovascular 
conditions in diabetic neuropathy. 
 
HbA1C can be used as a potential biomarker for predicting Neuropathy in 
type-II diabetic patients in addition to glycaemic control hence early diagnosis and 
may be utilized for screening high-risk diabetic patients for timely intervention with 
Neuropatic pain lowering drugs. To conduct nerve conduction study in few patients, 
after the study is showed   Significant improvements were documented in nerve 
conduction velocity and motor amplitude of common peroneal and tibial nerves. In 
addition, the distal latency of sural nerve was significantly improved after three 
months.   
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KADUKKAI CHOORANAM is indicates the protective role against diabetic 
neuropathy related pain. So, kadukkai choornan is to well control diabtes and 
hyperlipedemia. The secondary effect of kadukkai choornan is reducing the diabetic 
preiperal neuropathic pain. 
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ANNEXURE -I 
PREPRATION OF THE TRIAL DRUGS 
DRUGS; 
KADUKKAI 
 
Purification and Preparation of Kadukkai Chooranam 
    Terminalia Chebula matured fruits weare collected and washed with water and 
then dried under the sunlight.  Cut and remove the inner seeds of fully matured dry 
fruits of Terminalia chebula shade dried and make into powder.                                                                                                                                                      
Ingredients of  Kadukkai Chooranam 
TAMIL 
NAME 
BOTANICA
L NAME / 
FAMILY 
PART 
USED 
IMPORTANT 
PHYTOCHEMIC
ALS 
ACTIONS 
THERAPEUTIC 
USES IN SIDDHA 
 Kadukkai  Terminallia 
Chebula  
Fruits  Chebulinic acid, 
Gallic acid, 
Tannic acid, 
Ascorbate, 
Ellagic acid, 
Streptozotocin-
N, Ethanolic 
acid  
Anti 
diabetic, 
Anti 
oxidant, 
Analgesic,                
Hypolipide
mic activity  
Mega disorders, 
Burning 
sensation of the 
upper and Lower 
limb, Thirst, 
Liver disease, 
Cardiac disease, 
General Debility 
polyurea. 
 
 
Dosage  : 25mg/ Kg/BW/daily two times a day 
Adjuvant  :  Warm water 
Duration  : 90 days 
Reference  : Gunapadam Mooligai Muthal Pagam Page No.201  
    Kadukkai, Vallaraiyin Thanimanbu  Pg.No. 9 
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ANNEXURE-III (A) 
 
BIO-CHEMICAL ANALYSIS OF KADUKKAI  
CHOORANAM PREPARATION OF THE EXTRACT 
 
The extract is directly prepared from the trial drug Kadukkai Chooranam. 
 
QUALITATIVE ANALYSIS 
 
Sl. 
No. 
EXPERIMENT OBSERVATION INFERENCE 
1. TEST FOR CALCIUM 
2ml of the above prepared extract 
is taken in a clean test tube.  To 
this add 2ml of 4% Ammonium 
oxalate solution. 
A white 
precipitate is 
formed. 
Indicates the 
presence of 
calcium. 
2. TEST FOR SULPHATE: 
2ml of the extract is added to 5% 
Barium chloride solution. 
No white 
precipitate is 
formed 
Absence of 
Sulphate. 
3. TEST FOR CHLORIDE 
The extract is treated with Silver 
nitrate solution. 
No white 
precipitate is 
formed. 
Absence of 
chloride. 
4. TEST FOR CARBONATE 
The substance is treated with 
concentrated Hcl. 
No brisk 
effervescence is 
formed. 
Absence of 
Carbonate. 
5. TEST FOR STARCH 
The extract is added with weak 
Iodine solution. 
No blue colour is 
formed. 
Absence of 
Starch. 
6 TEST FOR IRON FERRIC 
The extract is acidified with 
Glacial acetic acid and Potassium 
ferro cyanide. 
No blue colour is 
formed. 
Absence of 
ferric Iron 
7. TEST OF IRON FERROUS 
The extract is treated with 
concentrated Nitric acid and 
Ammonium thio cynaate solution. 
No blood red 
colour is formed. 
Absence of 
ferrous Iron.  
8. TEST FOR PHOSPHATE 
The extract is treated with 
Ammonium molybdate and 
concentrated Nitric acid. 
No yellow 
precipitate is 
formed. 
Absence of 
phosphate.  
9. TEST FOR ALBUMIN 
The extract is treated with 
Esbach’s reagent. 
No yellow 
precipitate is 
formed. 
Absence of 
albumin. 
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Sl. 
No. 
EXPERIMENT OBSERVATION INFERENCE 
10. TEST FOR TANNIC ACID 
The extract is treated with Ferric 
choloride. 
Blue black 
precipitate is 
formed. 
Indicates the 
presence of 
tannic acid. 
11. TEST FOR UNSATURATION 
Potassium permanganate solution is 
added to the extract. 
It gets 
decolourised. 
Indicates the 
presence of 
unsaturated 
compound. 
12. TEST FOR THE REDUCING 
SUGAR 
5ml of Benedict’s qualitative solution is 
taken in a test tube and allowed to boil 
for 2 mts and added 8-10 drops of the 
extract and again boil it for 2 mts. 
Colour change 
occurs. 
Indicates the 
presence of 
reducing sugar. 
13. TEST FOR AMINO ACID 
One or two drops of the extract is 
placed on a filter paper and dried it 
well. After drying, 1% Ninnydrin is 
sprayed over the same and dried it well. 
Violet colour is 
formed. 
Indicates the 
presence of 
amino acid. 
14. TEST FOR ZINC: 
The extract is treated with Potassium 
Ferrocyanide. 
No white 
precipitate is 
formed. 
Absence of 
Zinc. 
 
 
INFERENCE: Calcium, tannic acid, unsaturated compound, reducing sugar and 
amino acid are present in the trial drug Kadukkai Chooranam. 
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ANNEXURE-III (B) 
ANTIMICROBIAL STUDY OF KADUKKAI CHOORANAM 
ANTIMICROBIAL ACTIVITY PROCEDURE 
Antibacterial Activity Procedure: 
Dilution :1mg in 1ml (0.1g in 1ml) 
Test Organism: 
 The test microorganisms used for antimicrobial analysis Microorganism 
name were purchased from Microbial Type Culture Collection and Gene Bank 
(MTCC) Chandigarh. The bacterial strains were maintained on Nutrient Agar (NA) 
and fungi on Sabouraud Dextrose Agar (SDA). 
Nutrient Broth Preparation  
Pure culture from the plate were inoculated into Nutrient Agar plate and sub 
cultured at 37ºC for 24 h. Inoculum was prepared by aseptically adding the fresh 
culture into 2 ml of sterile 0.145 mol/L saline tube and the cell density was adjusted to 
0.5 McFarland turbidity standard to yield a bacterial suspension of 1.5×108 cfu/ml. 
Standardized inoculum Used for Antimicrobial test. 
Antimicrobial Test: 
The medium was prepared by dissolving 38 g of Muller Hinton Agar Medium 
(Hi Media) in 1000 ml of distilled water. The dissolved medium was autoclaved at 15 
Lbs pressure at 121
0
C for 15 min (pH 7.3). The autoclaved medium was cooled, 
mixed well and poured petriplates (25 ml/plate)the plates were swabbed with 
Pathogenic Bacteria culture viz.Microorganism name Finally, The Sample or 
Sample loaded Disc was then placed on the surface of Mullar-Hinton medium and the 
plates were kept for incubation at 37°C for 24 hours. At the end of incubation, 
inhibition zones were examined around the disc and measured with transparent ruler 
in millimeters. The size of the zone of inhibition (including disc) was measured in 
millimeters. The absence of zone inhibition was interpreted as the absence of activity 
(Kohner et al., 1994; Mathabe et al., 2006). The activities are expressed as resistant, if 
the zone of inhibition was less than 7 mm, intermediate (8-10 mm) and sensitive if 
more than 11 mm (Assam et al., 2010) 
ANTI FUNGI ASSAY BY DISC DIFFUSION METHOD (Bauer et al., 1966) 
Antibiotic susceptibility tests were determined by agar disc diffusion (Kirby–
Bauer) method. Fungi strains (Fungi Name) were swabbed using sterile cotton swabs 
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in SDA agar plate. Up to 40 μl of each concentration of the extract were respectively 
introduced in the sterile discs using sterile pipettes. The disc was then placed on the 
surface of SDA medium and the compound was allowed to diffuse for 5 minutes and 
the plates were kept for incubation at 22°C for 48 hours. At the end of incubation, 
inhibition zones were examined around the disc and measured with transparent ruler 
in milli meters. 
Minimum Inhibitory Concentration (MIC) Determination  
 This assay consists in the determination of chemical agent spectrum of action, 
according to resistance of studied micro organisms. It was developed the 
determination of minimum inhibitory concentration (MIC) for every chemical agent, 
through the classic method of successive dilution. In twelve numbered screw tubes 
(10 x 100 mm), 1 mL of TSB (trypticase soy broth) medium was distributed for every 
tube, except for the tube number 1. The tubes were submitted to autoclave under 
constant pressure and temperature of 121 °C. For the first and the second tubes of the 
series, 1 mL of tested sanitizing agent was added; tube 2 was stirred and 1 mL was 
withdrawn and transferred for tube 3. This successive transference was repeated until 
tube 11. It was added to all flasks, except for flask number 
 
ANTIMICROBIAL  RESULTS 
Sample 
Code 
Bacteria  Strains Name 
Staphylococcus 
aureus (G+) 
Streptococcus 
mutans (G+) 
 
Bacillus 
subtilis (G+) 
 
 
Klebsilla 
pneumonia 
(G-) 
E – coli 
(G-) 
KC 15 10 13 14 13 
PC 28           15 28 28 20 
NC - - - - - 
 
Keys 
             PC  -     Positive Control (Streptomycin) 
NC                  -    Negative Control 
 -                     -    No Zone 
Mm                -    Millimetre  
           G+                  -   Gram Positive Organism 
            G-                  -   Gram Negative Organism 
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 Picture: Anti-microbial activity  of Kadukkai chooranam 
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ANNEXURE-IV 
 
BIOSTATISTICAL ANALYSIS OF A PROSPECTIVE OPEN LABELLED NON RANDOMIZED 
PHASE-II CLINICAL TRIAL OF “KADUKKAI CHOORANAM” FOR AKKINI SELATHUMAM 
(DIABETIC NEUROPATHY)” 
The statistical analysis for the clinical study is done for 40 cases including 
both Out- patients and In-patients using SPSS statistical package version 20 was used 
for data analysis. Comparison between the investigated anthropometric, clinical and 
laboratory parameters were established using Pearson's correlation coefficient (r). 
Independent samples t-test (2- tailed) was used to compare means of different 
parameters. Correlation was significant at the 0.05, 0.01, 0.001 levels (2 tailed). 
Descriptive Statistics of FBS (after and before treatment) 
 N Minimum Maximum Mean Std. Deviation 
Statistic Statistic Statistic Statistic Std. Error Statistic 
FBSB 40 119.00 291.00 189.8250 5.94762 37.61607 
FBSA 40 95.00 264.00 153.2750 5.79478 36.64940 
Valid N  40      
Descriptive Statistics of PPBS (after and before treatment) 
 
 N Minimum Maximum Mean Std. Deviation 
Statistic Statistic Statistic Statistic Std. Error Statistic 
PPBSB 40 191.00 400.00 287.5750 7.54056 47.69072 
PPBSA 40 105.00 310.00 213.3500 7.13717 45.13941 
Valid N  40      
 
Descriptive Statistics of PAIN SCORE (after and before treatment) 
 N Minimum Maximum Mean Std. Deviation 
Statistic Statistic Statistic Statistic Std. Error Statistic 
PainscoreB 40 5.00 9.00 6.8750 .17970 1.13652 
PainscoreA 40 1.00 7.00 2.5750 .16751 1.05945 
Valid N  40      
 
Descriptive Statistics of HBA1C(after and before treatment) 
 N Minimum Maximum Mean Std. Deviation 
Statistic Statistic Statistic Statistic Std. Error Statistic 
HBAICB 40 7.10 10.00 8.7700 .12896 .81562 
HBAICA 40 6.80 9.80 8.4575 .13373 .84577 
ix  
Valid N  40      
 
 
Correlations of FBS,PPBS,HBA1C,PAIN SCORE and BMI in study samples (after and before treatment) 
  
FBSB 
 
FBSA 
 
PPBSB 
 
PPBSA 
 
HBAIC
. B 
 
HBAI 
C.A 
Pain 
score. 
B 
Pain 
score. 
A 
 
BMI.B 
 
BMI.A 
 
FBSB 
Pearson Correlation 1 .707** .642** .464** .342* .402* .019 .120 .047 .034 
Sig. (2-tailed) 
 
.000 .000 .003 .031 .010 .909 .462 .772 .837 
N 40 40 40 40 40 40 40 40 40 40 
 
FBSA 
Pearson Correlation .707** 1 .520** .665** .268 .341* .043 .243 -.055 -.051 
Sig. (2-tailed) .000 
 
.001 .000 .094 .031 .794 .130 .734 .754 
N 40 40 40 40 40 40 40 40 40 40 
 
PPBS 
B 
Pearson Correlation .642** .520** 1 .692** .211 .281 .097 .006 -.248 -.245 
Sig. (2-tailed) .000 .001 
 
.000 .190 .079 .552 .971 .123 .128 
N 40 40 40 40 40 40 40 40 40 40 
 
PPBS 
A 
Pearson Correlation .464** .665** .692** 1 .162 .272 -.125 .051 -.205 -.203 
Sig. (2-tailed) .003 .000 .000 
 
.318 .089 .444 .755 .205 .209 
N 40 40 40 40 40 40 40 40 40 40 
 
HBAI 
CB 
Pearson Correlation .342* .268 .211 .162 1 .946** .101 .166 -.005 -.040 
Sig. (2-tailed) .031 .094 .190 .318 
 
.000 .535 .306 .974 .805 
N 40 40 40 40 40 40 40 40 40 40 
 
HBAI 
CA 
Pearson Correlation .402* .341* .281 .272 .946** 1 .024 .180 .012 -.017 
Sig. (2-tailed) .010 .031 .079 .089 .000 
 
.885 .267 .940 .918 
N 40 40 40 40 40 40 40 40 40 40 
Pain 
sc ore 
B 
Pearson Correlation .019 .043 .097 -.125 .101 .024 1 .487** -.097 -.077 
Sig. (2-tailed) .909 .794 .552 .444 .535 .885 
 
.001 .550 .635 
N 40 40 40 40 40 40 40 40 40 40 
Pain 
score 
A 
Pearson Correlation .120 .243 .006 .051 .166 .180 .487** 1 -.034 -.015 
Sig. (2-tailed) .462 .130 .971 .755 .306 .267 .001 
 
.835 .928 
N 40 40 40 40 40 40 40 40 40 40 
 
BMI 
B 
Pearson Correlation .047 -.055 -.248 -.205 -.005 .012 -.097 -.034 1 .994** 
Sig. (2-tailed) .772 .734 .123 .205 .974 .940 .550 .835 
 
.000 
N 40 40 40 40 40 40 40 40 40 40 
 
BMI 
A 
Pearson Correlation .034 -.051 -.245 -.203 -.040 -.017 -.077 -.015 .994** 1 
Sig. (2-tailed) .837 .754 .128 .209 .805 .918 .635 .928 .000 
 
N 40 40 40 40 40 40 40 40 40 40 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 Correlations of LIPID PROFILE in study samples (after and before 
treatment) 
 
TCB HDLB LDLB VLDLB TGLB TCA HDLA LDLA VLDLA TGLA 
 
 
TCB 
Pearson Correlation 1 -.013 .706** .294 .462** .292 -.336* .285 .172 .317* 
Sig. (2-tailed) 
 
.935 .000 .065 .003 .068 .034 .075 .288 .046 
N 40 40 40 40 40 40 40 40 40 40 
 
HDL 
B 
Pearson Correlation -.013 1 -.280 -.120 -.240 -.305 .027 -.243 -.156 -.150 
Sig. (2-tailed) .935 
 
.080 .462 .135 .056 .870 .130 .337 .356 
N 40 40 40 40 40 40 40 40 40 40 
 
LDL 
B 
Pearson Correlation .706** -.280 1 -.167 .038 .165 -.112 .002 .064 .236 
Sig. (2-tailed) .000 .080 
 
.302 .815 .309 .491 .990 .694 .142 
N 40 40 40 40 40 40 40 40 40 40 
 
VLD 
LB 
Pearson Correlation .294 -.120 -.167 1 .907** .205 -.265 .302 .129 .313* 
Sig. (2-tailed) .065 .462 .302 
 
.000 .204 .099 .058 .427 .049 
N 40 40 40 40 40 40 40 40 40 40 
 
TGL 
B 
Pearson Correlation .462** -.240 .038 .907** 1 .333* -.298 .477** .198 .393* 
Sig. (2-tailed) .003 .135 .815 .000 
 
.036 .062 .002 .220 .012 
N 40 40 40 40 40 40 40 40 40 40 
 
 
TCA 
Pearson Correlation .292 -.305 .165 .205 .333* 1 -.007 .585** .089 .076 
Sig. (2-tailed) .068 .056 .309 .204 .036 
 
.966 .000 .583 .640 
N 40 40 40 40 40 40 40 40 40 40 
 
HDL 
A 
Pearson Correlation -.336* .027 -.112 -.265 -.298 -.007 1 -.073 -.144 -.199 
Sig. (2-tailed) .034 .870 .491 .099 .062 .966 
 
.655 .377 .218 
N 40 40 40 40 40 40 40 40 40 40 
 
LDL 
A 
Pearson Correlation .285 -.243 .002 .302 .477** .585** -.073 1 .062 .086 
Sig. (2-tailed) .075 .130 .990 .058 .002 .000 .655 
 
.705 .597 
N 40 40 40 40 40 40 40 40 40 40 
 
VLD 
LA 
Pearson Correlation .172 -.156 .064 .129 .198 .089 -.144 .062 1 .747** 
Sig. (2-tailed) .288 .337 .694 .427 .220 .583 .377 .705 
 
.000 
N 40 40 40 40 40 40 40 40 40 40 
 
TGL 
A 
Pearson Correlation .317* -.150 .236 .313* .393* .076 -.199 .086 .747** 1 
Sig. (2-tailed) .046 .356 .142 .049 .012 .640 .218 .597 .000 
 
N 40 40 40 40 40 40 40 40 40 40 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
